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Abstract 
Retinal blood vessels become occluded due to inflammation and thromboembolic 
diseases, the complications of which can cause dramatic visual loss. The main aim of 
this thesis is to identify features of vascular occlusions in two groups of patients, one 
with co-existing ocular inflammation and the other with circulating anti-
phospholipid antibodies (aPL) to better understand risk factors for their 
development.  
 
Demographic and clinical variables were extracted from medical records belonging 
to patients from these separate sample groups at Moorfields Eye hospital. 34 patients 
were identified with a history of retinal vein occlusion (RVO) upon attending uveitis 
clinics between 2009-2011. The patients presented with a RVO at a younger age 
compared to the general population, with an overall prevalence of 1.83%. In the 
absence of active inflammation, cardiovascular disease (CVD) risk factors were 
present which were found to be associated with systemic steroid treatments. 
Highlighting the need to assess long term CVD risk in young uveitic patients on 
steroid treatments to prevent future RVO risk.  
 
It is known that aPL promote thombus formation contributing to systemic and ocular 
complications. To understand this disease within an Ophthalmology setting, patients 
who had aPL testing performed during 2010 were followed. aPL testing was found 
to be potentially over investigated in low risk patients with other systemic risk 
factors and confirmatory re-testing was rarely performed. Important suggestions for 
investigation and re-testing of aPL are made.  
 
Patients recruited into the initial Ozurdex for uveitis phase III clinical trial were 
followed to investigate the lasting effects of the implant beyond 6 months. Long 
term efficacy and safety of the Ozurdex steroid implant to treat uveitis macular 
oedema are detailed. In addition to a favourable side effect profile compared to 
intravitreal preparations, after implantation, tapering down of high dose systemic 
immunosuppression to maintenance levels were experienced over three years.  
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1. Introduction  
Inflammation in humans is an involuntary bodily response with the aim of removing 
a stimulus and initiate healing. The process can be split into two, an exudative 
component involving vascular changes, oedema and blood stasis. The other 
involving leukocytes, granules and mediators, the cellular part. Antibodies bind to 
antigens, mechanical irritation or tissue trauma. In reaction to these stimuli, 
inflammatory mediators are synthesised and released into the blood, causing 
localised vasodilation, increased vascular permeability, extravasation of proteins and 
migration of leukocytes to the affected tissues, which in turn cause the patient to 
experience heat, pain, redness, swelling and loss of function of a particular tissue. 
This in turn stimulates, through positive feedback loops, the production of additional 
inflammatory cells known as cytokines. The hypothalamic–pituitary–adrenal axis as 
well as steroids limit and resolve this inflammatory process. Inflammation can be 
classified into: ulcerative, granulomatous, fibrinous, purulent or serous. Acute 
inflammation  involving granulocytes can takes place in a controlled manner, if 
localised and can be beneficial, however if chronic or excessive, inflammation can 
cause destruction of healthy tissue, a process that can occur within the eye. (1–3) 
 
1.1 UVEITIS 
Uveitis is a group of ocular inflammatory diseases which can affect patients of any 
age and can cause significant visual loss in one or both eyes. It is the fifth 
commonest cause of visual loss in developed countries and importantly is potentially 
treatable in many cases.(4) Inflammation flourishes within the uveal structures, in 
part or as a whole, including the iris, ciliary body and choroid as well as affecting the 
optic nerve, vitreous, retina and surrounding vasculature. The reported incidence of 
uveitis globally varies between 14 to 52.4/100,000 people and peaks during the 20 to 
50 age groups. The overall global prevalence is approximately 0.73%.(3,4) The 
pathogenesis of uveitis is not well understood, endogenous cases could be due to 
autoimmune processes or infection, commonly herpes viruses, toxoplasma gondii, 
mycobacterium tuberculosis or treponema pallidum. Associations with systemic 
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diseases such as Sarcoidosis, Behçet’s or HLA-B27 positive diseases have been 
identified in the past. However, the majority of new uveitis cases are idiopathic.(4)  
 
1.1.1 Classification of uveitis 
Uveitis can be classified in various ways: 
1.1.1.1 Anatomical Classification 
The Standardisation of Uveitis Nomenclature (SUN) criteria was introduced to help 
standardise clinical trial reporting. (5)  The classification system is based on the 
anatomical location of inflammation noted on clinical examination of the eye. 
Inflammation occurring primarily in the anterior chamber is termed anterior uveitis; 
inflammation primarily in the vitreous is called intermediate uveitis; inflammation in 
the retina or choroid is also known as posterior uveitis and panuveitis is 
inflammation occurring throughout the eye.  
 
1.1.1.2 Pathological Classification 
Causes of uveitis can also be divided into granulomatous or non-granulomatous 
types. Granulomatous uveitis can be caused by an infection with toxoplasma gondii, 
mycobacterium tuberculosis, treponema pallidum or a virus which are generally 
treatable. Local reactivation of ocular Toxoplasmosis is the most commonest cause 
of posterior uveitis worldwide. (5) A granulomatous uveitis can also be associated 
with systemic inflammatory diseases such as Sarcoidosis, Behçet's disease, VKH, 
masquerade syndromes (Lymphoma, leukaemia or ocular metastasis) which should 
be considered in patients over 60 presenting with their first episode of uveitis, or in 
the presence of human leukocyte antigen eg HLA-B27. Acute anterior uveitis is 
associated with HLA-B27 in 60% of cases. 
 
1.1.1.3 Classification by pattern of disease 
Uveitis is also classified temporally according to the acute or chronic pattern of the 
disease process. Acute anterior uveitis is the most common type of acute disease and 
carries the best visual outcome. Anterior uveitis that persists longer than 3 months is 
classed as chronic. The other classes of uveitis tend to be chronic and can be 
associated with systemic disease. Chronic persistent disease can cause inflammatory 
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damage to ocular structures and are associated with visually impairing complications 
such as macular oedema, cataract and glaucoma. A poor visual prognosis is generally 
associated with Posterior or Panuveitis. 
 
1.1.2 Prognosis and complications associated with uveitis 
Loss of vision in patients with uveitis can occur due to many reasons including: 
macular oedema, glaucoma, cataract and retinal ischaemia. Macular oedema can 
occur at any time during the course of uveitis and often responds to treatment with 
corticosteroids or immunosuppressive agents.(6) In the long term however, macular 
oedema may become resistant to treatment and management frequently involves a 
difficult balance of efficacy versus safety. Together, cataract and macular oedema 
are responsible for visual loss in 64.5% of uveitis patients, which can be preventable 
and/or treated successfully when managed early. The time to resolution of uveitis 
varies, some patients experience complete resolution but others develop a visually 
impairing chronic disease pattern that results in chronic damage to important ocular 
structures such as at the macula. Visual prognosis in patients with uveitis is poor 
(6/60 or worse) in patients with posterior and panuveitis. (4) 
 
1.1.3 Local and systemic treatments for uveitis 
The control of inflammation in uveitis can be very complex and require many 
changes in therapy until the correct diagnosis and regime is found individually for 
each patient. The correct treatment of uveitis is important to treat sight threatening 
inflammation and minimise complications from the inflammation to preserve vision 
and prevent ocular and non-ocular morbidity. Essentially current uveitis management 
plans should aim to: suppress immune reactions, eradicate any infectious causes and 
reverse causes of visual loss. For example, the treatment of anterior uveitis should 
control pain, photophobia, posterior synechiae and macular oedema. Likewise, 
retinitis, chorioretinitis, macular oedema, optic disc oedema and retinal vasculitis 
should be controlled to prevent visual loss due to posterior segment inflammation.  
 
Corticosteroids are steroid hormones that are produced in the adrenal gland cortex of 
humans and are useful for treating non-infectious cases of uveitis and macular 
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oedema. They are involved in the normal physiology for stress, immune responses 
and regulate inflammation, carbohydrate metabolism, protein catabolism and 
electrolyte levels. One form of corticosteroids are known as glucocorticoids, which 
are powerful immunosuppressive agents that act in a complex manner through 
multiple signalling pathways reducing wound scarring and inflammation. They 
provoke immune cell apoptosis, differentiation, inhibition of cytokine circulation and 
migration. In the eye, steroids reduce the immune response and repress inflammation 
by suppressing the production of inflammatory mediators: interleukin-6, 
prostaglandins and VEGF, whilst reducing fibrous proliferation. In addition, these 
steroids augment endothelial and RPE cell adhesion by stabilising RPE tight 
junctions. As a result steroids reduce blood-retinal barrier breakdown, vascular 
permeability, neovascularisation and scarring.(7)   
 
The basic structure of corticosteroids are adapted at various sites to produce different 
biological properties and effects. A hydroxyl group on C17 in the α-position is 
present in corticosteroids with anti-inflammatory properties. Prednisolone has an 
extended half life due to an added second double bond between C1 and C2. 
Dexamethasone and Triamcinolone have a fluorine atom at C9 which creates a more 
potent anti-inflammatory effect.(1,8)  
 
Commonly used steroid treatments in patients with uveitis include Prednisolone, 
Dexamethasone and Triamcinolone. They have an average onset rate of 
approximately 24 to 48 hours. Different mechanisms of drug delivery for 
corticosteroids are also available and include oral, intravenous, topical, intravitreal 
implants and injections. Among these, Dexamethasone is one of the most potent, 
with an anti-inflammatory activity that is six-fold greater than that of 
Triamcinolone.(1,7,9) Delivering the correct therapeutic level of steroid to the eye is 
difficult when simultaneously trying to minimise systemic exposure and associated 
side effects. Topical steroids are used to treat anterior located inflammation in uveitis 
but are inadequate for treating posterior segment diseases due to their 
pharmacokinetic properties. Therefore, difficulty arises when treating posterior 
segment inflammation as drug delivery into this area of the eye is complex owing to 
the presence of the blood-retina barrier.  
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Unfortunately steroids are associated with many side effects that can involve 
multiple organ systems such as those shown in Table 1-1. Side effects can be greater 
in patients using a prolonged steroid course at high doses. Some of the side effects 
such as in mesenchymal tissues cause skin atrophy, muscle weakness and 
osteoporosis, which appear to be due to the catabolic actions of steroids. Insulin 
resistance and diabetes can also be caused by steroids through disruption of 
metabolic gluconeogenesis the liver. Subconjunctival, orbital floor and intravitreal 
routes produce effective but short lived concentrations of steroid to the eye and are 
still associated with significant side effects. (9-10) 
 
Adrenal gland  Adrenal atrophy, Cushing’s syndrome 
Cardiovascular 
system  
Dyslipidemia, hypertension, thrombosis, vasculitis 
Central nervous 
system  
Changes to behaviour, cognition, memory, and mood 
cerebral atrophy 
Gastrointestinal 
tract 
Gastrointestinal bleeding, pancreatitis, peptic ulcer 
Immune system  Immunosuppression, activation of latent viruses 
Skin 
Atrophy, delayed wound healing, erythema, hypertrichosis, perioral 
dermatitis, petechiae, acne, striae, telangiectasia 
Musculoskeletal 
system  
Bone necrosis, muscle atrophy, osteoporosis, retardation of longitudinal bone 
growth 
Eyes  Cataracts, glaucoma 
Kidney  Increased sodium retention and potassium excretion 
Reproductive 
system  
Delayed puberty, fetal growth retardation, hypogonadism 
Table 1-1: Systemic side effects of steroids(2) 
 
Steroid induced ocular hypertension has been reported for over 40 years ago.(10) All 
routes of steroid delivery have an associated increased risk of elevating IOP. This is 
thought to be due to increased aqueous outflow resistance and upregulation of 
glucocorticoid receptors on the trabecular meshwork. Patients with steroid induced 
ocular hypertension are detected on clinical examination as patients have very few 
symptoms. IOP rises depend on the steroid dose administered. Responses are seen 
usually after 3 to 6 weeks after topical steroid use, but can be variable. The normal 
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population can be divided into 3 groups according to their response to topical 
corticosteroids shown in table. Increases with systemic corticosteroids average 
approximately 60% of those produced by topical steroids. Steroid induced IOP can 
be seen as 1.4 mm Hg increases in mean IOP for each 10 mg increase in the average 
daily dose of oral Prednisolone but is also variable.(10)  
 
Risk factors associated with higher IOP rises include patients with primary open-
angle glaucoma and a positive family history; older ages; and patients with type 1 
diabetes or rheumatoid arthritis, high myopia, and angle recession glaucoma. The 
steroid-induced intraocular pressure increase is usually short-lived and reversible by 
discontinuation of steroids if the drug has not been used for more than 1 year. The 
definitive treatment for steroid induced ocular hypertension requires the 
discontinuation of steroid therapy. IOP usually returns to normal within 2 to 4 weeks 
once the steroid has been withdrawn, but normalisation of IOP may take longer in 
patients with a history of chronic steroid use. Discontinuation of a steroid treatment 
may not always be an easy decision to make. If the steroid treatment needs to be 
continued, a lower dose, concentration, or strength of steroid could be considered to 
reduce the risk of glaucomatous damage as a result of uncontrolled IOP rises. In 
cases with repository steroid injection and high intraocular pressure, removal of the 
residual sub-conjunctival or intraocular steroid may or may not4 help. With systemic 
steroids, steroid-sparing agents, such as systemic non-steroidal anti-inflammatory 
agents, are a potential substitute. However, it may not be possible to discontinue the 
steroid and the elevated intraocular pressure should be managed medically or 
surgically. Most patients who develop steroid induced glaucoma can be controlled 
with topical anti-glaucoma therapy. In those who are unresponsive to medical 
therapy, laser trabeculoplasty or surgical interventions such as trabeculectomy may 
be required. 
 
In eyes at risk of steroid induced ocular hypertension, Rimexolone, or Loteprednol 
are topical steroids associated with a lower risk of inducing IOP changes. The 
management of IOP elevation after IVTA therapy is made difficult by the inability to 
remove the inciting agent, the significant magnitude of IOP elevation in many cases, 
the long duration of IOP elevation after even a single injection, and the failure of 
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conservative management to lower IOP to a safe range in a significant minority of 
cases.  
 
1.1.3.1 Local steroid treatments for uveitis 
Topical, periorbital and intravitreal routes of steroid administration are used for the 
management of uveitis and will be discussed in detail in chapter four. 
 
1.1.3.2 Systemic corticosteroids 
Oral steroids are commonly used to treat classes of intermediate and posterior uveitis 
typically involving bilateral cases or those associated with systemic diseases. Oral 
steroids are rapidly absorbed from the small intestine, with plasma levels peaking 
after approximately 1 to 2 hours. Systemically administered Dexamethasone is able 
to penetrate cells within the choroid, retina and sclera better than topical routes. (2) 
 
Adult dosing of oral corticosteroids varies according to: the severity of the uveitis, 
previous individual response to treatment and in association with systemic disease. 
To control uveitis, adult starting doses are: 1–2 mg prednisolone per kilogram per 
day. When choosing to use oral steroids their side effects should not outweigh their 
benefits in patients with uveitis. Patient education of side effects is important as well 
as monitoring of blood pressure, blood sugar and weight changes. DEXA imaging 
scans are needed to monitor and diagnose osteopenia or osteoporosis which is a 
recognised side effect of steroid use. In patients with chronic disease, initial 
treatment with high dose oral prednisone, followed by a tapering down regime and 
long term low maintenance does of corticosteroid therapy may be necessary to 
control the inflammation. (3) 
 
1.1.3.3 Intravenous corticosteroid  
Intravenous methylprednisolone is reserved for the rapid control of the inflammation 
in severe sight-threatening cases of uveitis for example in Behçet’s disease, VKH 
and uveitis associated with multiple sclerosis. Intravenous methylprednisolone 1g 
over 1 hour for 3 days is followed by oral prednisolone 1 mg/kg/day. Hospitalisation 
of the patient is necessary, not only for the treatment itself, but also to monitor for 
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potential side effects including: seizures, anaphylactic reactions and rarely sudden 
death. (24) 
 
1.1.3.4 Immunosuppressive drugs  
Second line agents such as Cellcept and Ciclosporin for example, may be added to 
the treatment regime when steroids are not effective at controlling the unrelenting 
intraocular inflammation or are used when vision is severely compromised. When 
systemic corticosteroids are insufficient to control the inflammation or a 
corticosteroid-sparing agent is required to reduce corticosteroid side effects or long-
term use of systemic corticosteroids, immunosuppressive drugs can play a role. 
Classes of Immunosuppressive drugs include: anti-metabolites (Azathioprine, 
Methotrexate and Mycophenolate Mofetil), T-cell inhibitors (Ciclosporin, 
Tacrolimus) and alkylating agents (Cyclophosphamide. and Chlorambucil). They can 
take several weeks to start working, so initial treatments would include oral 
corticosteroids as well. Once stable, corticosteroids are tapered to stop or are 
maintained at a lowered dose.(11)  
 
1.1.3.5 Azathioprine (AZA) 
Oral AZA is administered orally at a dose of 1 to 3 mg per kg per day (adjusted 
based on response and side effects). It is a purine nucleoside analogue, its 
metabolites which influences DNA replication and RNA transcription. AZA 
decreases peripheral T and B lymphocytes and reduces mixed lymphocyte reactivity, 
interleukin-2 synthesis and IgM production. Randomized clinical trials data are 
limited. The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort 
Study(12) outcomes of a large number of ocular inflammation patients. AZA was 
administered to patients with ocular inflammatory diseases (2.4% of the total SITE 
cohort), 63% had uveitis. 62% of patients treated with AZA reached complete 
inactivity of inflammation for approximately 28 days. AZA required several months 
to achieve successful outcomes. 47% tapered associated systemic corticosteroids to ≤ 
10 mg daily and stabilised inflammation for at least 1 year. AZA was most effective 
in managing intermediate uveitis (90% of inflammation were stabilised within 1 
year). Common reasons for stopping AZA treatments for uveitis include: side 
effects, ineffectiveness or disease remission. Reversible bone marrow suppression 
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can occur with AZA in addition to: hepatoxicity, gastrointestinal upset (nausea and 
vomiting) and is a reason for stopping treatment. Thus regular monitoring of blood 
counts and liver function tests are needed. If levels are raised, the dose should be 
reduced or stopped accordingly. AZA is not used in conjunction with MXT or MMF. 
(13) 
 
1.1.3.6 Methotrexate (MXT) 
MXT is a folic acid analogue and acts on DNA replication to reduce cell 
proliferation of leukocytes and other rapidly dividing cells. MXT has an anti- 
inflammatory effect, increasing the rate of T-cell apoptosis and alters cytokine 
production. MXT is administered once a week along with folate concurrently to 
reduce nausea. MXT is used in the management of rheumatoid arthritis, juvenile 
rheumatoid arthritis and systemic lupus erythematosus for example, it takes roughly 
6 to 8 weeks to work. MXT has been reported to preserve or improve VA, as well as 
reduce corticosteroid use and reduce ocular inflammation. Of 384 patients from the 
SITE(12) study managed with MXT, 32.8%, 9.9%, 21.4%, had anterior uveitis, 
intermediate uveitis, posterior or panuveitis respectively. In these groups, complete 
suppression of inflammation was sustained for over 28 days but many months are 
required before therapeutic success is obtained. MXT allowed for corticosteroid-
sparing within 6 months among 46.1%, 41.3%, 20.7%, of anterior uveitis, 
intermediate uveitis, posterior or panuveitis, respectively. MXT was generally well 
tolerated, within a year MXT was stopped in 42% of patients: 13% due to 
ineffectiveness, 16% due to side effects. Side effects were reversed when MXT was 
stopped or reduced. Side effects of MXT include: gastrointestinal upset, nausea, 
hepatoxicity (0.1% risk of cirrhosis),low blood counts and pneumonia it is 
contraindicated in pregnancy. Blood counts should be monitored every 1 to 2 
months. MXT is not used together with MMF or AZA. (13) 
 
1.1.3.7 Mycophenolate mofetil (MMF) 
MMF is effective for control of ocular inflammatory disease, when used in 
combination with other agents. MMF is used for non-infectious ocular inflammation. 
It is a selective inhibitor of inosine monophosphate dehydrogenase, an enzyme that 
interferes with guanosine nucleotide synthesis. MMF prevents T and B lymphocyte 
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proliferation, suppresses antibody synthesis, interferes with cellular adhesion to 
vascular endothelium and decreases recruitment of leukocytes to sites of 
inflammation. Caution should be shown with using MMF in patients with renal 
impairment or gastrointestinal disorders which might affect absorption. MMF is an 
effective corticosteroid-sparing agent which can act faster than Methotrexate and 
Azathioprine. (13) 
 
236 (397 eyes) patients from the SITE study treated with MMF, 20.3%, 11.9%, and 
39.8% had anterior uveitis, intermediate uveitis, and posterior uveitis or panuveitis 
respectively. Inflammation was controlled for 28 days in 73% of patients within 1 
year of commencing treatment. Oral Prednisolone was reduced to 10 mg or less, 
while maintaining sustained control of inflammation, in 41% and 55% of patients in 
6 months and 1 year, respectively. 12% discontinued MMF within the first year 
because of reversible side effects of therapy. Side effects include: gastrointestinal 
problems (nausea, vomiting, and diarrhoea), pain, myalgia, fatigue and headaches. 
Blood counts should be monitored regularly for leucopenia and liver function. MMF 
is not used in conjunction with MXT or AZA. (12,13) 
 
1.1.3.8 Ciclosporin 
Ciclosporin (A) is an 11-amino acid cyclic peptide, which inhibits transcription of T 
lymphocytes during cell division phases G0 and G1 blocking their replication and 
the ability of the body to produce lymphokines (IL-2) necessary for the proliferation 
and maturation of T cells, interferon-γ and the activation of macrophages. Ocular 
uses in oral preparations are typically used and available in 2 forms: oil-based gelatin 
capsules and a microemulsion, which has a greater consistent bioavailability. Of 
373(681 eyes) patients in the SITE study treated with Ciclosporin, 33.4% by 6 
months and 51.9% by 1 year gained sustained or complete control of inflammation 
for at least 28 days. Corticosteroid-sparing success was achieved by 22.1% by 6 
months and 36.1% within 1 year. 10.7% stopped treatment due to toxicity within 1 
year, which was three times more common to occur in patients over 55. Ciclosporin 
is administered in an equally divided dose based on response and side effects. 
Prolonged treatment with high doses of Ciclosporin can cause nephrotoxicity.  Other 
side effects include: hypertension (blood pressure should be monitored at clinic 
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visits), rarely hepatotoxicity, gingival hyperplasia, myalgia, tremor, paresthesiae, 
hypomagnesemia and hirsutism. (14)  
 
1.1.3.9 Cyclophosphamide 
Cyclophosphamide is cytotoxic to both resting and dividing lymphocytes. 
Cyclophosphamide suppresses both primary and established cellular and humoral 
immune responses and generally inhibits the immune system. It is a nitrogen 
alkylating agent with active metabolites which alkylate purines in DNA and RNA. 
Resulting cross-linking, aberrant base pairing, ring cleavage and depurination occurs 
preventing cells from replicating leading to increased cell death. Activated T 
lymphocytes decrease, helper T lymphocyte functions are suppressed and B 
lymphocytes decreases for months thereafter. (12,13) 
 
Cyclophosphamide can be administered orally or intravenously. It can be used to 
manage ocular manifestations of systemic autoimmune diseases such as: Wegener 
granulomatosis, systemic lupus erythematosus, rheumatoid vasculitis, polyarteritis 
nodosa and Behçet's disease. Side effects of Cyclophosphamide include: fatigue, 
nausea, vomiting, alopecia and headache. Bone marrow suppression occurs and is 
more common in over 65s. Suppression is reversible and dose dependent. Blood 
counts should be monitored for neutropenia, which increases the risk of bacterial 
infections and lymphopenia, which increases the risk of opportunistic infections. 
Myelodysplasia can occur with long-term oral therapy. Cessation of treatment is 
indicated with bladder toxicity and is contraindicated in pregnancy, ovarian 
suppression, testicular atrophy, and azospermia. (12,13)  
 
20.4% of patient with uveitis from the SITE study were treated with 
cyclophosphamide. 76% gained sustained control of inflammation within 12 months. 
Corticosteroid-sparing success was gained by 30.0% and 61.2% by 6 and 12 months, 
respectively. Disease remission at or before 2 years. Cyclophosphamide was 
discontinued by 33.5% of patients within 1 year because of side effects, usually of a 
reversible nature. titrate therapy properly and to minimize the risk of serious 
potential side effects, a systematic program of laboratory monitoring is required. 
(12,13) 
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1.1.3.10 Biologics 
Another classes of drugs used for the treatment of uveitis are Biologics, they include 
antibodies and monoclonal antibodies and such as: TNF antagonists (including 
Etenercept and Infliximab), Monoclonal antibodies (Rituximab), Immunoglobulins 
(interferon alpha) and Kinase inhibitors.  
 
TNFα is a cytokine produced by monocytes and macrophages. It is implicated in the 
pathogenesis of many chronic inflammatory diseases such as rheumatoid arthritis. It 
mediates the immune response by increasing the transport of white blood cells to 
sites of inflammation and through additional molecular mechanisms which initiate 
and amplify inflammation. Inhibition of its action by anti TNFs reduces the 
inflammatory response needed when treating autoimmune disease. They effect the 
function of myofibroblasts, osteoclasts, and production of interleukin-10 but not pro-
inflammatory cytokines. Infliximab is a chimerical monoclonal antibody against 
TNF-α. systemic infliximab for the treatment of different types of ocular 
inflammation. TNF-α antagonists treatment of some chronic inflammatory diseases 
by It neutralizes soluble TNF-α  or blocks TNF receptors from binding to their 
ligands promoting an anti-inflammatory microenvironment. The use of infliximab in 
ophthalmology is more commonly used for JIA and Behçet's associated uveitis and 
vasculitis and scleritis. It works quickly and toxicity depends on the individual 
medication and includes exacerbation of heart failure and multiple sclerosis for 
example. Infliximab is very costly and concerns remain with regard to the inhibition 
of TNF and the risk of malignancy development. Therefore their use is balanced 
against the potential risks and benefits in patients with uveitis. (14) 
 
Interferon α-2B is being investigated to control ocular inflammation in Behçet’s 
disease. It is delivered subcutaneously and side effects include: headaches, malaise, 
thrombophlebitis, sterile meningitis, abnormal liver enzymes and occasionally 
stroke. (14)  
 
Rituximab is a chimeric monoclonal antibody that works against proteins found on B 
Lymphocytes. It is used for treatment of Lymphoma, Leukaemia and Autoimmune 
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disorders such as Rheumatoid arthritis. Rituximab can reduce ocular inflammation in 
Wegner’s Granulomatosis. 
 
1.1.3.11  Morbiditiy and mortality with immunosuppressant 
medication 
Nearly any ocular inflammatory disorder requiring chronic systemic corticosteroid 
treatment may require immunosuppressive drugs in an effort to reduce the dose of 
corticosteroids. The probability of using an immunosuppressive drug will vary 
depending on the severity of the underlying disease. However, the 
immunosuppressive agents most commonly used for treatment of ocular 
inflammation, have potential short term toxicities which can be overcome if 
recognized early. There are also long term risks of which raise important concerns as 
to whether some of these agents may increase the risk of cancer and mortality. (15) 
 
Overall and cancer related mortality among patients with ocular inflammation treated 
with immunosuppressive drugs were investigated in a retrospective cohort study of 
2340 of 7957 patients with ocular inflammation treated with immunosuppressive 
drugs. Immunosuppressive drugs tested included: MXT, AZA and MMF, 
cyclosporin, systemic corticosteroids. They found no significantly increased risks of 
death or of death from cancer after adjusting for confounding factors. Treatment with 
cyclophosphamide was not associated with significant increases in overall mortality, 
but there was a non-significant suggestion of increased cancer mortality. Long term 
data for TNF inhibitors and MMF require further investigation to report any 
increases of overall or cancer mortality. Thus risk benefit analysis should be 
evaluated prior to commencing any of these medications. (15) 
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2. Retinal Vein Occlusions 
in uveitis patients 
2.1 INTRODUCTION  
Retinal vein occlusions (RVO) are a common retinal vascular disorder second to 
diabetic retinopathy in incidence and prevalence. RVO are classified into either 
branch (BRVO), central (CRVO) or hemi (HRVO) retinal vein occlusions according 
to the site of obstruction within the retinal venous circulation and can present as 
monocular or rarely bilateral disease. RVO can occur at any age and when left 
untreated can result in ocular complications and significant visual loss.(16) The Blue 
Mountains Eye Study(17) found RVO was the fifth most frequent cause of unilateral 
blindness, after age-related macular degeneration, cataract, amblyopia, and trauma. 
 
2.1.1.1 Epidemiology 
The incidence of BRVO is 3 to 10 times(16)  greater than CRVO. Population studies 
estimate globally from pooled data, 16.4 million adults are affected by RVO (2.5 
million by CRVO and 13.9 million by BRVO). (18) The age and sex standardised 
prevalence is 5.20 (per 1000) for any RVO and in populations aged over 30 years: 
4.42 for BRVO and 0.80 for CRVO. (18) The prevalence of RVO is strongly 
associated with increasing age, ethnic differences but not gender.(17)(18)  
 
2.1.1.2 Pathogenesis 
A combination of mechanisms contribute to the pathogenesis of thrombus formation 
in RVO including the presence of diseased endothelial vascular cells, abnormal 
blood constituents and/or increased blood viscosity reducing retinal blood volume 
and increasing stasis.(17)(19)(20) Impaired venous drainage cause capillaries to 
become permeable leaking red blood cells and plasma and a hypoxic retinal becomes 
ischaemia. This upregulates the release of cytokines VEGF and IL6 to stimulate 
angiogenesis, further increasing vascular permeability and breakdown of the blood 
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retinal barrier causing retinal and macular oedema. Eyes with increased blood and 
plasma viscosity have been shown to be more vulnerable to retinal ischaemia.(21) 
Those with narrowing of the veins primarily at arterio-venous crossing sites cause 
distal endothelial damage and thrombus formation, (22) and localised endothelial 
swelling of deep vascular layers.(23) Normally, blood flows through the vascular 
circulations of both the retina and choriocapillaris but immediately after an occlusion 
of a retinal vein, a process called reversed capillary blood flow, has been 
described.(24)(25) A rise in intravascular pressure causes the capillaries to dilate, 
leak and eventually close off leaving behind localised retinal oedema.(26) If an area 
is left non-perfused, the retina becomes hypoxic and ischaemic changes ensue.(27) 
Collateral vessels later develop to assist the flow of blood from areas of capillary 
non-perfusion and are associated with improved visual outcome in the long run. 
Occlusive retinal vasculitis, involving inflammation of small blood vessels can be 
idiopathic or associated with autoimmune or infective processes. 
 
2.1.1.3 Presenting features of RVO 
A summary of the characteristics of different RVO types are shown in Table 2-1. 
Whether a patient is likely to present with visual symptoms of RVO commonly 
depends on macular involvement, although significant peripheral visual loss can also 
occur. In an eye with a RVO, patients can experience sudden painless decrease in 
vision, which is worse in the morning(30). Baseline BCVA is generally reduced to 
6/12 - <6/60 (16) worse with CRVO, with an associated visual field defect in BRVO 
eyes. (16) (31) 
 
2.1.1.4 Examination findings of branch and central retinal vein occlusions 
The diagnosis of RVO is essentially based on clinical examination findings including  
haemorrhages, cotton wool spots, vessel tortuosity, disc swelling. Ischaemic changes 
including a RAPD, new vessels (at the angle, iris, disc or elsewhere on the retina) 
and macular oedema may also be found. Signs of vasculitis may include vitritis, 
arteroilar attenuation, sheathing, cotton wool spots, microaneurysms or telengectatic 
vessels. (16)(31)(32) 
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Characteristic Branch retinal vein occlusion Central retinal vein 
occlusion 
Frequency  1.8% 5years (28) 
0.9% 15 years (19) 
0.42 per 1000 (18) 
0.5%15-year incidence (28) 
0.80 per 1000 (18) 
RVO  66% (16) 
69.5%(17) 
34%(16) 
25% (17) 
Presenting VA 67% present with good VA (16)  6/60 or less in 60%  
Age at 
presentation 
46% younger ages BRVO 17% >80(29) 13% < 45 years (29) 
53% >80 
Retinal signs retinal signs found only in one area of the retina:  
scattered superficial and deep retinal haemorrhages 
retinal oedema 
optic disc hyperaemia/oedema 
occluded and sheathed retinal veins 
dilated and tortuous veins 
extensive retinal signs are 
seen in all 4 quadrants 
including: 
scattered superficial and 
deep retinal haemorrhages 
retinal oedema 
optic disc 
hyperaemia/oedema 
occluded and sheathed 
retinal veins 
dilated and tortuous veins 
Table 2-1: Characteristics of different retinal vein occlusion types 
 
2.1.1.5 Investigations - Ocular and systemic 
Ocular risk factors for RVO such as raised IOP should also be excluded. A detailed 
history should be taken for patients presenting with RVO, including a thorough 
clinical assessment and laboratory investigations to check for the presence of risk 
factors such as hypertension, hypercholesterolemia and diabetes, associated with a 
higher risk of recurrent RVO. Thrombophilia is an associated RVO risk in 51.4 % of 
young patients. High serum alpha 2-globulin, resistance to activated protein C, factor 
XII deficiency, hyperhomocysteinemia, anticoagulant protein deficiency and anti-
phospholipid antibodies are also associated with a higher risk of RVO in younger 
age groups see Table 2-2. Once risk factors are identified they should be well 
controlled to reduce further visual loss associated with RVO.(33) 
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Young patients <45 years Patients over 50  years 
Resistance to activated protein C Hypertension 
Anti-phospholipid antibodies Elevated serum IgA levels 
Anticoagulant proteins deficiency   
Factor XII deficiency  
Table 2-2: Different risk factors for retinal vein occlusions according to age(33)(34) 
 
2.1.1.6 Investigations - Imaging 
Colour fundus photographs, fluorescein
 
angiogram (FA) and optical coherence 
tomographic (OCT) images are all modalities used to document and evaluate the 
severity of RVO and associated complications including macular oedema and 
capillary non-perfusion. The
 
Early Treatment for Diabetic Retinopathy Study and the 
SCORE Study provide grading systems for classification of FFA and OCT findings 
associated with RVO and macular oedema. (35)(36) 
 
2.1.1.7 Fluorescein angiogram (FA) 
FA involves the intravenous injection of fluorescein sodium into a patient's upper 
limb vein, then a rapid sequence of fundus photographs using a special camera image 
the dye passing through the retinal vessels. The purpose of which would show 
leakage from the vessels and areas of non-perfusion and ischaemia. FA can be 
difficult to interpret in RVO involving masking by intra-retinal blood which may be 
falsely interpreted as areas of capillary non-perfusion. Signs of RVO on FA would 
include delayed arterio-venous transit time which may affect a particular branch, 
hyperfluroescence along vascular arcades, extension of the foveal avascular zone. 
Macular oedema can be notes by the presence of late macular staining. Capillary 
non-perfusion is defined as
 
the absence of retinal arterioles and/or capillaries seen as 
a darker appearance of the choroid. capillary non-perfusion and fluorescein leakage 
are measured by
 
comparing late and early phase images. Leaking capillaries are 
shown on FA when performed 3 months after RVO. The fovea is a depression in the 
retina where highest visual acuity is maintained and blood vessels are absent. This 
foveal avascular zone enlarges with RVO and is associated with impaired vision. 
Macular oedema is seen as areas of cystoid changes during late phase images. Large
 
diffuse areas of retinal thickening may also be seen.(37)  
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2.1.1.8 Optical coherence tomographic (OCT) 
Optical coherence tomography (OCT) is a non-invasive, safe, reliable, high-
resolution, imaging technique to quantify anatomical changes. This technique 
involves infrared light, reflectance, interference showing patterns of retinal structures 
and measures retinal thickness. OCT can be used to monitor and diagnosing 
structural defects such as intraretinal cystoid spaces, subretinal fluid, and 
vitreoretinal interface abnormalities when slit lamp examination and FA are 
inadequate. OCT is able to provide additional information regarding the 
pathophysiology of RVO such as frequency of occurrence of subretinal fluid and 
subretinal haemorrhage. According to protocols from the ETDRS and SCORE 
guidelines cystoid spaces can be identified as round, well-defined spaces within the 
neurosensory retina. The cyst cavity is dark or minimally reflective. Similarly 
subretinal fluid appears as a dome-shaped dark space between the posterior boundary 
of the neurosensory retina and an intact RPE/Bruch junction. Abnormalities on OCT 
images of RVO eyes can be due to large superficial and deep retinal haemorrhages 
that cause shadowing. Moreover, the quality of the OCT images should be evaluated 
for artefacts that could affect retinal thickness measurements. (35) 
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2.1.2 Branch retinal vein occlusion – BRVO 
The second most common retinal vascular disease after diabetic retinopathy is 
BRVO. Previous population based studies have reported prevalence rates of BRVO 
ranging from 0.3% to 1.1%, 4.42 per 1000 in pooled analysis. (16)(38) Venous 
thrombosis occurs at arteriovenous crossing sites, a sign of arterial disease. 
Thickening and atherosclerosis of a retinal artery causes compression of adjacent 
vein which share a common adventitial sheath. Hypoxia ensues as a result of 
localised endothelial damage, increased flow and thrombus formation. 
 
2.1.2.1 Risk factors for BRVO 
Over half (51%)(29) of BRVO cases occur in patients over 65 years, (incidence is 
0.7% <60s compared to 4.6% >80 years(17)). Risk factors for BRVO include older 
age, coexisting cardiovascular diseases and signs of chronic hypertensive damage to 
the retina (focal retinal arteriolar narrowing and arteriovenous nicking), see 
photograph 2-1. The strongest risk factor associated with an increased risk of BRVO 
is hypertension. Hypertension is associated with 50% - 63% of BRVO cases.(39) 
Poor control of hypertension is associated with recurrence of RVO in either the same 
or fellow eye. Hayreh et al(31) found that patients with BRVO had a significantly 
higher prevalence of hypertension, peripheral vascular disease, venous disease, 
peptic ulcer, and other gastrointestinal disease than in patients with CRVO. Type 
two diabetes is also a common risk factor for BRVO, 17.9 % vs 7.9% when 
compared to controls.(33) Diabetic patients present with RVO at an earlier age 
(compared to controls) in association with hypertension and hyperlipidaemia.(40) 
BRVO is not associated with the presence of diabetic vascular disease and retinal 
neovascularisation is not more likely to occur.(41)  
 
2.1.2.2 Classification of BRVO 
The location of the branch involved in a RVO should be documented and classified 
into two main groups, major (first order) or macular (second order). The prognostic 
value of the two classes differs. If an occlusion is isolated to a macular branch, 
macular oedema is frequently a complication affecting the vision achieved, whereas 
VH and NVG is less common. In addition, major branch occlusions may be 
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asymptomatic in patients when involving nasal or peripheral vessels as vision is less 
likely to be affected.(16) 
 
 
2.1.2.3 Branch of retinal vein involved in BRVO 
Published studies have found that branch vein occlusions frequently occur in 
temporal retinal vein branches in 77.7% to 99%(42)(43) of eyes and are more 
common than occlusions that occur in nasal branches due to the higher numbers of 
arterio-venous (artery over vein) crossing sites.(44) Therefore the risk of BRVO in 
an eye is also related to the number of arterial overcrossings present in a vulnerable 
eye compared to fellow or control eyes. With superio-temporal occlusions more 
likely to be symptomatic than nasal occlusions 
 
2.1.2.4 Clinical features of BRVO 
Symptomatic BRVO cases present with poor VA at baseline, mean presenting 
BCVA is approximately 0.75 logMAR units or worse. Depending on which retinal 
vein branch is occluded, arcuate, central, or paracentral scotomas together with a 
visual field defect causing a segmental reduction in peripheral vision. Commonly 
inferior and nasal BRVO are an incidental finding. In BRVO clinical signs are 
present in only one quadrant of the retina depending on which venous branch is 
Cardiac risk 
factors 
Blood abnormalities Ocular risk factors Inflammatory 
risks 
hypertension  high serum alpha 2-globulin Raised IOP Arteriosclerosis 
cigarette smoking resistance to activated protein C 
(APCR) 
shorter axial length  
< 22.89 mm. 
Sarcoidosis  
diabetes factor XII deficiency Hypermetropia 
(63.68%-70.7%) of 
BRVO eyes 
Behcets disease 
increased BMI 
at 20 years of age 
Hyperhomocysteinemia 
Factor V Leiden 
Polyarteritis nodosa 
History of CVD 
or IHD 
Anticoagulant protein 
deficiency 
Wegners 
granulomatosis 
Antiphospholipid antibodies  
Table 2-3: Ocular and systemic risk factors for branch retinal vein occlusion(16)  
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affected including: retinal oedema, superficial and deep retinal haemorrhages, 
occluded and sheathed retinal veins, dilated and tortuous veins, see photograph 2-
1.(16) 
 
2.1.2.5 Prognosis and complications of BRVO 
Prognostic factors associated with retinal vein occlusion are shown in Table 2-4. 
Vision in an untreated BRVO eye generally improves with time, but only 50% retain 
a vision of 6/12 or better, whilst 25% will have vision of <6/60. It has been shown 
that occlusions involving the superotemporal vein are associated with a better visual 
prognosis compared to inferior vein occlusions. (16) 
Good visual prognostic factors Poor prognostic factors 
Ages 41-60 Ages <40 or > 60 
superior and inferotemporal BRVO ischaemic maculopathy 
No pre-retinal neovascularisation pre-retinal neovascularisation 
No vitreous haemorrhage vitreous haemorrhage  
 subfoveal serous retinal detachment 
Table 2-4: Prognostic factors associated with retinal vein occlusion(16)(45) 
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2.1.3 Central retinal vein occlusion - CRVO 
CRVO are a major contributor of sight-threatening retinal vascular diseases. 
Prevalence rates of CRVO range from 0.1% to 0.5% in older populations and it is 
rare in young adults under 40 years of age (10–15%). (32) Occlusion of the central 
retinal vein can occur at or proximal to the lamina cribrosa where the central retinal 
vein exits the eye. The central retinal vein travels along with the central retinal artery 
in one sheath to the lamina cribrosa through which the retinal vein narrows making 
the vessel vulnerable to occlusion if compressed by an atherosclerotic artery for 
example see photograph 2-2. (39)(46) HRVO occurs with occlusion of one branch if 
there is an anatomical bifurcation of the central retinal vein through the lamina 
cribrosa which in turn causes signs visible on one half of the retina. 
 
2.1.3.1 Risk factors for CRVO 
Atherosclerosis of the central retinal artery causes compression of the adjacent vein. 
Resulting venous stasis, endothelial damage and increased blood viscosity contribute 
to thrombus formation causing occlusion of the central retinal vein. Systemic risk 
factors associated with cardiovascular disease contribute to altering the above factors 
including hypertension, arteriosclerosis and diabetes. Hayreh et al(29) showed that 
patients with ischemic CRVO have a significantly greater prevalence of arterial 
hypertension and diabetes compared to patients with non-ischemic CRVO. 
 
2.1.3.2 Classification and clinical features of CRVO 
CRVO are divided into either ischaemic or non-ischaemic types which is important 
as their natural history differs. Retinal ischaemia results after areas are left without 
blood flow after occlusion of the central retinal vein which in turn increases the 
pressure and non-perfusion of the capillary system. An ischaemic retina is generally 
defined by 10 disc areas of capillary non-perfusion on fluorescein angiography. VA 
at presentation is very poor (Snellen VA of 6/60 or worse) in approximately 90% of 
ischaemic eyes and is usually associated with a relative afferent pupillary defect. 
Haemorrhages and cotton wool spots are seen in both CRVO types but are more 
extensive with the presence of ischaemia. (31)(32) Signs of  an old RVO include 
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collaterals and the disc, macular oedema, RPE changes, venous dilatation, tortuosity, 
sheathing and arteriolar narrowing. 
 
2.1.3.3 Prognosis and Complications of CRVO 
In general the visual prognosis of an eye with a CRVO depends on the BCVA at 
presentation. The Central Vein Occlusion Study (CVOS) (47) gave prognostic signs 
for VA over three years. If a patient presents with a good VA, visual prognosis is 
favourable. Patients presenting with a visual acuity of 6/12 or better could retain 
good vision in the long run, but generally an improvement of more than 6/9 is rarely 
seen. However 80% of patients who present with a VA of 6/60 or worse are less 
likely to see any visual improvement over time when left untreated. (31)(32) A non-
ischaemic CRVO at presentation can convert to the ischaemic type with a reported 
conversion rate of 3.3% (range 0% to 27%) from non-ischemic to ischemic CRVO 4 
months after RVO and 34% by 3 years. (47) 
 
2.1.4 Complications and causes of visual loss with CRVO 
Complications of a RVO can compromise the visual prognosis of the affected eye 
through the development of retinal ischaemia, macular oedema, vitreous 
haemorrhage, neovascularisation and neovascular glaucoma as a result of hypoxic 
damage. Long term monitoring of eyes is required because complications can arise at 
or after presentation. (16)(31)(32)  
 
2.1.4.1 Macular oedema 
Macular oedema is essentially due to the breakdown of the blood retinal barrier, 
leaky capillaries and VEGF production. Fluid collects around photoreceptors in 
intercellular spaces in the outer plexiform layer. Following starling's law, osmosis 
and hydrostatic pressure processes, hypoxia causes dilation of arterioles reducing 
resistance and increased pressure in capillaries and venules pushing water out. 
Dilated vessels are therefore a sign of high hydrostatic pressure. Macular oedema 
can be observed on examination of both RVO types at presentation but is more 
commonly seen in eyes with a CRVO. Macular oedema can develop in an eye with a 
BRVO within one year if not present initially.(16) The impact of visual loss due to 
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macular oedema for patients is often significant. Increased levels of VEGF and IL-6 
appear to be involved in the pathogenesis of macular oedema at areas of non-
perfusion.(48) Published data detailing the percentage of eyes that develop macular 
oedema due to RVO varies depending on the study you read and can fall anywhere 
between 5-15% and 60% in some eyes. Macular oedema has been shown to resolve 
in approximately 18 to 41% of eyes within 4 and 7 and a half months without 
treatment but can take longer in eyes with a CRVO. (16)(31)(32)  
 
2.1.4.2 Neovascularisation 
Angiogenesis is the formation of new blood vessels from pre-existing ones. Factors 
stimulate receptors of endothelial cells (VEGFR) causing proteases (tyrosine kinase) 
that degrade the basement membrane of endothelial causing cells to escape and 
proliferate in the surrounding matrix space migrating using integrins connecting 
blood vessels. Neovascularisation or the formation of new blood vessels are more 
likely to develop in over half of eyes with greater than 4 disc diameters of retinal 
non-perfusion. (16)(31)(32) Ischemia triggers the release of factors (VEGF, PDGF, 
TGF-B, integrins, PAI-1 and FGF) that both inhibit and promote the ocular 
angiogenesis pathway of new vessel growth. Elevated levels of VEGF released from 
retinal cells. New vessels can develop on the iris (NVI), angle (NVA), optic disc 
(NVD) or elsewhere on the retina (NVE) from 0 to 20% over 8 to 9 months in 
ischaemic CRVO eyes.(49) The incidence of neovascularisation in eyes initially 
presenting as non-ischaemic CRVO ranges from 0 to 33% over 12 to 15 months in 
association with the late development of ischaemia which supports the need for long 
term follow up of eyes even with the absence of ischaemia on presentation.  These 
new blood vessels are fragile and can cause visually impairing vitreous haemorrhage 
when injured.(26) The development of vitreous haemorrhage has been reported to 
occur in 41% and 10% of BRVO and CRVO eyes respectively within 9 months of 
presentation.(16)(32)  
 
Peripheral anterior synechiae and progressive angle closure cause neovascular 
glaucoma (NVG) due to obstruction of the trabecular meshwork by a proliferation of 
fibrovascular tissue, including vessels over the trabecular meshwork associated with 
retinal ischemia. This causes intraocular pressure to rise, which is often difficult to 
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control, increasing the risk of visual loss for the patients. The cumulative incidences 
for NVI or NVG at 12 and 36 months were 6.1% and 8.5%, respectively in the 
SCORE-CRVO trial and 1.3% and 2.4% in the SCORE-BRVO trial.(50)(51) The 
CRVO Study(52) found that 10% of eyes with non-ischemic CRVO and 6% of eyes 
with ischemic CRVO had neovascularisation of the angle without iris new vessels.  
 
2.1.4.3 Fellow eye involvement 
RVO can present as unilateral or bilateral disease. Bilateral RVO is rare, affecting 
4.5 to 6.5% of BRVO eyes and between 0.4 and 4.3% for CRVO eyes. Patients with 
BRVO have a 10% chance of fellow eye involvement and 1.4% for CRVO eyes over 
3 years. 5% of CRVO cases developed a further RVO over a 1 year period.(16)(32)  
 
2.1.4.4 Morbidity and mortality 
RVO may be the first presenting feature of a systemic disease associated with 
significant morbidity and mortality. Investigations for associations such as 
cardiovascular disease risk factors on presentation of RVO. A higher cardiovascular 
mortality rate has been shown in patients aged under 70 presenting with RVO from 
pooled data from the BMES and BDES. 15.7% and 4.1% mortality due to 
cardiovascular and cerebrovascular disease over 12 years. Long term studies 
following RVO patients are needed to evaluate the possibility that RVO is associated 
with a higher long term risk of vascular mortality. (53) 
 
2.1.5 Current management options and guidelines for BRVO 
The management of RVO is aimed at preventing and treating complications that 
cause loss of vision and identifying and controlling risk factors.  
 
2.1.5.1 Referral for medical investigation and treatment of associated risk 
factors 
The Royal College of Ophthalmologists suggests appropriate tests for cardiovascular 
disease risk factors along with a medical referral should be made within 2 months of 
diagnosis  including the recommendation of lipid and glucose level control, blood 
pressure monitoring and weight reduction. The Framingham algorithm (1991) can 
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accurately determine cardiovascular risk to aid initiation of treatment for high risk 
patients appropriate to prevent disease recurrence and other potential sites of organ 
damage.(33) However updated NICE guidelines (2010) to say calculations based on 
the Framingham equation may overestimate risk in UK populations and recommends 
the use of QRISK or ASSIGN methods which are more applicable to our patients. 
ASSIGN was developed using a Scottish cohort and QRISK using data from UK general 
practice databases to evaluate 10 year risk. They include measures of social deprivation 
and family history in addition to age, ratio of serum total to HDL cholesterol, systolic 
BP, BMI, smoking status, and use of one or more BP treatments.(54)(55) When such 
cardiovascular risk factors are within a normal range, screening for coagulation 
disorders is warranted, especially in young patients, and patients presenting with 
bilateral disease who have a of previous or family history of thrombosis. (56) 
 
2.1.6 Current management options and guidelines for RVO 
Various treatments have been studied to manage the complications associated with 
BRVO as only 50% of eyes with BRVO will retain a VA of 6/12 or better without 
treatment. The management varies in the presence of macular oedema, 
neovascularisation and ischaemia. Even with the initiation of a treatment for either 
RVO type visual prognosis is guarded if the initial VA is poor. (16) 
 
The Royal College of Ophthalmologists published guidelines for the management of 
RVO in September 2010.(57) A summary of their recommendations and supporting 
evidence are described below.  
 
2.1.6.1 Management of Branch retinal vein occlusion 
Macular grid and sectoral panretinal photocoagulation (PRP)  
Early treatment benefits of retinal laser were first reported prior to 1974.(58) Laser 
works through the theory of destroying healthy retina coagulating photoreceptors and 
RPE leaving inner retina intact. Oxygen consumption and therefore demand of the 
retina is then reduced. The outer retina gets the majority of its supply from the 
choriocapillaris. Destroying the outer retina allows the inner retinal oxygen supply to 
increase. Increasing vascular diameters reducing oxygen tension. Increased oxygen 
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levels cause vasoconstriction and reduced flow. Laser causes vessels to constrict. 
(59) The Branch retinal vein occlusion study looked at grid laser treatment for 
macular oedema versus observation. Laser to treat macular oedema is beneficial for 
eyes with moderate visual loss (no worse than 6/60) when initiated early.  
 
Grid photocoagulation should be used to manage macular oedema after three to six 
months after presentation and after the majority of haemorrhages have disappeared. 
Multiple treatments may be required (59) The Branch Retinal Vein Occlusion 
study(60) showed that VA can improve by up to 1.33 lines by 3 years, compared to 
only 0.23 lines in untreated eyes with grid laser. However the effects of grid laser are 
associated with a guarded visual prognosis if a patient presents with a VA of worse 
than 6/60, macular ischaemia or if the treatment is delayed for more than 12 months. 
 burns of 50-100 micrometers in diameter with exposure of 0.05 to 0.1 
seconds were applied in a grid pattern to the macula - with burns no closer to 
the fovea than the edge of the foveal avascular zone and extending no further 
than the arcades.  Repeat treatments were performed as necessary.  
 
Sectoral argon photocoagulation applied to the area of capillary closure is used to 
manage neovascularisation in the presence of retinal ischaemia. 
 eyes without neovascularisation, treated eyes developed significantly less 
neovascularisation (P<0.009) than non-treated eyes over the course of 
follow-up (mean follow-up 3.7 years)  
 eyes with neovascularisation, treated eyes developed significantly less 
vitreous haemorrhage (P=0.005) 
 sectoral PRP was performed in the region of distribution of the affected vein. 
100 to 400 laser burns were applied with spot size 200 to 500 microns in 
diameter and exposure 0.1 to 0.2 seconds, avoiding the fovea and optic disc 
(60)(61) 
 Collaterals should be avoided and so should the foveal avascular zone 
 1200-1500 burns 0.5mm can reduce oxygen consumption by 20%. 
 
The results of the BVOS trial established macular grid laser as the Gold-Standard 
treatment for macular oedema due to branch retinal vein occlusions and sectoral 
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scatter PRP as the Gold-Standard treatment for prevention of neovascularisation and 
vitreous haemorrhage in branch vein occlusions.  Recent evidence suggests that 
newer treatment modalities may be more efficacious than laser in this condition. 
 
Steroids  
Triamcinolone is a potent steroid to improve vision, however effects of one injection 
are short lived and are associated with complications including cataract and ocular 
hypertension. (51) The Standard Care vs Corticosteroid for Retinal Vein Occlusion 
(SCORE) Study(51) showed that repeated doses of IVTA can reduce macular 
oedema and improve visual outcome far better than observation but does not provide 
a better alternative to standard care grid laser and associated with more adverse 
events. Small case series have shown a significant improvement of VA with the 
combined treatment of IVTA followed by laser photocoagulation in patients with 
macular oedema secondary to BRVO.(62) OFI can also be used to treat macular 
oedema due to RVO, however the effects are short lived.  
 
Ozurdex intravitreal dexamethasone implant for BRVO NICE have approved the use 
of the Ozurdex intravitreal implant for the management of macular oedema due to 
BRVO. Results from the Geneva study group showed 30% of eyes can achieve a >15 
letter improvement at day 60 and improvement in BCVA at day 180 is better than in 
un-treated eyes. Eyes with shorter durations of macular oedema fair better. (63) 
 
Anti-VEGF Agents  
Patients with RVO have higher vitreous vascular endothelial growth factor (VEGF) 
levels than patients with unaffected eyes. Currently anti-VEGF treatments are not 
licenced in the UK for the treatment of CRVO. 
 
Intravitreal Ranibizumab - Lucentis   
Lucentis is a fast, effective, well-tolerated and safe treatment for macular oedema 
secondary to RVO approved in the US to treat macular oedema due to RVO. (64) It 
is an antibody derived Fab fragment of Avastin, that stays in the vitreous for 29 days. 
The Ranibizumab for the treatment of macular oedema following Branch Retinal 
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Vein Occlusion (BRAVO) showed Lucentis provided 3 lines improvement (≥15 
ETDRS letters) in 61%, 55% and 29% were seen in 0.5 mg, 0.3 mg and control 
groups respectively. A rapid resolution of macular oedema (90% reduction in CRT) 
with low rates of associated adverse events were also found. At 12 months, 
improvements in VA were maintained in the initial Lucentis treatment groups. 
Macular oedema tended to recur between injections after 3 to 9 months. Risks 
include ocular (retinal tears, detachments and endophthalmitis) and systemic events 
(CVA, MI). Macular oedema recurs after 3-9 months. (65) 
 
Intravitreal Bevacizumab - Avastin is a VEGF inhibitor that rapidly accumulates on 
VEGF receptors on vessel walls and within photoreceptors at the fovea.(1) Macular 
oedema responds quickly to Avastin leading to near normal macula anatomy after 7 
days. Multiple injections are needed for significant short and long-term improvement 
of vision  associated with a low risk of serious adverse side effects. (66)(67) Macular 
oedema recurs in 65.2% patients within approximately 13.3 weeks. 33.3% resolve 
after another injection. Avastin should be started within 12 months after RVO. 
Rebound of macular oedema may be effectively avoided by waiting at least 8 weeks 
after the onset of RVO. Poor visual outcome is seen in eyes with longstanding 
BRVO. (68) Repeated Avastin injections are a possible treatment for eyes that do not 
respond to laser treatment, but is still currently unlicensed. Short term results are 
similar those obtained for grid laser, and offer only a small improvement when 
compared to grid laser photocoagulation.  
 
2.1.6.2 Management of Central retinal vein occlusion 
The Royal College separates the management of ischaemic and non-ischaemic 
CRVO into different management plans.  
Laser photocoagulation - macular grid and panretinal photocoagulation (PRP) 
Treatment with laser photocoagulation was based on the results of the CVOS 
randomized clinical trial. (47)(69)(53) Macular grid photocoagulation was effective 
in reducing evidence of macular oedema but did not improve visual acuity. 
Prophylactic PRP for non-ischemic CRVO did not prevent the development of iris 
neovascularization in eyes with 10 or more disc areas of retinal capillary non-
Page 44 of 162 
 
perfusion confirmed by FA but can reduces the patients peripheral visual field as a 
complication. Therefore it was demonstrated that it is safe to wait for the 
development of early iris neovascularization before applying PRP. 
 
Steroids 
Macular oedema can be managed with IVTA, although RCT suggesting this tested a 
form of IVTA that is not available in the UK (TRIVARIS). IVTA can increase VA, 
including reading vision but its effects are less so in ischaemic eyes. The SCORE 
Study(50) showed that IVTA is far better compared to observation for treating vision 
loss associated with macular oedema secondary to RVO, but is no different to grid 
laser. The effects of 1 dose of IVTA last less than 1 year and are associated with 
complications. cataract formation, rises in IOP which can be controlled by topical 
medication. The Ozurdex intravitreal dexamethasone implant is approved for use to 
treat macular oedema due to CRVO. 29% of eyes achieve a >15 letter gain in VA by 
day 60. (63) 
 
Anti-VEGF Agents  
Currently anti-VEGF treatments are not licensed in the UK for the treatment of 
CRVO. Lucentis is approved in America, monthly Lucentis injections significantly 
increased BCVA and reduced macular oedema, compared with sham. Repeated 
injections were necessary to maintain improved VA. (54)  
 
2.1.6.3 RVO treatment options discussion  
Differences in treatments used in current clinical practice and population types 
include in studies used to obtain support for the above treatments exist. 
 Early trials with laser treatments for BRVO waited three months before 
treatment in perfused eyes with less than 6/12 vision once the haemorrhage 
had all cleared. 
 SCORE trial investigating IVTA used a different non-dispersive preparation 
of the steroid to the type used in current clinical practice in the UK where the 
exact dose of the steroid administered into the eye is known.  
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 Duration of macular oedema included in trials differ that ultimately effects 
the visual prognosis with treatment. For example 40% of the SCORE 
population had CMO <3 months compared to 17% of the Geneva Ozurdex 
population. 
Results with Avastin appear promising but is not yet licenced for the treatment of 
RVO. Results of Efficacy and Safety head to head trials of Ranibizumab Versus 
Dexamethasone Intravitreal Implant in Patients With CRVO (COMRADE-C) and 
BRVO (COMRADE-B) as well as the efficacy of large combination treatment trials 
are awaited. 
 
In summary, where laser photocoagulation was the only beneficial treatment for 
macular oedema due to BRVO, newer treatments including the Ozurdex steroid 
implant and the various anti-VEGF agents have shown similar results. Where these 
new agents have come to afore is for the treatment of macular oedema secondary to 
CRVO where no treatment was proven to be of benefit in the past.   
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2.2 AIMS AND PURPOSE  
Despite significant improvements in the treatments available for uveitis, visual loss 
still occurs in up to 35–40% of these patients.(4) As part of the vision loss in uveitis 
programme, retinal vein occlusion was identified as a cause of visual loss in this 
population. The frequency of retinal vein occlusion among patients with uveitis is 
not known, patients with a history of uveitis tend to be excluded from studies of 
RVO.  
 
Oral steroids and second line immunosuppressive agents such as Cellcept and 
cyclosporin are used to manage inflammation associated with non-infectious uveitis 
affecting the posterior segments of the eye. However they are associated with 
undesirable side effects on blood pressure, insulin resistance, lipid profile, body 
weight, fat distribution and proteins involved in blood coagulation that significantly 
increase a patient's risk of CVD.(7)  
 
The purpose of the study is to determine the relationship between exposure to steroid 
treatments and other immunosuppressive agents, cardiovascular disease risk factors 
and RVO events in patients with uveitis. 
 
This study aims to: 
1. outline demographic and ocular examination features of RVO in uveitis 
patients  
2. identify whether cardiovascular disease risk factors such as hypertension and 
hyperlipidaemia are associated with an increased risk of RVO in uveitis 
patients  
3. to find an association between oral steroid and IS exposure within subgroups 
that differ in the status of inflammation on presentation of RVO to identify 
whether the steroid and immunosuppressant agents used to manage uveitis 
contribute to increasing a patient's cardiovascular disease risk profile 
4. outline visual outcome in these patients and complications including 
neovascularisation, vitreous haemorrhage and recurrence of disease.   
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2.3 METHODOLOGY  
2.3.1 Study Population 
Study participants were selected from those attending Moorfields Eye Hospital, a 
tertiary referral centre as part of the vision loss in uveitis programme (ethical 
approval LIGS1023 (Visual loss in uveitis)). Patients aged over 18 attending 
Professor Lightman's Uveitis clinic at Moorfields Eye hospital with a history of 
RVO were eligible for inclusion into the study. Patients were identified from a 
database of patients attending the uveitis clinic plus any new attendees during the 
study period from June 2008 to 2010.  
 
2.3.2 Data collection and definitions 
A retrospective review of consecutive medical records of patients who were 
diagnosed with a retinal vein occlusion was carried out. Demographic and clinical 
data from medical records were recorded on a proforma. Data included: age at onset 
of RVO, gender, eye(s) involved, presence and type of uveitis at RVO presentation, 
episodes of uveitis prior to, at and after RVO presentation, drug history including 
any steroid or immunosuppressant use at the time of diagnosis. Pre-defined co-
morbidities of particular interest included vascular risk factors such as smoking, 
hypertension, diabetes and hyperlipidaemia. 
 
Examination details recorded include: best corrected visual acuity prior to, at and 
after presentation of RVO (at 1,3,6,12,18 months and last recorded visit), associated 
ocular findings, date and location of RVO, location and severity of inflammation, 
duration of inflammation, prior and future episodes of uveitis activity, contributors 
visual loss. IOP was documented at presentation with specific reference to raised 
levels at baseline and changes over 1,3,6,12,18 months and last recorded visit. In 
addition, the presence of complications and surgical interventions were recorded 
including: macular oedema, neovascularisation, neovascular glaucoma and retinal 
detachment.  
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2.3.3 Definitions and classifications used in this study 
The following are defined/classified below: central, branch and hemispheric retinal 
vein occlusion, hypertension, diabetes, cardiovascular disease, uveitis, Sarcoidosis, 
Behçet’s disease, raised IOP, visual acuity, macular oedema. 
Age 
Current age was defined as the age at presentation of RVO. 
Drug History 
Medications were considered to be used if the patients were taking medication on a 
regular basis at the time of each ocular diagnosis. These determinations were based 
on historical chart notes at the time of diagnosis and not by later patient recall. 
Steroid medications 
All oral and intra/periocular steroid injections were included, all other methods of 
administration such as  inhaled, topical routes were excluded. Dates of 
administration and doses were recorded. 
Hypertension  
A history of hypertension was defined from the patient history if they were being 
followed up by a GP for high blood pressure and/or currently receiving 
antihypertensive medication. Hypertension at presentation was defined as a mean 
systolic blood pressure of 140mmHg or higher and/or a mean diastolic blood 
pressure of 90 mm Hg or higher and/or current use of antihypertensive medication at 
the time of RVO presentation.  
Cardiovascular disease  
CVD was defined as a history of angina pectoris, myocardial infarction, or stroke.  
Diabetes mellitus  
DM was defined as a history of previous diagnosis controlled by diet, oral 
hypoglycaemic medication or insulin.  
Smoking status 
Status was considered as ever or never. Statistical calculations were only performed 
on the total number of patients with documented smoking histories.  
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Uveitis  
Uveitis was classified
 
according to the Standardization of Uveitis Nomenclature 
criteria(5). If inflammatory cells were found in the anterior chamber, vitreous or 
retina/choroid the diagnosis of anterior, intermediate or posterior uveitis was made 
and/or a previous diagnosis was documented in the notes or in referral letters from 
other ophthalmology units. Panuveitis was defined by inflammatory cells present 
throughout the eye (anterior chamber, vitreous and the retina or choroid). 
Inflammation was classed as acute if sudden onset and of a limited duration, 
recurrent if repeated episodes occurred in between episodes of inactivity without 
treatment ≥3 months in duration or chronic if persistent with relapse in <3 months. 
Uveitis remission was defined as inactive disease for ≥3 months after discontinuing 
all treatments for eye disease.  
Sarcoidosis  
Clinical features of Sarcoid uveitis include: mutton-fat keratic precipitates, iris 
nodules, peripheral anterior or posterior synechiae, vitreous cellular infiltrates, 
opacities, haze, posterior vitreous detachment, multiple, yellowish, elevated 
choroidal lesions, snowballs (white opacities) in the anterior inferior vitreous and 
vasculitis. Diagnosis of Sarcoidosis was confirmed if serum ACE levels were raised, 
along with the presence of hilar lymphadenopathy,
 
pulmonary granulomas or a 
ground glass parenchymal appearance on chest xray if performed.  
Behçet's disease 
The classic fundus findings seen during ocular involvement in Behçet’s disease 
include: retinal vasculitis (both arteries and veins), venous engorgement, retinal 
haemorrhages, exudates, white focal retinal infiltrates and retinal oedema. Optic disc 
oedema and vitreous infiltrates are present in acute stages secondary to inflammation 
as are. sheathing of retinal vessels, chorioretinal scars and retinal and optic nerve 
atrophy may be present with repeated inflammation. 
Central retinal vein occlusion  
Central retinal vein occlusion was characterised by widespread scattered superficial
 
or deep retinal haemorrhages with or without optic disc hyperaemia
 
or oedema, 
retinal oedema, venous dilatation, or occluded and sheathed retinal veins. Further 
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sub-classification into non-ischaemic or ischaemic types were made based on the 
combined data from VA, slit lamp examination and FA.  
Branch retinal vein occlusion  
Branch retinal vein occlusion was characterised
 
by retinal haemorrhages occurring 
within the retinal sector corresponding
 
to the blood supply sector of the occluded 
venule.
 
The affected branch (superotemporal, inferotemporal, superonasal or 
inferonasal)
 
was documented.  
Hemispheric retinal vein occlusion  
Hemispheric retinal vein occlusion was classified when either the superior or inferior 
branch of the central vein was occluded creating fundal signs in the corresponding 
upper or lower half of the retina. Pathogenetically, central retinal vein occlusion and 
hemi-central retinal vein occlusion are identical in nature and were combined into a 
single group.  
Visual acuity (VA)  
Assessment of VA was measured using a Snellen chart viewed at six metres in the 
clinic. The Snellen chart is designed to measure visual acuity in angular units in 
which the numerator is the testing distance (in feet or meters), and the denominator 
is the distance at which a letter subtends the standard visual angle of 5 minutes of 
arc. The reciprocal of the Snellen fraction represents the minimum angle of 
resolution (MAR). The negative base 10 logarithm of the reciprocal Snellen fraction 
is the logarithm of the minimum angle of resolution (logMAR), which converts the 
geometric Snellen progression into a linear function. Baseline visual acuity was 
defined as the best corrected VA (BCVA) when vision is documented after 
correcting for refractive errors using a pinhole. 
 
VA was documented and converted to logMAR see Table 2-5.(70) When Snellen 
VA was documented as incomplete lines, the nearest complete line was used. 
LogMAR values of 2.00, 3.00, and 4.00 were substituted for VA levels reported as 
“count fingers,” “hand movements,” and “no light perception,” respectively. A 
change of at least 3 Snellen lines, equivalent to a LogMAR 0.30, was considered a 
significant change. For evaluation purposes, patients were classified into three 
categories based on changes in VA after RVO: normal (6/12 or better), visual 
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impairment (6/12 or worse but better than 6/60) or severe visual loss (worse than 
6/60)) in the effected eye.  
LogMAR Snellen Equivalent 6 Metres 
-0.3 3 
-0.2 3.8 
-0.1 4.8 
0 6 
0.1 7.5 
0.18 9 
0.2 9.6 
0.3 12 
0.4 5 
0.48 18 
0.5 18.9 
0.54 21 
0.6 24 
0.7 30 
0.76 34.2 
0.8 37.5 
0.88 45 
0.9 48 
1 60 
2 600 
3 6000 
LogMAR = logarithm of the minimum angle of 
resolution 
Table 2-5: LogMAR and snellen visual acuity conversion table 
 
Raised Intra ocular pressure  
Raised IOP was diagnosed when greater than 21mmHg on Goldmann applanation 
tonometry. Glaucoma was defined if previously known and/or the patient was using 
topical or oral intraocular pressure lowering medication. Ocular hypertension was 
diagnosed in participants with no characteristic glaucomatous optic disc changes 
present with an intraocular pressure greater than 21 mmHg in the effected eye. 
Rubeotic, secondary or angle closure glaucoma were also documented. 
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Macular oedema   
Macular oedema is the accumulation of extracellular fluid in the outer plexiform 
layer of the retina. Visual acuity depends on the macular function. Poor visual acuity 
in RVO primarily is the result of macular oedema. Evaluation of the macular oedema 
could be made on clinical examination and confirmed by further imaging (FA and/or 
OCT) where appropriate.  
 
2.3.4 Statistical analysis used in this study 
Demographic and clinical variables were charted using a standardized data collection 
paper. Data were entered into a computer database and analyzed using SPSS and 
Excel. A chi-square test was used for all categorical variables and t tests were used 
for continuous variables. Fisher exact test was used when the sample number was 
less than five. Complication parameters were summarised and calculated including 
patients with BCVA improvements. Differences in risk factors, type of RVO and 
complications were investigated for all patients with the chi-square test. A P value 
<0.05 was considered statistically significant when comparing variables.   
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2.4 RESULTS 
Between June 2008 and June 2010 a total of 2023 patients with uveitis were 
examined at Professor Lightman's uveitis clinic at Moorfields Eye Hospital. A 
history of RVO was documented in 37 patient's notes or a new event during the 
study period, giving a prevalence of 1.83% for RVO in our study population. A total 
of 29 patients were included in this study. Demographic and baseline characteristics 
for these patients are shown in Table 2-6 at each RVO event. 8 patients were 
excluded from any further analysis in this study either because presenting baseline 
characteristics at the time of RVO were not available from their medical notes or 
because the notes were not located.  
 
 
 
 
 
 
 
2.4.1 Demographic details of patients with a history of RVO 
2.4.1.1 Age at presentation  
The average age at presentation of RVO in our uveitis population was mean 54.44 
years, median 58 years, (SD±15.03) (95% CI of the mean 49.20 - 59.69 years) and 
ranged from 25 to 79 years, see Table 2-6. No patients in our study population were 
aged over 80 years. Distribution of ages for all RVO events are shown in Figure 2-1, 
and according to RVO type in Figure 2-2 and Figure 2-3. No significant association 
between presenting age and RVO type were found (t test p=0.92).  
Characteristics 
All RVO  
(n=34) 
BRVO 
(n=25) 
CRVO 
(n=9) 
Mean age at presentation 
(years) 
54.44 54 55 
% Right eyes 50% 52% 44%  
% Male patients 53% 52% 56% 
Table 2-6: Baseline gender and age characteristics for all retinal vein occlusions (RVO) types 
and events. BRVO = branch retinal vein occlusion, CRVO = central retinal vein occlusion 
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Figure 2-1: Distribution of ages of patients with retinal vein occlusion (RVO) 
 
 
Figure 2-2: Distribution of ages of patients with branch retinal vein occlusion (BRVO) 
 
 
Figure 2-3: Distribution of ages of patients with central retinal vein occlusion (CRVO) 
44% 
32% 
40% 
20% 
Distribution of ages of patients with 
BRVO  
Patients <50 
Patients ≥50-59  
Patients ≥60-69  
Patients ≥70-79  
33% 
22% 
33% 
11% 
Distribution of ages of patients with 
CRVO  
Patients <50 
Patients ≥50-59  
Patients ≥60-69  
Patients ≥70-79  
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2.4.1.2 Gender and RVO 
Of 34 RVO events 53% occurred in male patients, see Table 2-6. There were no 
significant associations between gender and RVO type (x
2
 p=0.85).   
 
2.4.2 Ocular examination findings on presentation of RVO 
Of 34 RVO events, a history of BRVO was the most frequent presenting RVO type 
see Figure 2-4. There were no significant associations between RVO type and eye 
affected (x
2
 p=0.35). From our sample population 2(6.9%) patients had a history of 
bilateral RVO and 10.34% with recurrent disease. All analysis from hereon have 
been calculated by RVO event including these bilateral and recurrent events (total 
number of RVO events =34) unless specified otherwise. 
 
 
Figure 2-4: Percentage of eyes with CRVO = central retinal vein occlusion and BRVO = branch 
retinal vein occlusion 
 
2.4.2.1 Visual acuity at presentation  
76% of patients were symptomatic of one or more of the following: reduced vision, 
floaters, blurred vision or pain, on presentation of RVO. Mean presenting visual 
acuity was poor, 0.78 and 0.80 LogMAR for BRVO and CRVO eyes respectively, 
see Table 2-7. However no statistical significance between mean presenting 
LogMAR VA were found between RVO type (unpaired t test p=0.99). 
 
 
Page 56 of 162 
 
LogMAR BCVA BRVO (n=20) CRVO(n=8) 
Mean 0.78 0.80 
Median 0.3 0.5 
SD 0.98 0.83 
SEM 0.22 0.30 
95% CI 0.32-1.24 0.10-1.50 
Table 2-7: Unilateral retinal vein occlusion by type and presenting LogMAR best corrected 
visual acuity (BCVA) BRVO = branch retinal vein occlusion, CRVO = central retinal vein 
occlusion 
 
2.4.2.2 Quadrant involved in BRVO 
Frequency of quadrant involvement in BRVO are shown in Figure 2-5. 
Superotemporal BRVO counted for a total of 38% of all RVO events in our study 
population. Patients with bilateral BRVO had involvement of different retinal vein 
branches in either eye. One patient had a superonasal BRVO in one eye and an 
inferonasal BRVO in the other, whilst the other patient had an inferotemporal BRVO 
in one eye and superotemporal BRVO in the other. Involvement of nasal branches 
were commonly an incidental finding on routine follow up appointments. 
 
 
Figure 2-5: Distribution of quadrants involved in branch retinal vein occlusions (BRVO) 
 
2.4.2.3 Other associated examination findings 
Other ocular examination findings documented on presentation of RVO are 
summarised in order of frequency in Table 2-8. 
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Ocular findings 
Number 
of eyes 
No inflammation 13 
AC Cells 10 
Vitritis 11 
Macular oedema 8 
Vasculitis 4 
Cotton wool spots 4 
Vascular sheathing 1 
Exudates 1 
Neovascularisation 1 
Retinitis 1 
Retinal Oedema 1 
Choroidal lesions 1 
Table 2-8: Ocular findings at presentation of RVO in uveitis patients 
 
2.4.2.4 Uveitis history 
The percentage of patients with RVO by uveitis classification are shown in Table 
2-9. A history of posterior or panuveitis was the most common uveitis type 
associated with RVO in our population in Table 2-9. 18(52.94%) eyes had signs of 
active intraocular inflammation on presentation of RVO of which 78% had a history 
of pan or posterior uveitis.  
 
Uveitis type All RVO BRVO CRVO 
Anterior uveitis 6% 4% 11% 
Intermediate uveitis 21% 29% 0% 
Pan/posterior 
uveitis 
55% 50% 67% 
Table 2-9: Distribution of uveitis type and retinal vein occlusion type. BRVO=branch retinal 
vein occlusion, CRVO=central retinal vein occlusion 
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Figure 2-6: Percentage of retinal vein occlusion (RVO) events by uveitis type 
 
Systemic inflammatory conditions including Sarcoidosis or Behçet's disease were 
associated with 13(38.24%) RVO events, see Table 2-10, with not quite a significant 
difference between presenting RVO type (x
2
 p=0.07). Patients with Behçet’s disease 
were younger, mean 42.17 years (SD11.84) compared to the rest of the sample 
population with RVO, mean 56.96 years (SD 14.58) (unpaired t test p=0.03). 57% 
and 83% of Sarcoid and Behçet's patients respectively had active intraocular 
inflammation, with no significant difference between RVO type (x
2
 p=0.56). 
 
 Sarcoidosis Behçet's disease 
Total number of eyes with a history of RVO 7 6 
Mean age of patients at presentation of RVO (years) 54.86 (SD21.26) 42.17 (SD 11.84) 
Number of BRVO:CRVO events 7:0 3:3 
Table 2-10: Characteristics of retinal vein occlusions associated with Sarcoidosis or Behçet's 
disease 
 
2.4.3 Presence of risk factors for retinal vein occlusion 
Known risk factors for RVO include ocular hypertension, systemic inflammatory 
diseases such as Sarcoidosis and Behçet's disease and cardiovascular disease risk 
factors including hypertension, hyperlipidaemia and diabetes). A matrix of results 
are shown in Table 2-11. Raised intraocular pressure was present in 5(14.7%) eyes at 
6% 
21% 
56% 
Percentage of uveitis type associated with eyes 
presenting with RVO 
Anterior uveitis 
Intermediate uveitis 
Posterior/panuveitis 
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presentation of RVO of which 2 patients had a history of glaucoma or uncontrolled 
ocular hypertension.  
 
 Raised 
IOP 
Active 
inflammation 
Presence of 1 
CVD risk factor 
Hypertension Hyperlipidaemia Diabetes History of 
steroid/IS use 
Age <50 1(20%) 8(47%) 3(23%) 1(11%) 3(27%) 1(25%) 8(44%) 
Raised IOP 5(14.7
% of 
all 
eyes) 
2(12%) 4(31%) 3(33%) 3(27%) 0(0%) 3(17%) 
Active 
inflammation 
2 17(50% of all 
eyes) 
4(31%) 1(11%) 4(26%) 2(50%) 10(56%) 
Presence of 1 
CVD risk factor 
4 4 13(38% of all 
eyes) 
9(100%) 11(100%) 4(100%) 11(61%) 
Hypertension 3 1 9 9(26.5% of 
all eyes) 
7(64%) 2(50%) 8(44%) 
Hyperlipidaemia 3 4 11 7 11(32% of all 
eyes) 
2(50%) 8(44%) 
Diabetes 0 2 4 2 2 4(11.8% 
of all 
eyes) 
2(11%) 
History of 
steroid/IS use 
3 10 11 8 8 2 18(53% of all 
eyes) 
Table 2-11: Systemic and ocular risk factors on presentation of RVO. IOP=intraocular 
pressure, CVD = cardiovascular disease 
 
Table 2-12 shows the significance of associations between cardiovascular disease 
risk factors and RVO type. 
Risk Factors 
 
All RVO 
events 
(n=34) 
 
BRVO  
(n=25) 
 
CRVO  
(n=9) 
Significance of risk factor between RVO 
type 
(Fishers exact test/x
2
) 
Smoking 9(26%) 9(36%) 0 P=0.07 
Hypertension 13(38%) 9(36%) 4(44%) P=0.70 
Hyperlipidaemia 9(26%) 7(28%) 2(22%) P=1.00 
Diabetes 2(6%) 2(8%) 0 P=1.00 
Table 2-12: Frequency of cardiovascular  disease risk factors for both retinal vein occlusion types, 
BRVO=branch retinal vein occlusion, CRVO = central retinal vein occlusion 
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Mean age of patients presenting with RVO in the presence of a cardiovascular 
disease risk factor are significantly greater (mean 60.95 years SD 10.25) than 
patients without (mean 44.93 years SD 14.20) (unpaired t test p=0.0013). A history 
of hypertension was a common presenting feature present in older patients compared 
to patients presenting with RVO without a history of hypertension, see Table 2-13. 
7(20.59%) patients had raised blood pressure documented on presentation and 57% 
of these patients were already taking anti-hypertensive treatment.  
Cardiovascular 
risk factor 
Mean age if risk 
factor present (SD) 
Mean age if risk 
factor absent 
Significance between 
groups (unpaired t test) 
Smoking 60.89(4.65) 52.00(16.86) P=0.13 
Hypertension 63.69(8.83) 48.38(15.30) P=0.0025 
Hyperlipidaemia 61.44(14.07) 51.80(14.89) P=0.10 
Diabetes 51.00(4.24) 54.56(15.53) P=0.75 
Table 2-13: Cardiovascular risk factor by age(years) for all retinal vein occlusion events 
Analysis between eyes presenting with and without inflammation and RVO are 
shown in Table 2-14. These results also show that the presence of a CVD risk factor 
is more frequently found in a patient with no intraocular inflammation on 
presentation of RVO, of which hypertension is very nearly a significant association 
in this uveitis population. 
Characteristics No-inflammation (n=17) Inflammation (n=17) Fischer's/x
2
  
Mean age (years) 
Median 
Range 
95%CI 
58.24 
60 
25-79 
54.12-65.35 
50.47 
55 
26-78 
42.40-58.54 
Unpaired T test  
P=0.14 
Gender %male 12(71%) 6(35%) P=0.084 
BRVO: CRVO 12:5 13:4 P=1.000 
Sarcoidosis or Behçet's 5(29%) 8(47%) P=0.481 
1 CVD risk factor 9(53%) 4(29%) P=0.296 
Hypertension 8(48%) 1(12%) P=0.057 
Hyperlipidaemia 7(41%) 4(24%) P=0.465 
Diabetes 2(12%) 2(12%) P=1.000 
Previous or current steroid 
use 
8(47%) 10(59%) P=0.732 
Table 2-14: Characteristics of eyes presenting with or without active intraocular inflammation 
and RVO 
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2.4.4 Oral steroids/immunosuppressive agents and cardiovascular 
disease risk factors 
Prior to presenting with a RVO, 24(70.59%) patients had a past drug history 
documented in their medical notes. 16(66.67%) had a history of oral steroid use. 
Mean presenting age of patients on steroid treatment was 52.60 years (SD 15.83) 
compared to patients with RVO not on steroid treatments at presentation of RVO, 
mean 55.08 years (SD 15.07) (unpaired t test p=0.28). Oral steroid use was not 
associated with active inflammation on presentation of RVO when compared to non-
steroid use RVO events from our study population (x
2
 p=0.43).  
 
14(41.17%) of RVO events were associated with at least one cardiovascular disease 
risk factor. Steroid of IS use was associated with 61% of patients with at least one 
CVD risk factor.  
 
 Steroid /IS use N=18  Non-steroid/ IS use N=16  
1 CVD risk factor  61%  38%  
Hypertension  44%  25%  
Hyperlipidaemia  44%  25%  
Diabetes  11%  0%  
Sarcoid or Behçet's disease 39%  31%  
Table 2-15: History of steroid  or immunosuppressant use and risk factors at RVO presentation 
 
Table 2-16 shows a sub-group analysis of 17 patients without inflammation on 
presentation of RVO. A previous history of steroid/IS use was associated with  a 
higher percentage of patients with at least 1 CVD risk factor compared to patients 
with no prior steroid/IS use  (Fischer’s p=0.0406). 
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Characteristics Steroid/IS 
n=8 
No steroid/IS 
n=9 
Statistical significance 
(Fischer's/x
2
) 
Mean age (years) 
Median 
Range 
95%CI 
60.38 
64 
31-79 
47.29-73.46 
56.33 
58 
25-69 
46.60-66.07 
Unpaired t test 
P=0.565 
Gender %male 5(63%) 7(78%) P=0.620 
BRVO: CRVO 6:2 6:3 P=1.000 
Sarcoidosis or 
Behçet's 
4(50%) 1(11%) P=0.131 
1 CVD risk factor 6(75%) 3(33%) P=1.000 
Hypertension 5(63%) 2(22%) P=0.153 
Hyperlipidaemia 5(63%) 2(22%) P=0.153 
Diabetes 2(25%) 0(0%) P=0.206 
Table 2-16: Sub-group analysis of patients with no inflammation on presentation of retinal vein 
occlusion and steroid/IS use 
 
2.4.5 Visual outcome and complications of RVO in this uveitis 
population 
Prognosis after RVO was measured by known complications associated with RVO 
including, visual loss, disease recurrence, ischaemia, macular oedema, vitreous 
haemorrhage and neovascularisation over a mean 39.47 months of follow up, range 0 
to 128.7 months. 
 
2.4.5.1 Visual loss and visual impairment 
Changes in BCVA over time for both unilateral RVO types are shown in Figure 2-7. 
After one year of follow up, 50% of all eyes (n=18) saw an improvement in BCVA 
from baseline. Over half of all patients with BRVO improved vision in the effected 
eye after one year.  
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Figure 2-7: Changes in LogMAR best corrected visual acuity (BCVA) of retinal vein occlusion 
types from presentation and 1,3,6,12 and 18 months follow up. BRVO=branch retinal  vein 
occlusion, CRVO = central retinal vein occlusion. 
 
2.4.5.2 Ischaemic RVO 
3 patients presented with ischaemic CRVO, all in left eyes, see Table 2-17. 2 patients 
had a history of systemic inflammatory disease, one in combination with anti-
phospholipid syndrome, and another with two cardiovascular disease risk factors. No 
patients converted from non-ischaemic to ischaemic CRVO over mean 32.55 months 
of follow up (range 8.9 months to 88.9 months). 
 
CRVO type 
Mean 
Age 
Male:female 
ratio 
Mean presenting 
LogMAR BCVA 
Mean LogMAR 
BCVA at 1 year 
Ischaemic (n=3) 45 1:2 1.73 2.00 
Non-ischaemic 
(n=6) 
57.8 1:3 0.29 0.84 
Table 2-17: Characteristics of ischaemic and non-ischaemic central retinal vein occlusion 
(CRVO) events BCVA = best corrected visual acuity 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
1.8 
Lo
gM
A
R
 B
C
V
A
 
Follow up time periods 
Change in LogMAR BCVA of RVO types from baseline 
BRVO 
CRVO 
Page 64 of 162 
 
2.4.5.3 Development of macular oedema 
Macular oedema was present in 36%  eyes at presentation, with no significant 
difference between RVO type (x
2
 p=0.20). Age of patients with macular oedema at 
presentation was not statistically significant, mean 50.89 years (SD15.74) when 
compared to subjects without macular oedema, mean 55.60 years (SD14.99) 
(unpaired t test p=0.43). Macular oedema resolved in 4 eyes by 1 month, persisted in 
5 eyes, and two eyes developed oedema at 1 month after presenting with RVO. 
7(29.17%) eyes that did not develop macular oedema during follow up belonged to 
patients that were on steroid or immunosuppressant treatments. Time for macular 
oedema to resolve in untreated eyes ranged from a month to 1 year and 1 to 4 months 
in CRVO and BRVO eyes respectively. Late development of macular oedema 
occurred in 14% of eyes which resolved after approximately 1 month to 3 years later. 
CRVO eyes that later developed macular oedema during follow up, resolved after 2 
and 7 months with no interventions.  
 
2.4.5.4 Development of vitreous haemorrhage 
2 eyes with CRVO developed vitreous haemorrhage, one was in an eye with 
recurrent RVO. The other belonged to a female patient under 50, with Lupus and 
APS, presenting with macular oedema and active ocular inflammation, whilst on 
steroid treatment. VH in this case persisted for 4 years resulting in HM vision. No 
BRVO eyes developed vitreous haemorrhage. 
 at presentation RVO Developed later 
Macular oedema 5(20%) BRVO 14% BRVO within 1 month to 1 year 
 3(38%) CRVO eyes at 
presentation 
 2(25%) CRVO, one at 3 and the other at 6 
months 
Vitreous 
haemorrhage 
2 CRVO 1  after 3 months  
Neovascularisation 1 CRVO 1 CRVO after a month 
Collaterals 2(25%) CRVO  1(13%) CRVO after 6 months  
 2(10%) BRVO 
Ischaemic CRVO 3 0 
Table 2-18: Complications associated with retinal vein occlusion in uveitis patients 
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2.4.5.5 Development of neovascular outcomes 
Development of new vessels at the disc or elsewhere on the retina were found in 
2(6.25%) eyes with CRVO. No eyes developed neovascular glaucoma during mean 
35.37 months follow up, range 8.9 to 88.9 months. Neovascularisation and 
neovascular glaucoma did not occur in any eye with BRVO. 
 
2.4.5.6 Disease recurrence and fellow eye involvement 
Of our uveitis patients with RVO, 3(10%) patients had a second
 
RVO episode in the 
fellow eye within an average of 31 months follow up. One patient presented with a 
left BRVO then subsequently a right BRVO 4 years later. Another patient presented 
with a left CRVO then a right CRVO 2 years later and another with a right BRVO 
then left CRVO and BRVO within 2 years.  
 
2.4.5.7 Treatments used to improve vision after RVO 
An OFI was administered to one patient 6 months after RVO, with no adjunct steroid 
treatment after presenting with 6/6 vision which deteriorated with continuing 
inflammation. One patient required IVTA 6 months after RVO after presenting with 
1/60 vision and macular oedema, their final VA was improved to 3/60. Another 
patient was administered an IVTA at presentation of RVO with BCVA of CF which 
improved to 6/36 by 1 month and 6/18 by the last visit.  
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2.5 DISCUSSION  
This study reports the characteristics of RVO in uveitis patients and highlights the 
risk of cardiovascular disease risk factors in patients treated with steroids and 
immunosuppressive agents in the absence of inflammation.  
 
2.5.1.1 Similarities of demographic and examination findings 
Similarities were found between this cohort of patients with those included in 
general population studies. In this population, BRVO occurred 2.78 times more 
frequently than CRVO. In general population studies BRVO prevalence is much 
higher than CRVO by 3 to 10 times (50, 72). The prevalence of RVO in our 
population was 1.83%, which is similar to 1.89% in the BMES but a lot higher than 
many of the other larger studies shown in Table 2-19.  
 
Population study All RVO BRVO (n)(%) CRVO(n)(%) 
ARIC 23 of 12,604 19(0.1)  4(0.03)  
Beaver Dam 37 of 4792 29(0.6) 8(0.2) 
Beijing Eye Study 35 of 4439 31(0.7) 5(0.1) 
Blue Mountains Eye study 67 of 3542 50(1.4) 17(0.4) 
Cardiovascular health  study 8 of 2824 7(0.2) 1(0.03) 
EUREYE 39 of 4753 30(0.6) 9(0.2) 
Los Angeles Latino Eye Study 58 of 6013 51(0.8) 7(0.1) 
Rotterdam Eye Study 39 of 6418 34(0.5) 6(0.1) 
Shihpai Eye Study 22 if 1058 19(1.8) 3(0.3) 
Singapore Malay Eye Study 22 of 3265 18(0.6) 5(0.2) 
Table 2-19: Prevalence of retinal vein occlusion types from population studies. BRVO=branch 
retinal vein occlusion, CRVO = central retinal vein occlusion, ARIC= The Atherosclerosis Risk  in 
Communities.(17,28,71–75)  
 
Age and gender 
In the general population average presenting age at RVO lies between 65 and 68 
years. (109, 172), see Table 2-20. 53% of patients presenting with CRVO present 
over 80 years and only 2%-9% are aged under 50. Patients with BRVO have been 
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shown to present younger (less than 70) compared to those with CRVO (46% vs 
13%). (51)(52)(173)(104) The average age at presentation of RVO in our uveitis 
population was younger than the general population, mean 54 years. 32% of our 
uveitis population presented with RVO aged under 50. No patients presented with 
RVO over the age of 80. This is significant as older age (over 70) is associated with 
different risk factors for RVO such as hypertension and visual prognosis.(106)  
 
Age group (years) SMES  BES BDES  BMES  MESA  ARIC  
Mean prevalence 0.7 (0.4 to 1.0) 1.3  0.8 1.6 1.1  
 40 to 49 0.1(0.0 to 0.4) 0.3 0.3  0.3 < 60 
 0.1 50 to 59 0.5 (0.1 to 1.0) 1.3 0.4 0.7 1.1 
60 to 69 1.2 (0.4 to 1.9) 2.1 1.2 1.2 1.5 0.3 
 ≥70 1.0 (0.2 to 1.7) 2.8 1.9 2.1 1.3 0.6 
 p for trend  0.01   <0.0001   <0.001 
Table 2-20: Age prevalence of retinal vein occlusion from population studies. (SMES=Singapore 
Malay Eye Study, BES=Beijing Eye Study, BDES=Beaver Dam Eye Study, BMES=Blue 
Mountains Eye Study,  MESA=Multi-Ethnic Study of Atherosclerosis, ARIC=The 
Atherosclerosis Risk  in Communities & Cardiovascular Health studies)(17,19,28,71,74) 
 
VA at presentation compared to general population studies 
Poor presenting visual acuity of our uveitis patients were associated with prior poor 
VA, male patients, CRVO, presence of ischaemia, macular oedema, amblyopia, 
vitreous haemorrhage, ERM and cataract. Presenting VA was poor in eyes with 
BRVO in older patients (over 50 years) and conversely worse in younger patients 
(under 50) in eyes with CRVO. Other factors are shown in Table 2-21. Eyes with 
chronic damage due to irreversible complications of uveitis prior to presenting with 
RVO would have a guarded prognosis. 60% of patients from the BMES had a VA of 
6/60 or less with CRVO, and 14% with BRVO.(17) 
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Age and macular 
oedema 
All RVO BRVO CRVO 
Age <50 years 0.57(n=11) 0.33(n=8) 1.32(n=3) 
Age >50 years  0.72(n=16) 0.80(n=11) 0.54(n=5) 
Macular oedema 1.43(n=8) 1.44(n=4) 1.42(n=4) 
No-macular oedema 0.34(n=19) 0.38(n=14) 0.17(n=4) 
Table 2-21: The effect of macular oedema, steroids and age on presenting LogMAR best 
corrected visual acuity 
 
2.5.1.2 Steroids/IS agents and cardiovascular disease risk factors 
Oral steroids and second line immunosuppressive (IS) agents used to manage uveitis 
can influence such risk factors including blood pressure, insulin resistance and lipid 
profile to significantly increase a patient's risk of CVD.(7) In the general population 
these factors are also known to contribute to a high risk for RVO due to 
atherosclerotic vessel damage.(39,46,71) Results from this study showed that 
patients presenting without inflammation and RVO with a previous history of oral 
steroid/IS use were associated with at least 1 CVD risk factor compared to patients 
with no prior steroid/IS use. Similarities can be drawn with other conditions where 
steroid treatments display pro-atherogenic effects increasing CVD disease risk 
factors in patients with SLE(76), ankylosing spondylitis, rheumatoid and psoriatic 
arthritis.(7)(77)(78)  
 
This study highlights the need for uveitis patients that require oral steroid/IS agents 
be assessed as high risk for CVD  compared to the normal population which would 
aim to prevent their future risk of RVO. Current methods of assessing patient's CVD 
risk for the general population may not accurately predict CVD risk for these 
patients due to their relatively younger age, which would be used if a patient suffers 
from a RVO. Therefore it is proposed that uveitis patients that require oral steroids 
be assess for CVD risk factors early and managed aggressively to prevent CVD 
events including RVO and its complications. 
 
2.5.1.3 Prognosis - visual outcome and complications 
The difference between mean BCVA at 1 year by RVO type was found to be 
statistically significant (unpaired t test p=0.047). Worse visual outcome was 
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associated with CRVO eyes compared with BRVO eyes, 1.15 and 0.30 LogMAR 
units respectively. CRVO patients generally see a decline in VA over time, 50% of 
uveitis patients with CRVO get worse see Table 2-22 attributable to ischaemic 
damage to the retina. There were no significant findings with the presence of 
inflammation or steroid use at one year see Table 2-23.  
 
 
All RVO 
(n=18)(%) 
BRVO 
(n=12)(%) 
CRVO 
(n=6)(%) 
Improve 9(50) 7(58.3) 2(33.3) 
Stable 4(22.2) 3(25) 1(16.7) 
Worse 5(27.8) 2(16.7) 3(50) 
Table 2-22: Changes in visual acuity in eyes with retinal vein occlusion (RVO) from baseline to 
1 year. BRVO = branch retinal vein occlusion, CRVO = central retinal vein occlusion 
 
Macular oedema might be another reason for the poor visual outcome in our 
population. If left untreated or undertreated, macular oedema may result in 
permanent photoreceptor damage of the macula and loss of central vision. (181) 
Macular oedema was present in 36% of eyes, with similar levels found for patients 
with intermediate, posterior and panuveitis. Macular oedema was associated with 
active inflammation in 17% of eyes. The development of macular oedema secondary 
to RVO in patients with uveitis, without active inflammation in 10% of cases could 
be due to RVO and not secondary to uveitis, macular oedema has been reported to 
occur in 20% to 44% of patients with intermediate uveitis and is a major cause of 
visual loss.(178-179) A lack of significant association could be as a result of the 
retrospective and size limitations of this study.  
 
The majority of patients on steroids at the time of RVO presented with a poor VA 
compared to patients not on steroid treatment (mean logMAR 0.7 Vs 0.63). CRVO 
patients on steroids had worse than 3 lines difference in presenting BCVA compared 
to patients not on steroids. 
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Risk factor LogMAR BCVA SD Unpaired t test 
comparison of means 
Intermediate uveitis 0.83 1.02  
Pan/posterior uveitis 0.83 1.18 
Idiopathic uveitis 0.54 1.16 
Age <50 years 0.44 1.02 P=0.67 
Age >50 years 0.63 0.98 
Active inflammation 0.74 1.12 P=0.46 
No-inflammation 0.42 0.78 
Systemic inflammatory disease 0.16 0.38 P=0.12 
No systemic inflammatory disease 0.84 1.13 
Steroids 0.83 1.27 P=0.35 
No steroids 0.43 0.71 
Hypertension history 0.40 0.75 P=0.50 
No Hypertension history 0.70 1.09 
Table 2-23: Ocular and systemic risk factors for retinal vein occlusion and best corrected visual 
acuity (BCVA) at 1 year of follow up where available 
 
In uveitis patients it appears overall, only 58% of eyes see an improvement in VA 
over time. Prior damage due to uveitis and its complications including macular 
oedema and retina ischaemia could not be properly studied here because previous 
data was not present in all patients prior to presenting with RVO. Thus the influence 
on the visual prognosis and severity of ocular injury may not be solely attributed to 
RVO alone. Also the contribution of other ocular risk factors such age related 
macular degeneration and cataract would favour a poor VA. Populations which 
excluded uveitis patients, they report macular oedema develops in around 5-15% of 
patients. Macular oedema 18-40% is at presentation resolve, 18% resolve in 4.5 
months, 41% by 7.5 months.23% of BRVO patients have macular oedema which is 
usually observed, and takes roughly 1-4 months to resolve.  
 
The strengths and limitations of this study 
Retrospective studies are useful in investigating diseases of low incidence, however 
the availability and integrity of medical records can be a concern of this method. 
Page 71 of 162 
 
Owing to this study design there was no control over how the original data was 
collected and therefore dependent on what the Ophthalmologist decided to document 
at the time of consultation, which could be biased to include or not include certain 
pieces of information that would later be relevant for this study.  
 
Again, the reliability and validity of medical record review for steroid and IS 
exposure are dependent upon completeness and accuracy of data documentation 
within the medical records by the consulting Ophthalmologist. Attempts were made 
to reduce this recall bias by scrutinising supporting documentation in medical 
records, drug prescriptions, GP summary forms and assumed all patients were 
compliant with their medication. Ultimately, these retrospective data cannot be used 
to determine causality between steroids/IS agents and CVD in uveitis. Longer term 
studies of this or similar populations would be warranted to document cardiovascular 
disease mortality and morbidity in this group of patients with a longer duration of 
steroid use in a patient's life time beyond this study period as well as observing 
future ocular complications associated with RVO.   
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2.6 SUMMARY OF RESULTS  
This study emphasises RVO as a cause of unilateral visual loss in this younger 
uveitis population. Although inflammation should be controlled to prevent further 
intraocular damage, the agents used to do so are associated can increase a patient's 
risk of various cardiovascular disease risk factors which in turn contribute to a high 
risk of RVO and visual loss associated with its complications. The study also 
provides information on presentation and 1 year prognosis of RVO in uveitis 
patients.  
 
From a population of 2023 patients with uveitis a prevalence of 1.83% for a new or 
previous history of RVO was found. Mean age at presentation for any RVO event in 
this population was 54 years. Similarities to general populations studies such as the 
Blue mountain eye study were found including: BRVO occur more frequently than 
CRVO, the superotemporal branch was the most common vein involved in BRVO, a 
small percentage of patients present with bilateral RVO and no relationships between 
eye or gender was found. Diabetes, haematological disorders and raised intraocular 
pressure were not common predisposing factors for the development of RVO in 
these uveitis patients. 
 
Ocular features of RVO in this population included 38.24% with no associated 
intraocular inflammation on presentation of RVO, 55% had a history of pan or 
posterior uveitis. Macular oedema was present in 24% of eyes. Mean presenting 
visual acuity was poor in the affected eye 0.79 LogMAR and ranged from -0.1 to 
2.00 LogMAR units for all RVO types. 72% of eyes saw an improvement in BCVA 
or stabilised by 1 year, poor visual outcome was associated with 50% of CRVO 
events. Treatment was used to control inflammation and reduce macular oedema 
with OFI or IVTA 6 months after RVO in three patients. Previous retinal injury due 
to uveitis and disease recurrence after RVO have a bearing on the visual prognosis 
for these patients.  
 
Risk factors in this uveitis population include raised IOP 14.7%, active inflammation 
44.1% and the presence of 1 CVD risk factors in 41.2%. 20% were associated with a 
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known previous history of oral steroid of immunosuppressant use. 38.24% were 
under 50 years of age and 30.77% had a history of hypertension and 
hyperlipidaemia. 53.85% of patients with Sarcoidosis or Behçet's disease had an 
associated cardiovascular disease risk factor, that could be attributable to previous 
steroid or immunosuppressant use.  
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3. Anti-phospholipid 
antibodies 
3.1 INTRODUCTION  
 
The retina, contains photoreceptors responsible for is the transduction of different 
wavelengths of light to the brain. These cells require oxygen, nutrients and a way to 
dispose of its cellular wastes obtained via two circulation pathways. The central 
retinal artery bringing oxygenated blood through the centre of the optic nerve and 
branches out to four quadrants of the retina and the central retinal vein facilitates the 
outflow of blood. The second pathway supplies oxygenated blood via the choroidal 
plexus that lies underneath the retina which is supplied by the posterior ciliary 
arteries. Blood circulates through the capillaries of the choroid, then exits the eye via 
the vortex veins. 
 
Retinal ischemia is an important cause of visual loss that occurs as a consequence of 
various diseases and disease processes including: atherosclerotic vascular disease, 
diabetes, retinal vascular occlusion and retinal vasculitis. Lack of oxygen to the 
retina causes retinal cell death, dysfunction, and reduced vision. Retinal ischaemia 
can be demonstrated by areas of non-perfusion on FFA. 
 
In response to the ischaemic retinal injury the retina promotes the expression of 
VEGF within the eye. The growth of new blood vessels are stimulated through the 
process of angiogenesis via hypoxia induced factors (PDGF, VEGF, IL6). Abnormal 
blood vessels (neovascularisation) grow on the surface of the retina, disc and iris 
from existing nearby blood vessels to deliver an alternative source of oxygen. Visual 
complications of neovascularisation include vitreous haemorrhage and neovascular 
glaucoma that develop because these new vessels are abnormal, fragile and leak. 
Collateral vessels should not be confused with these fragile new vessels. Instead they 
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are vessels that develop at the disc bypassing the vascular occlusion with the attempt 
of re-establishing the circulation at the disc. 
 
The visual prognosis and recovery with extensive retinal ischaemia is very poor 
without treatment. Peripheral retinal scarring by argon pan-retinal photocoagulation 
laser, anti-VEGF and steroids injections are methods employed to reduce VEGF 
production and inhibit new vessel growth.  
 
3.1.1 Anti-phospholipid antibodies (aPL) 
aPL are a group of auto-antibodies that target phospholipids and phospholipid-
binding proteins on cell membranes. The group of aPL antibodies are comprised of 
three main immunoglobulins: lupus anticoagulant (LA), anti-cardiolipin antibodies 
(aCL) and β-2 glycoprotein-I antibodies (aβ2GP-1). They are identified by enzyme 
linked immunosorbent assays (ELISA). aPL are one cause of acquired 
thrombophilia. Anti-phospholipid syndrome (APS) is the term used to characterise 
the presence of these circulating aPL with a history of recurrent arterial and venous 
thrombosis and pregnancy loss, which was previously referred to as Hughes' 
syndrome, named after Dr. Graham R.V. Hughes, a Rheumatologist in London.(79) 
 
3.1.2 Epidemiology of aPL 
Epidemiological data describing the rates of aPL and APS in populations are not 
very clear due to poor standardization of diagnostic tests and small population 
numbers used in clinical studies. From published papers, it can be considered that 
within a healthy general population, aPL are likely to be present in about 2–7% of 
young adults, where levels would be seen to rise with increasing age.(80) aPL 
antibodies are associated with systemic lupus erythematosus (SLE) in 34–44% of 
patients where 30% may not manifest any signs or symptoms of APS. (81)(82)  
 
3.1.3 Pathogenesis of APS and thrombus formation 
A thrombus can form in any organ system including the retinal vasculature through 
the abnormal activation of the coagulation pathway. (83) aPL antibodies are present 
as IgG, IgA, and IgM isforms. IgG aCL antibodies are found more frequently than 
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IgM isoforms. aPL are attracted to negatively charged phospholipids found in cell 
membranes, cardiolipin, β2GP-1 and pro-thrombin plasma proteins. β2GP-1 or 
apolipoprotein H inhibits coagulation, serotonin, factor 10 and protein C. aCL bind 
to cardiolipin, an inner mitochondrial membrane phospholipid discovered in 1906 in 
patients with syphilis. aCL bind using the plasma phospholipid-binding protein 
β2GP-1, which is specifically associated with APS and SLE, but independently in 
syphilis patients. In patients with syphilis the antibodies react to cardiolipin 
independently from β2GP-1. This became the basis of the VDRL syphilis diagnosis 
test and explains why patients with SLE yield positive VDRL tests in the absence of 
a syphilis infection. (79) 
 
APS is an type 1 antigen specific autoimmune response involving class II molecules: 
Th1 CD4+ T cells and antigen presenting cells. Histopathology from patients with 
APS show evidence of ischaemia caused by thrombotic microangiopathy, proximal 
arterial thromboemboli and peripheral emboli from a vein, artery or cardiac source. 
Acutely, capillary congestion and intra-capillary thrombi form without the presence 
of inflammation. These fibrin thrombi and fragmented blood cells block vascular 
lumen. Vasculitis when present with thrombi are more likely to occur in patients 
with APS in association with SLE. Later chronic damage occurs when the lesions 
heal and scar causing further local ischaemic hypoperfusion, atrophy and fibrosis. 
The mechanisms of how aPL antibodies encourage thrombosis is not well 
understood and several theories exist.  
 
One theory is based on the interaction of aβ2GP-1 bound to resting endothelial cells. 
It is thought that aβ2GP-1 stimulates these endothelial cells to up-regulate adhesion 
molecules, cytokines - interleukin-1β, interlukin-6 and 8 and the metabolism of 
prostacyclin. These pro-inflammatory cytokines induce thrombosis through further 
activation of tumour necrosis factor by monocytes and endothelial cells to initiate 
coagulation cascades. The aPL antibodies also disrupt phospholipid-binding 
proteins: pro-thrombin, protein C and tissue factors, that regulate the coagulation 
process. It is thought that this chronic low grade stimulation could contribute to the 
formation of thrombi. The aPL interact with activated platelets and apoptotic cells 
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that have lost their phospholipid structure, exposing anionic phospholipids that 
eventually promote the formation of thrombi. (84) 
The second theory behind the pathogenesis of APS has been linked to 
atherosclerosis. Consequences of injury to vascular endothelium via oxidant 
mediated pathways is thought to be a cause of thrombosis in APS. Activated 
macrophages engulf oxidised low-density lipoprotein (LDL) causing injury to 
endothelial cells. Oxidised LDL serum lipoproteins contain phospholipids and 
modified LDL. aCL antibodies recognise both these oxidised phospholipids and 
phospholipid-binding proteins. Complexes are formed with aβ2GP-1 that become a 
target for aPL antibodies. The oxidized LDL antibodies do not directly interfere with 
blood coagulation but instead are involved in vascular wall inflammation present in 
atherosclerosis and vasculitis. Raised concentrations of IgG antibodies against 
oxidised LDL have been found in 80% of patients in a sample with secondary 
APS.(85) Raised levels of oxidised LDL and aCL antibodies could be used to predict 
mortality from cardiovascular disease.(86) 
 
Associations between aPL antibodies causing thrombosis in SLE and oxidised LDL 
antibodies link both thrombotic and atherosclerotic processes with SLE. Perhaps 
within the atherosclerotic plaque, β2GP-1 or prothrombin plasma proteins might be 
found bound to endothelial surfaces contributing to the formation of atherosclerotic 
thrombosis by changing the balance of haemostasis toward a hypercoagulative 
state.(85)(87)  
 
3.1.4 Classification and diagnosis of APS 
The Sapporo classification criteria for APS was put together at the 8th International 
Symposium on Antiphospholipid Antibodies in Sapporo, Japan, 1998.(88) The 
criteria were later updated in 2007 in Australia due to the emergence of new clinical, 
laboratory and experimental advances.(89) APS is diagnosed in a patient with 
recurrent vascular thrombosis or pregnancy complications plus one of the laboratory 
criteria see Table 3-1. Patients with APS and triple positivity for aPL according to 
the Soporo criteria, are at a higher risk of developing future thromboembolic events. 
Patients with circulating aPL are 3–10 times more likely to have recurrent arterial 
and venous thrombosis compared to healthy individuals. (83) Reported associations 
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with APS in the literature not included in the above criteria include: 
thrombocytopenia, valvular heart disease, livedo reticular, nephropathy and 
neurological manifestations. (5) 
 
APS = at least 1 clinical criteria and 1 laboratory criteria 
Vascular thrombosis >1 clinical episode of arterial, venous or small vessel thrombosis in any 
tissue or organ. For histopathologic confirmation, thrombosis should be 
present without significant evidence of inflammation in the vessel wall.  
Pregnancy morbidity >1 unexplained deaths of a morphologically normal fetus at or beyond the 
10th week of gestation, with normal fetal morphology documented by 
ultrasound or by direct examination of the fetus 
or  
>1 premature births of a morphologically normal neonate before the 34th 
week of gestation because of: (i) eclampsia or severe pre-eclampsia 
defined according to standard definitions [11], or (ii) recognized features 
of placental insufficiency,  
or  
>3 unexplained consecutive spontaneous abortions before the 10th week 
of gestation, with maternal anatomic or hormonal abnormalities and 
paternal and maternal chromosomal causes excluded.  
Laboratory criteria Lupus anticoagulant (LA) present in plasma on >2 occasions at least 12 
weeks apart detected according to the guidelines of the International 
Society on Thrombosis and Haemostasis (Scientific Subcommittee on 
LAs/phospholipid-dependent antibodies) 
Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum or 
plasma present in medium or high titre (i.e. >40 GPL or MPL, or >the 
99th percentile) on >2 occasions, at least 12 weeks apart, measured by a 
standardized ELISA  
Anti-β2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or 
plasma (in titre >the 99th percentile) on >2 occasions, at least 12 weeks 
apart, measured by a standardized ELISA  
Table 3-1: Diagnostic criteria for antiphospholipid syndrome 
 
APS is sub-divided into three different categories: primary, secondary and 
catastrophic APS see Table 3-2. Primary APS comprise about 50% of cases and 
refers to the presence of idiopathic aPL in the absence of systemic diseases. The 
diagnosis of secondary APS is made when aPL are detected in a patient with a 
Page 79 of 162 
 
collagen vascular disease such as SLE, in the presence of an infectious process or 
with the use of certain drugs, see Table 3-2. SLE is diagnosed based on serum ANA 
testing and clinical signs and associations include: a malar discoid rash, 
photosensitivity, ulcers, arthritis and Raynaud's. (5)  
 
Classification Definition  Ocular features 
Primary APS Idiopathic 
without clinical 
evidence of another 
autoimmune disease 
 
Venous or 
Arterial thromboembolic 
disease,  
thrombotic stroke 
Sterile endocarditis with 
embolism 
Recurrent pregnancy failure 
 
72.7% present with 
visual symptoms 
86.4% normal anterior 
segment  
68.2% posterior segment 
involvement venous 
dilatation and tortuosity.  
22.7% retinal vascular 
occlusive disease  
Secondary 
APS 
aPL + autoimmune 
diseases  
 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Systemic sclerosis 
Behçet's syndrome  
Temporal arteritis  
Sjogren's syndrome 
Psoriatic arthropathy 
 
aPL + infection  
acute self-limiting and 
chronic infections 
 
Viral, e.g. HIV, varicella, 
hepatitis C 
Bacterial, e.g. syphilis 
Parasitic, e.g. malaria 
aPl+drug In drug exposure 
Phenothiazines 
Procainamide 
Phenytoin 
Quinidine  
Hydralazine 
Catastrophic 
APS 
 
aPL + rapid organ 
failure due to 
thrombosis 
Multiple vascular occlusive 
events in small vessels over a 
short period of time 
 
Table 3-2: Classification of anti-phospholipid syndrome(80) 
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The classification system has been validated for use in clinical studies of primary, 
secondary and lupus-like diseases.(90) The sensitivity and specificity of the system 
was measured as 71% and 98% respectively. The positive predictive value and 
negative predictive values of the classification system were 95% and 88% 
respectively.  
 
3.1.5 Systemic manifestations of APS 
This risk for thrombosis is higher in patients with aPL than in patients without. 
Thrombosis can affect any organ and involve both arteries and veins of varying size 
compared to most other thrombophilic states, which usually result in only arterial or 
venous thrombosis. Certain vascular sites are more at risk of thrombosis in APS 
depending on blood vessel health, size and length of the ongoing thrombotic process. 
Thrombotic events in smaller arterioles, venules and capillaries evolve as chronic 
processes causing a gradual decline in function of the target organ.  
 
Central nervous system Cardiovascular system Haematopoietic system 
Stroke Hypertension Haemolytic anaemia 14 – 
23% 
Transient ischemic attack Valvular heart disease Thrombocytopenia 40 – 50% 
(platelet count < 100×109/L) 
Recurrent Migraine Myocardial infarction Skin 
Epilepsy Coronary thrombosis Recurrent skin ulcers,skin 
nodules 
Transverse myelopathy DVT Livedo reticularis 11 – 22% 
Dementia Endocrine system Gastrointestinal system 
Pulmonary system Adrenal thrombosis  Hepatic thrombosis 
Pulmonary hypertension Renal system9% Gut ischaemia 
Pulmonary 
thrombosis/embolism 
Renal vein thrombosis Pregnancy 
 Malignant hypertension with renal 
insufficiency 
Recurrent fetal loss  
Table 3-3: Systemic manifestations of antiphospholipid syndrome(82) (91)(92) 
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20% of patients with aPL develop systemic manifestations within 5 years such as 
those shown in Table 3-3. Transient rises in aPL levels pose a much lower risk of 
thrombosis in healthy individuals.(93) There are no significant differences in the 
clinical manifestations between patients with primary and secondary APS, the only 
difference is the association of the systemic autoimmune condition.  
 
A meta-analysis by Wahl et al(30) of seven studies observing the risk for aPL 
associated venous thromboembolism in primary APS showed that the presence of 
LA increased the risk of venous thrombosis by 10 times. The overall odds ratio for 
venous thrombosis in patients with high titres of aCL and LA was 3.21 (95% CI, 
1.11-9.28) and 11.1 (95% CI, 3.81-32.3) respectively. (29) Arterial thrombosis occur 
less frequently than venous thrombosis. 29–55% of patients with APS present with 
deep vein thromboses (DVT). 23% of APS thrombotic events involve coronary 
arteries and 27% involve subclavian, renal, retinal and pedal arteries. (91)(92) The 
risk of thrombosis is six times higher in patients with SLE compared to patients 
without LA and twice as high than those without aCL.(94) In a cohort study of 
patients with venous or arterial thromboembolism and catastrophic APS the 
cumulative incidence of thromboembolism was 12.2% after 1 year, 26.1 after 5 years 
and 44.2% after 10 years. (95) Recurrent thromboses tend to occur in the same 
vascular area as previous events.  
 
Gender and age are associated with different systemic manifestations of aPL. Female 
patients with SLE, are prone to suffer from migraine, arthritis, livedo reticularis, 
thrombocytopenia and leucopenia. In contrast, male patients with secondary APS are 
more likely to present at older age and suffer from myocardial infarction, epilepsy 
and lower limb arterial thrombosis. Children can present with chorea and jugular 
vein thrombosis whereas older onset patients are more frequently associated with 
increased rates of stroke and angina.(82)  
 
Secondary risk factors for thrombosis can act as an additive effect to the risk already 
posed by circulating aPL such as factor promoting stasis and vascular injury - oral 
contraceptives and atherosclerosis and disease recurrence. High risk of recurrent 
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infarcts of brain and eye are significantly associated with the presence of cigarette 
smoking and hyperlipidaemia.(96)  
 
APS and the heart 
Manifestations of the cardiovascular involvement in APS are shown in Table 3-3. 
The average carotid intima media thickness is greater in patients with primary APS 
than healthy controls.(97) It has been reported from one study that as high as 21% of 
young patients who suffer myocardial infarction are aPL positive. (7) LA can be 
found in 3% of patients diagnosed with a myocardial infarction, compared to only 
0.7% of healthy individuals.(98) Cardiovascular morbidity in APS patients is 
increased in the presence of other known associated cardiovascular risk factors such 
as hypertension and hyperlipidaemia.(99) The odds ratio for myocardial infarction in 
patients with APS has been reported as 5.3, increasing to 21.6 in women using oral 
contraceptives and 33.7 in patients who smoked.(26) 
 
APS and the central nervous system 
Cerebral vessels are a common site of occlusion in APS patients, where 50% result 
in stroke and 2.3% a transient ischaemic attack. LA has been shown to be present in 
17% of female ischaemic stroke patients.(99) The odds ratio for ischaemic stroke in 
patients with APS in one study was 43.1, which increased to 201.0 in women who 
used oral contraceptives and 87.0 in those who smoked. 6-18% of young patients 
who suffer a stroke have aPL.(83) Cerebral angiography of APS patients with 
cerebrovascular involvement can be normal or reveal large vascular occlusions or 
stenosis in the absence of any vasculitic changes. One-third of patients under 50 
years with cerebral ischemia have aPL. Cerebral ischaemia can develop either as 
multiple or localised infarcts associated with dementia, epilepsy or movement. (96) 
Migraines may be a preceding symptom many years before diagnosing APS.(100) 
Other cerebrovascular disease risk factors add to the increased risk of recurrent 
ischemic events in the presence of aPL. 
 
APS and the eye 
Ophthalmic features in APS include thrombosis involving the vasculature of the 
retina, choroid, ocular motor nerves and the visual pathways. 8–88% of patients with 
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APS have some ocular involvement.(83) An ocular thrombotic event can be an early 
manifestation of the syndrome more likely in young female patients. Six to 33% of 
patients with ocular thrombosis have an average age of 39 years. Manifestations 
occur within any structure of the eye, either simultaneously or remain limited to the 
anterior or posterior segment. (93) The prevalence of aPL is 22.5% in patients with 
retinal thrombosis in the absence of any other associated thrombotic risk factor.(101) 
Signs and symptoms of ocular involvement in APS are shown in Table 3-4. 
Symptoms range from transient visual loss, diplopia, migraine, permanent visual 
field defects and even as severe as unilateral or bilateral visual loss.(2) Visual 
disturbances are associated with migraine in 10% of cases and transient losses tend 
to be related to disturbances within the central nervous system. Therefore it may not 
be common to find abnormal ocular signs in asymptomatic patients or those with 
transient visual disturbances. Visual impairment occurs due to ischaemia and 
haemorrhage from neovascularisation. (80)(93) The diagnosis of APS should be 
considered in all unexplained cases of retinal arterial and venous thromboses with 
neovascularisation at presentation. (102) 
 
33% of patients with retinal vascular occlusions, involving both artery or vein, have 
aPL. Raised levels can be found in 24% of patients with RVO compared to 9% in 
patients with inflammation and 8% of controls. (104) Patients with circulating LA 
and aCL are also at a higher risk of bilateral retinal vascular disease. 15% of patients 
with secondary APS are at high risk of developing retinal vascular disease and 
ischemic optic neuropathy, a major cause of blindness in these patients.(103)  
 
APS and pregnancy 
Women with antiphospholipid antibodies have a high incidence of pregnancy 
complications, with about one-quarter of successful pregnancies delivering 
prematurely(105), The prevalence of aPL in women with recurrent miscarriage is 
between 7 to 42%, owing to the research variability in laboratory testing and 
unavoidable addition of transiently positive aPL patients. There is a 90% fetal loss 
rate in patients with APS, where the majority of miscarriages occur before 14 weeks 
of gestation. aPL are also associated with placental insufficiency and the early onset 
of severe pre-eclampsia. (106) 
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Symptoms 
 
Anterior segment 
involvement 
Posterior segment 
involvement 
Reduced visual acuity (VA) Bilateral episcleritis Venous tortuosity 
Transient visual field defects Microaneurysms Optic disc oedema  
Monolateral/bilateral amaurosis 
fugax 
Conjunctival telangiectasia Optic atrophy  
AION 
Scintillating scotoma Limbal keratitis Vitreous haemorrhage 
Transient diplopia  Cotton-wool spots 
  Vitreous bands 
  Serous detachment of the 
macula 
  Retinal capillary 
abnormalities 
  Central retinal artery and/or 
vein thrombosis 
  Branch retinal artery and/or 
vein thrombosis 
  Thrombosis of the retinal 
arterioles and/or venules 
  Retinal capillary non-
perfusion 
Table 3-4: Ocular manifestations of anti-phospholipid syndrome(80)(93)(103)  
 
APS and mortality 
Fewer than 1% of episodes of venous thromboembolism are fatal. The most common 
cause of death in APS patients is from thrombotic complications. A European cohort 
study of APS patients calculated a 5-year mortality rate of 5.3% in their sample 
population.(82) Patients with APS develop significant morbidity and mortality 
despite any treatment or preventive strategies. Catastrophic APS is associated with a 
higher mortality rate than other sub-classifications of APS due to acute multi-organ 
failure. 40% of the APS deaths are due to myocardial infarction, stroke and 
pulmonary embolism. The presence of SLE in patients with APS is a poor prognostic 
factor. (107) (108)  
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3.1.6 Differential diagnosis of venous and arterial thromboembolism 
(TE) 
Causes of venous and arterial TE are shown in Table 3-5. Homocystein is 
biosynthesised from methionine, that is associated with CVD due to thrombi 
formation caused by endothelial damage and inflammation. Raised levels can be 
hereditary, or associated with increasing age, vitamin B 6,9 and 12 deficiencies and 
excess exercise or alcohol consumption. 
 
 
3.1.7 Indications and description of laboratory testing for aPL  
A thrombophilia screen should be requested to identify patients with either an 
inherited or acquired tendency to venous or arterial thrombosis of which aPL is one 
cause, see Table 3-6 and are described in Table 3-8 Thrombophilia screening for 
arterial thrombosis is indicated in patient < 40 years with TIA, cerebral thrombosis 
and MI as well as establishing other risk factors such as smoking, BP, lipids, 
diabetes. 
 
Causes of  
venous thrombosis 
Causes of  
arterial thrombosis 
Causes of  
arterial and venous thrombosis 
Protein C deficiency  
 
Atherosclerosis  
(High serum LDL cholesterol 
and triglycerides) 
Anti-phospholipid syndrome 
Anti-thrombin III 
deficiency 
Cigarette smoking Activated protein C resistance 
Pro-thrombin mutation  Diabetes Mellitus Factor V Leiden mutation 
Malignancy  Hypertension Protein S deficiency 
Immobilisation  High serum lipoprotein a levels Oral Contraceptive Pill 
Surgical operation Factor VIII polymorphism Hyperhomocysteinaemia 
Congenital  Infection (Chlamydia, CMV) MTHFR enzyme mutation 
Pregnancy Obesity  
 Congenital  
Table 3-5: Causes of venous and arterial thrombosis 
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Table 3-6: Thrombophilia screening for venous and arterial thrombosis 
 
The current standard for diagnosis of APS relies on the expression of either LA by 
coagulation tests or aCL by solid phase immunoassays. aPL are identified using 
diverse laboratory procedures through solid phase testing for aCL and aβ2GP-1 
antibodies and liquid phase assays for LA from a sample of a patient’s blood serum. 
LA is an anti-phospholipid antibody so called because it was first described in 
association with SLE.(79) LA antibodies appear more specific and aCL antibodies 
more sensitive as tests predictor of APS. An average frequency of 44% for aCL 
antibodies and 34% for LA in patients with SLE. (109) Some patients may be 
negative for one test and positive for another. Laboratory tests used to confirm the 
presence of LA are shown in Table 3-7. 
 
The presence of LA may be suggested by unexplained prolongation of clotting times 
in phospholipid-dependent coagulation tests Activated Partial Thromboplastin Time 
(APTT) and the dilute Russell’s Viper Venom (DRVV) test without specifically 
inactivating any individual coagulation factor. At least one complete testing 
procedure (screening, mixing and confirmation) performed either with the dRVVT 
or the APTT-based method is sufficient to diagnose LA. Although a normal APTT 
does not exclude the presence of LA antibodies. 
Thrombophilia screening for 
venous thrombosis 
Thrombophilia screening for arterial thrombosis 
anti-thrombin Antithrombin activity  
protein C - Factor V Leiden,  Protein C activity  
protein S - pro-thrombin gene 
mutation 
Free protein S antigen Total protein S antigen  
Activated Protein C resistance Classic + Modified APCR  
lupus anticoagulant - 
anticardiolipin antibodies 
Anticardiolipin antibodies Lupus anticoagulant screen 
homocysteine    lipoprotein A 
 Protein C antigen*  
 IgG & IgM ß2-GPI antibodies*  
 Antithrombin antigen*  
 Plasminogen activity* 
* These assays are not part of routine first line thrombophilia testing 
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In the DRVV test the reagent contains dRVV, plant phospholipid and calcium ions. 
dRVV activates Factor X directly bypassing the intrinsic and extrinsic coagulation 
pathways. Coagulation is via the common pathway and prothrombinase complex 
formation which is dependent on phospholipid for thrombin generation.  
 
The reagent is added to the patient’s plasma and resulting clot formation is timed. 
When present aPL neutralise the phospholipid component of the reagent resulting in 
a prolongation of the clotting time. The DRVV test has been shown to be more 
specific for LA because it is not influenced by intrinsic factor deficiencies or 
intrinsic factor inhibitors which cause prolongation of the APTT. The result is 
expressed as a ratio of the patient’s DRVV clotting time over the DRVV clotting 
time of normal plasma. If the DRVV ratio is raised, the presence of a LA is 
confirmed. By repeating the test using a reagent containing DRVV, calcium ions and 
a high concentration phospholipid which will neutralise any LA present so that 
thrombin formation is not inhibited. This confirmatory test is performed on patient 
and normal plasmas, the ratio is calculated and the result reported as the percentage 
correction of DRVV Test ratio. 
 
Performance of the prothrombin time and thrombin time tests is important as the 
results assist in the interpretation of LA tests and evidence of an inhibitor 
demonstrated by mixing studies.  
 
Upon detection, LA must be confirmed on a second occasion 12 weeks apart. No LA 
test consistently shows 100% specificity and sensitivity just one assay may lead to 
false negative aPL assessments because of the heterogeneous nature of aPLs, more 
than one test system should be used as a patient could be positive for LA or aCL 
independently of each other. Higher level of support for APS is considered when 
there are positive test combinations, when higher-titre aPL results are identified 
together with persistence in aPL. It is generally accepted that patients who are 
positive for both tests are at increased risk for clinical events.(110)  
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The aPL antibodies persist for many years and can be positive with the presence of 
other conditions such as cancer, haemodialysis and drug administration where IgM 
antibodies are present at low levels and are not significantly associated with a higher 
risk of thrombotic events. False results can occur as transient positive results can 
arise with infection but are independent of aβ2GP-1. (79)(81)(111) A positive aPL 
antibody test may also be associated with positive antinuclear antibodies, circulating 
immune complexes, complement deficiency, rheumatoid factor, thromboplastin 
APA(8) and C-reactive protein. (5, 9) 
 
Conditions which require caution with results interpretation include the concurrent 
antithrombotic treatment (heparin, oral anticoagulants and direct thrombin 
inhibitors), the presence of high-titre antibodies directed against clotting factors and 
the close proximity to the acute thrombotic event. Aspirin and clopidogrel do not 
interfere with LA assays.  LA detection is not recommended during or close to the 
occurrence of a thrombotic event. In addition to the above-mentioned interference of 
the antithrombotic treatment, it should also be noted that increasing levels of acute 
phase reactants such as factor VIII, a frequent finding during acute thrombosis, may 
influence the results of the APTT-based methods. (112) 
 
Table 3-7: Lupus Anticoagulant (LA) diagnostic tests 
 
 
 
 
 
 
 
LA detection tests 
(APTT (plus 80:20 mix))  
(Prolonged APTT that does not correct in an 80:20 mixture with normal human plasma) 
Kaolin clotting time (KCT) 
Dilute thromboplastin time (TDT/DTT)  
Prothrombin time 
dRVVT 
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  Deficiency is associated with 
Anti-thrombin 
III 
 
Natural inhibitor of blood coagulation 
proteases - thrombin, II a, X a , IX a and XI 
a. 
A high risk of thrombosis 
 
Protein C 
activity 
 
Vitamin K dependent protein synthesised in 
the liver. activated by thrombin in the 
presence of phospholipid and calcium ions. 
Activated Protein C is enhanced by a co-
factor, Protein S, as a blood clotting 
inhibitor that regulates the coagulation 
process by neutralising Factors Va and 
VIIIa. 
Low levels may be inherited or 
acquired and  predisposing 
patients to thrombosis.  
 
Free Protein S 
 
Protein S is a vitamin K dependent cofactor 
for the anticoagulant activity of activated 
protein C .  
Two forms of protein S are present in 
plasma : free protein S (40%) and protein S 
linked to the C4b-binding protein (60%). 
The free form has functional cofactor 
activity. 
Protein S deficiency may be 
hereditary or acquired 
associated with a high risk of 
developing venous 
thromboembolism in young 
patients. 
 
Activated 
Protein C 
Resistance  
(APCR) 
Hereditary defect of the Protein C 
anticoagulant pathway.  
Plasma does not produce an anticoagulant 
response to activated protein C termed APC 
resistance  
VQ506 gene mutation which produces 
factor V Leiden, a factor V molecule which 
is resistant to cleavage by activated protein 
C. 
Inherited resistance to activated 
protein C, associated with the 
factor V Leiden mutation G1691A 
has been shown to be present in 
20-50% of individuals with DVT  
which results in a pre-disposition 
to thrombo-embolic disease. 
Factor V 
Leiden 
mutation 
 
Found by PCR testing with a reduced APCR 
or family history of factor V Leiden. 
The Factor V Leiden genotype 
A/A is associated with a 50-100 
fold increased the risk of venous 
thrombosis.  
Prothrombin 
gene mutation 
(G-20210-A). 
Prothrombin G20210A variant and 
associated high levels of factor II  
 
(Prothrombin G20210A genotype 
G/A) 
increase the risk of venous 
thrombosis by up to 3 fold.  
Table 3-8:Other diseases uncovered by thrombophilia testing 
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Inherited causes 
Inherited causes that predispose to thrombosis deficiencies or abnormalities of 
natural inhibitor proteins of the coagulation system. These inhibitors exist to control 
the rate of formation of a blood clot. Causes of genetic thrombophilias are part of the 
differential diagnosis of APS and can coexist within some APS patients see Table 
3-9.  
 
Factor V Leiden variant Levels of protein C Plasminogen 
Pro-thrombin mutation free and total protein S tissue plasminogen activator (TPA) 
Factor VIII levels  Anti-thrombin Plasminogen activator inhibitor-1  
MTHFR mutation  β2glycoprotein 1 dependent 
anticardiolipin antibodies 
Table 3-9: Inherited causes of thrombosis 
 
3.1.8 Current opinion on the management of patients with APS 
Acute thrombosis 
An acute episode of thrombosis in APS should be managed the same as any other 
cause of thrombosis. Initial treatment includes anti-coagulation with unfractionated 
or low molecular weight heparin, followed by oral anticoagulation with Warfarin a 
vitamin K antagonist at a target INR of 2.5 (range 2-3) in the absence of 
contraindications. Intensity and duration of treatment should be determined on an 
individual basis, additional risk factors, the severity and the risk of bleeding. 
Management of recurrent events in patients who are already anticoagulated at a 
higher therapeutic INR is particularly difficult, recurrent venous thromboembolic 
events on treatment this group need a target INR of 3 to 4. It is recommended that 
anticoagulation should continue long term as patients with APS have a high risk of 
disease recurrence when treatment is stopped.(113) Recurrence remains frequent 
despite the use of oral anticoagulants. 
 
Venous thromboembolism in APS 
Long-term therapy with warfarin may be advantageous in some subjects with venous 
TE. Use of the combined oral contraceptive and of HRT are best avoided in female 
patients. (113) Patients with retinal vascular occlusions are generally started on 
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anticoagulation when found to be APS positive, however the long term benefit of 
anticoagulation in these patients still remains is unproven. (93)(114) 
 
Arterial thrombosis 
High risk of recurrence and likelihood of consequent permanent disability or death, 
stroke due to cerebral infarction in APS should be treated with long-term oral 
anticoagulant therapy. And as prohylaxsis at high risk times. Extracerebral arterial 
thromboembolic manifestations of APS will also warrant consideration of 
continuation of long-term anticoagulation with warfarin, plus management of 
additional thrombotic risk factors.  
 
Thrombocytopenia 
Thromboprophylaxis with warfarin may carry an increased haemorrhagic risk but 
should be considered where thrombosis is the principal clinical manifestation. 
Splenectomy has been safely and successfully performed and is appropriate 
treatment if clinically indicated.(115) 
 
Pregnancy and APS 
The aims of managing pregnancy in women with APS involves both prevention of 
maternal thrombotic complications and prevention of pregnancy morbidity, 
highlighting the need for close surveillance during pregnancy and ready access to a 
neonatal unit. Cases should be managed by a team including a haematologist, 
rheumatologist and obstetrician. The American College of Obstetricians and 
Gynecologists(116) have developed recommendations for prophylaxis and treatment 
during pregnancy. Female patients with aPL but no prior TE events should receive a 
daily prophylactic dose of Aspirin alone or along with heparin, during pregnancy and 
the postpartum period.  However, treated pregnancies are frequently complicated by 
foetal growth retardation, gestational hypertension and premature delivery.  
 
Management of systemic risk factors 
In addition to the above medical therapeutic agents, patients should be screened for 
hypertension, hyperlipidaemia, diabetes they should be controlled in addition 
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increasing exercise, smoking cessation and reduction of obesity. Such cardiovascular 
risk factors should be aggressively managed to reduce the risk of disease recurrence, 
miscarriage and mortality.  
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3.2 METHODS 
3.2.1 Aims and purpose 
Retinal vascular occlusions are known ocular manifestations of aPL and APS with 
the potential of causing significant visual loss for patients. If suspected early 
Ophthalmologists play an important role in diagnosis and prevention of further 
associated systemic manifestations and disease recurrence. Currently there are no 
specific guidelines outlining when and who to investigate for aPL in patients 
presenting with ocular disease. The purpose of this chapter is to outline aPL testing 
in an Ophthalmology scenario and make recommendation for testing. 
 
The aim of this study is to : 
1. outline the characteristics and ocular findings of patients tested for aPL while 
comparing those with positive tests results with those with negative results. 
2. identify systemic or ocular risk factors for thromboembolic events 
3. outline changes in visual acuity and treatments employed  
 
3.2.2 Patients 
aPL tests were requested for 142 Moorfield’s Eye patients from 1st January 2010 
until 31
st
 December 2010. Results of aPL testing for these patients were collected 
from a database of results from St Thomas’s hospital, London, where all aPL testing 
for Moorfields patients are undertaken.  
 
Patients were included if they had one or more aPL test performed and their medical 
records were found. 30.99% of patients were excluded due to one or more of the 
following reasons: 
1. aPL test was requested but laboratory testing was not performed on the 
sample, due to miss-labelling or wrong/no sample was sent  
2. No medical notes were located for the patient 
3. No presenting information from when the aPL test was requested was made 
available 
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Demographic details were recorded for all patients including gender, age, eye 
involved and drug history. Particular interest in past medical history in particular 
previous thromboembolic events and presence of systemic risk factors including 
hypertension and hyperlipidaemia. Details of ocular examination were recorded.  
Data were input into a SPSS database and statistical analysis performed. Chi squared 
tests were performed on categorical data, t tests for continuous data sets and p values 
of 0.05 or less were regarded as statistically significant. 
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3.3 RESULTS 
 
Medical records from 98 patients attending Moorfields Eye hospital for aPL 
screening tests for various ocular conditions were reviewed see Figure 3-1. 
Presenting demographic details are shown in Table 3-10. Patients have been grouped 
according to negative and positive aPL test results to allow for comparison. Patients 
with 2 positive aPL tests are discussed later. 
 
Figure 3-1: aPL test results of patients included in this study 
 
 
 
 
 
 
 
 
 
 
 
The variety of ocular vascular events that the consulting ophthalmologist felt 
warranted aPL testing are shown in Figure 3-2 and Figure 3-3 for patients with 
negative and positive tests. Retinal vascular occlusion accounted for 78(79.59%) of 
all events that aPL was tested for, 37(86.05%) and 41(74.55%) of positive and 
aPL testing 
requested for 
142 patients 
98 patients 
included 
55 ≥ 1 positive 
aPL test  
6 had ≥ two 
positive aPL 
tests 
43 with ≥1 
negative test 
44 patients 
excluded 
Characteristic Negative ≥ 1 positive 
Number of patients 43 55 
Age Mean 49 49 
Median 47 47 
Range 24-74 16-82 
Standard deviation 11 16.26 
95% CI 45.45 to 52.13 45.02 to 53.81 
Gender 
(Male:female) 
28:15 31:24 
% Right 48.84 56.36 
Table 3-10: Demographic details for aPL positive and negative patients 
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negative groups respectively. The cause of new vessels on the retina, periphlebits 
and Scleritis were other diagnosis where testing was performed.  
 
 
Figure 3-2: Ocular event that occurred in aPL negative patients 
 
 
Figure 3-3: Ocular event that occurred in aPL positive patients 
 
9% 
40% 
33% 
9% 
2% 
5% 2% 
Diagnosis of ocular event that occurred in aPL negative 
patients 
HRVO 
CRVO 
BRVO 
BRAO 
CRAO 
Other 
22% 
35% 
4% 
2% 
2% 
4% 
33% 
Diagnosis of ocular event that occurred in aPL positive 
patients 
BRVO 
CRVO 
HRVO 
BRAO 
CRAO 
Cilioretinal artery 
occlusion 
other 
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Ocular examination findings seen on presentation are show in Table 3-11. 
 
 Total number of eyes 1 positive Negative 
Number of patients 104 43 55 
Ischaemia  12(12%) 17(40%) 9(16%) 
RAPD 15(14%) 6(14%) 9(16%) 
Raised IOP at presentation 7(7%) 7(16%) 0 
AC inflammation 2(2%) 2(5%) 0 
Vitritis 2(2%) 2(5%) 0 
VH 5(5%) 4(9%) 1(2%) 
New vessels 11(11%) 7(16%) 4(7%) 
Macular oedema at 
presentation 
35(34%) 17(40%) 18(33%) 
Table 3-11: Common positive examination findings seen on presentation* 
(*where positive and negative findings were documented) 
 
Associated systemic risk factors for thrombosis 
Figure 3-4 and Figure 3-5 show the distribution of patients according to age and aPL 
test result. Table 3-12 shows the medical history of patients including cardiovascular 
risk factors associated with a higher risk of TE events. A higher proportion of 
patients with at least one positive test had a previous thromboembolic event, 
including RVO, CVA, DVT,PE or MI compared to the negative group. 
 
 
Figure 3-4: Distribution of patients with a positive aPL test according to age 
4% 
13% 
7% 
29% 
22% 
11% 
13% 
2% 
Distribution of patients with a positive 
aPL test according to age 
<19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80-89 
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Figure 3-5:  Distribution of patients with a negative aPL test according to age 
 
 
 
 
 
 
 
 
 
 
 
 
Risk factors for a thrombotic event found on systemic examination at presentation 
are shown in Table 3-13, where tested. 
 
Examination finding on presentation Total positive Negative P value 
High blood pressure 26(27%) 16(37%) 10(18%) 0.00405 
Hypercholesterolemia positive on 
testing 
21(21%) 9(21%) 12(22%)  
Raised inflammatory markers 8(8%) 2(5%) 6(11%) 0.4597 
Table 3-13: Systemic examination findings on presentation 
5% 
12% 
42% 
28% 
7% 
7% 
Distribution of patients  with negative 
aPL tests according to age group 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
Risk factor Total(%) 1 positive 
N=43 
Negative 
N=55 
P value 
Hypertension 44(45%) 25(58%) 19(35%) 0.0335 
Antihypertensive medication 23(23%) 14(33%) 9(16%)  
Hyperlipidaemia history 18(18%) 14(33%) 4(7%) 0.0017 
Smoking 17(17%) 10(23%) 7(13%) 0.1900 
Diabetes 14(14%) 11(26%) 3(5%) 0.0074 
Previous 
DVT/PE/MI/CVA/RVO 
13(13%) 11(26%) 2(4%) 0.0020 
Cancer 4(4%) 4(9%) 0 0.0342 
Table 3-12: Systemic risk factors present in positive and negative aPL groups 
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Ocular features 
 
Visual acuity 
Presenting visual acuity (VA) are similar for both groups of patients according to 
aPL test results, shown in Table 3-14. This included the VA of both eyes involved in 
patients presenting with bilateral disease. The difference between mean presenting 
VA of the two groups was not significant (unpaired t test p=0.92).  
 
 
 
 
 
 
 
 
Change in VA over 1,6 and 12 months of follow up. 
24 patients with a positive aPL test had 12 months of follow up data available. Mean 
VA from presentation (0.57 LogMAR) to 12 years (0.54 LogMAR) was 0.05 
LogMAR units (paired t test p=0.59), see Table 3-15. Similarly the mean change in 
VA from presentation to 12 months in 28 patients from the negative group improved 
from 0.67 LogMAR units (SD 0.86) to 0.46 LogMAR units (SD 0.85) (paired t test 
p=0.11) see Table 3-16. 5 eyes with a presenting VA of worse than 0.3 LogMAR 
improved to better than 0.3 logMAR at 12 months. 1 eye presenting with good VA 
got worse at 12 months. Macular oedema was persistent in 8 eyes at 1 year, 2 
developed within a year. 
 
Treatments used to manage ocular events in patients over 1 year of follow up are 
shown in Table 3-17. 
 
 
 
LogMAR VA 1 positive Negative 
Mean 0.56 0.58 
Median 0.3 0.3 
Range -0.2-3 -0.1-3 
Standard Deviation 0.70 0.74 
Number 61 43 
95% CI 0.39 to 0.74 0.35 to 0.81 
Table 3-14: Presenting LogMAR BCVA in the affected eye of all aPL positive patients 
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LogMAR VA Presentation 1 month 6 months 12 months 
Mean 0.56 0.76 0.57 0.54 
Median 0.3 0.3 0.34 0.55 
Range -0.2-3 -0.1-3 -0.2-3 -0.2-1.48 
Standard 
Deviation 
0.70 1.03 0.71 0.55 
Number 61 28 40 24 
95% CI 0.39 to 0.74 0.36 to 1.16 0.34 to 0.80 0.30 to 0.77 
Table 3-15: Change in LogMAR VA in eyes of patients that tested aPL positive over 1,6 and 12 
months of follow up 
 
 
 
 
 
 
 
 
Treatment administered  Negative Positive 
Laser PRP 5(9%) 11(26%) 
Lucentis 1(2%) 0 
Avastin 1(2%) 3(7%) 
IOP lowering medication 0 4(9%) 
Peripheral iridotomies performed 0 1(2%) 
Blood pressure lowering medication started 1(2%) 3(7%) 
Topical/oral/intavitreal implant steroid 1(2%) 3(7%) 
Aspirin/warfarin 1(2%) 6(14%) 
Vitrectomy 2(4%) 1(2%) 
Table 3-17: Treatments administered within 1 year of follow up 
 
 
 
LogMAR VA Presentation 1 month 6 months 12 months 
Mean 0.58 0.59 0.50 0.46 
Median 0.3 0.3 0.18 0.18 
Range -0.1-3 -0.1-3 -0.1-3 -0.2-PL 
Standard Deviation 0.74 0.78 0.78 0.85 
Number 43 37 39 28 
95% CI 0.35 to 0.81 0.33 to 0.85 0.25 to 0.75 0.13 to 0.79 
Table 3-16: Change in LogMAR VA in eyes of patients that tested aPL positive over 1,6 and 12 
months of follow up 
Page 101 of 162 
 
Patients with two positive aPL tests 
6(6%) patients had a second positive aPL test result and one patient already had the 
diagnosis of APS made in the past. Demographic details for these cases are shown in 
Table 3-18. The patient with a past history of APS did not present with a specific 
ocular disorder at the time of repeat testing during this year so was excluded. 4(80%) 
patients, mean age 43 years, presented with a unilateral retinal vein occlusion of 
which 2(50%) were ischaemic. The other patient presented with recurrent bilateral 
scleritis. LogMAR VA at presentation and follow up, are shown in Table 3-19. Mean 
change from presentation was 0.16LogMAR worse at 12 months in 5 patients (paired 
t test p=0.50). Three patients had another risk factors for TE disease, including 
cancer, pregnancy, hypertension and a history of smoking. 
 
Characteristic     Patients with 2 positive 
aPL tests n=6 
Mean age (years) 45.80 
SD (years) 6.26 
95% CI  38.0 to 53.6 
Median (years) 44 
Range (years) 40-56 
Gender (%male) 2(40) 
Eye (%right) 4(80%) 
Table 3-18: Demographic details of patients with 2 positive aPL tests 
 
 
 
 
 
 
 
Patients presenting with RVO 2(50%) had macular oedema on presentation. Mean 
presenting LogMAR BCVA is shown in Table 3-19 Where follow up data was 
provided, macular oedema was persistent in both eyes with macular oedema on 
LogMAR VA presentation 6 month 12 months 
Mean  0.43 0.47 0.68 
SD  0.73 0.72 0.70 
N        6 6 5 
95% CI  0.34 to 1.2 -0.27 to 1.23 -0.19 to 1.54 
Median  0 0.09 0.6 
range 0-1.78 -0.1-1.48 0-1.48 
Table 3-19: Changes in LogMAR visual acuity over 6 and 12 months of follow up 
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presentation and 3 months later in another. New vessels had formed at the disc of 
one eye. Collaterals had not developed at 12 months in 3 eyes with RVO.  Vitreous 
haemorrhage was present in one eye. One patient was treated with PRP, one was 
referred for haematologist review for management. 
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3.4 DISCUSSION  
 
The diagnosis of APS is known to be common in younger patients without known 
systemic risk factors presenting with an occlusive vascular disease.(3) Only 1(1%) 
patient from our population from a Ophthalmology tertiary hospital population was 
newly referred to haematology for further management of APS with two consecutive 
positive aPL tests in one year.  
 
What does a positive test mean? 
A prospective study of 185 patients with primary and secondary APS (LA and/or 
raised aCL) from an Italian registry(92) median age 39 years, range 2 to 78 were 
observed. Their natural history, risk factors for thrombosis, occurrence of arterial or 
venous thrombosis, the outcome of pregnancies, and any severe complications 
leading to morbidity or mortality for a median of 3.9 years (range 0.5 to 5) was 
undertaken. 34 patients developed a thrombotic event, with a total incidence of 2.5%. 
65% had primary APS and 35% as secondary APS of which 90% were women. 
Multivariate logistic regression analysis identified: a previous thrombosis (RR 4.9; 
95% CI, 1.76 to 13.7; P < 0.005) and IgG ACA titre above 40 units (RR 3.66; 95% 
CI, 1.24 to 10.8; P < 0.01) as two independent risk factors. 18 patients died due to 
vascular events or haematological malignancies. 
  
aPL occur in a variety of clinical disorders. The Montpellier study of 1014 patients 
admitted to a department of Internal Medicine department were tested (488 males-
526 females, mean age: 66.7 years, range 18-97). 7.1% patients were found aPL 
positive at least once: 44 males and 28 females, mean age 69 years, range 23 to 94. 
20 fulfilled the criteria of Primary APS: 10 patients were referred for DVT, 3 had 
history of DVT, 1 had both arterial thrombosis and a history of venous thrombosis; 2 
had thrombocytopenia; 3 had stroke, 1 had a history of a stroke. The most frequent 
associated disease was cancer in 14 patients.(91) 
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Characteristics of the positive group 
56.12% of patients tested positive for aPL. Patients were a mean age of 49 years. 
There was no significant gender difference. RVO occurred in 56.05%. A history of a 
previous TE event was present in 26% of aPL positive patients. 16.36% had a 
systemic risk factor for aPL  that might had yielded a false positive result if retested. 
74.55% had an associated systemic risk factor for RVO. 
 
Characteristics of the negative group 
43.88% of patients tested negative for aPL. Patients were a mean age of 49 years and 
58.14% were less than 50 years old and there was a male predominance. RVO 
occurred in 74.55%. A history of a previous TE event was present in 4% of aPL 
negative patients. 6.98% had a systemic risk factor for aPL that would have yielded a 
false positive result if retested. 58.14% had an associated systemic risk factor for 
RVO 
 
Retinal vascular occlusive events associated with a aPL 
aPL were detected in 9(42.9%) patients under 50 years old with a retinal vascular 
occlusion without other systemic risk factors for thrombosis. Negative tests were 
obtained for 41(95.35%) patients with retinal vascular events, the other two negative 
tests included investigation into causes of peripheral new vessels and phlebitis. 
13(31.71%) patients with retinal vascular events did not have a known systemic risk 
factor for TE of which 10(76.92%) were <50 years old. 
 
The presence of aPL are not more likely to cause ischaemic retinal vascular 
occlusions or ocular conditions with a worse visual prognosis compared to aPL 
negative patients. Features of RVO in aPL positive patients were classical and 
included venous tortuosity and retinal haemorrhages. aPL do not influence the 
development or persistence differently in positive or negative patients.  
 
How many positive patients were re-tested in 12 weeks? 
Results of aPL testing reported by the clinical laboratory show results both as 
clotting times for screening, mixing and confirmatory tests with a conclusive remark 
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expressed as either positive or negative LA result with recommendation to retest 
within 12 weeks to confirm persistence of aPL. (112)(117)  
 
A clinical audit of antiphospholipid antibody testing in a tertiary level teaching 
hospital over a 6 month period returned 268 hospital requests for investigation of LA 
and 1006 requests for aPL testing. (1) 4.1% were LA positive, 5.2% aCL positive, 
45.5% of the LA-positive samples also positive for aCL. 22 patients had repeat 
testing, 50% repeated in less than 12 weeks. (110) 
 
In our population only 8(19%) patients positive for LA on initial testing were re-
tested for persistence of the aPL antibodies within 12 weeks despite 
recommendations from laboratory for all 43 positive patients. Thus comments on 
transient rises in aPL cannot be made on the whole sample. The reason for lack of 
retesting is unknown but could be due to many reasons including: results are 
obtained late the other laboratory samples and not checked at a later date especially 
if not documented in the notes that the test had been requested. Some patients may 
have been discharged or failure to attend further follow up before test results are 
obtained. Repeat testing could also have been carried out by the patient's GP which 
would not be available on the Moorfields database. 
 
Calculating the sensitivity and specificity of aPL testing in our population 
LA detection is a complex diagnostic procedure with varied sensitivity. None of the 
tests currently used are able to detect with LA types with great certainty.(117)(111) 
The dRVVT has been shown to be sufficiently sensitive for LA detection, but results 
may vary within and between laboratories as tests are difficult to standardise 
according to the commercial brand used for testing. (111) 
 
Based on our population we cannot calculate accurate predictive values from 
sensitivity, specificity and prevalence of APS because not all patients from the 
positive group have a second positive result performed. The number of patients who 
tested positive who actually had the disease was not established nor do we know 
how many patients initially tested as negative would return a positive test. 
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Appropriate aPL testing requests 
Screening can be justified in a wide range of subjects. An investigation into aPL 
testing behaviours calculated testing was justified in 69% of their patients where aPL 
were positive in 18% positive for LA. The presence of the triple aPL positivity was 
found only in the justified requests (118) From our population, 26(47.27%) positive 
aPL patients were over 50 years, of which only 4(15.38%), mean age 53.75 years, 
had no associated systemic risk factors for TE. It would be difficult to discriminate 
whether the aPL or presence of systemic risk factors in particular contributed to the 
vascular event in these patients. But if all patients over 50 and those at presentation 
or with the presence of one or more systemic risk factor for TE were excluded, then 
potentially 68(69.39%) of tests could have been avoided. 
 
True analysis of false positive results relies on the repeat testing of aPL in patients 
with initially positive tests. To reduce false positive results, LA screening should not 
be performed during the acute phase after the patient presents with a clot. 
Haemolysis, under or overfilling of blood samples can also affect results. The 
relatively poor specificity of the testing procedures may increase the rate of false 
positive results.  LA testing should be reserved in subjects with incidental prolonged 
APTT and those with a history of venous and/or arterial thrombosis in association 
with autoimmune disease, at unusual sites and in young patients.  
 
Limitations of this study 
Limitations restricted by the retrospective nature of this study include the lack of 
standardised documentation of a substantial medical and drug history for all patients 
for example with smoking history. Bias towards documenting only positive findings 
does not allow this study to exclude the absence of risk factors if not documented as 
either present or absent as the factor may not have been sort. Other known risk 
factors for TE such as BMI and recent non-ocular surgical history rarely 
documented. Pregnancy complications were also not generally documented. Another 
limitation was not knowing whether patients had repeat testing for aPL out with the 
hospital setting to confirm persistence of circulating aPL. This study was also 
restricted by the 12 month follow up period, thus future ocular and systemic events 
that patients with positive tests incur would need further investigation. 
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Recommendations 
This study recommends guidelines are necessary to guide both clinical ordering and 
which tests laboratories should offer to reduce the risk of false positive and reduce 
the number of costly and unnecessary tests. Routine screening for aPL is not 
recommended at the first instance in patients over 50 years of age.  
 
Relevant history should be documented including TE risk factors and conditions that 
would yield false positive results including: 
 smoking history 
 recent surgical history 
 malignancy 
 current pregnancy  
 drug history including OCP and anti-coagulant use 
 current infections 
 previous TE events 
 
Initial testing should investigate common causes associated with a high risk of 
thrombosis including: 
 hypertension 
 hyperlipidaemia 
 diabetes 
 raised IOP 
 
In an Ophthalmology scenario aPL should be tested after the acute event so as not to 
yield false positive results in patients with: 
 venous or arterial thromboembolism in the absence of cardiovascular risk 
factors such as hypertension, diabetes or hyperlipidaemia  
 especially in those under 50 years of age including patients with recurrent 
thrombotic events  
 or young patients with recurrent events in the presence of other controlled 
risk factors  
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aPL investigation in the presence of inflammation should be reserved after 
investigation of common causes are excluded. 
 
Documentation of aPL requests should be specifically made in the medical notes to 
aid follow up of results at future visits when made available. 
 
When requesting aPL tests: 
 blood samples must be clearly labelled with the patients first name, surname, 
D.O.B, hospital number and the date the sample was taken.  
 The details on the sample must correspond to the request form.  
 Current anticoagulant medications should be specified as additional tests 
may be required.  
 Relevant clinical details including ocular diagnosis, previous thrombosis, 
pregnancy and OCP use should be included.  
 State the haemostasis investigation required  
o Thrombophilia profile 
o Antiphospholipid profile  
o or other specialist investigation  
 
St Thomas's laboratory antiphospholipid antibody markers include: IgG, IgM & IgA 
Anticardiolipin antibodies and IgG and IgM anti-beta2-glycoprotein 1 antibodies by 
special arrangement. All samples negative by DRVVT and dAPTT will receive: 
mixing studies and a confirmatory test where indicated. Patients receiving oral 
anticoagulation additionally receive: TSVT, Ecarin time (ET) and mixing studies 
where indicated. 
Ophthalmologists should remember that upon return of 1 positive test this does not 
diagnose APS. Requests should be made with the knowledge that repeat testing 
would be indicated. Repeat testing should be performed within 12 weeks to confirm 
persistent aPL which should be performed in the hospital setting or request to the GP 
if the patient has been discharged. Communication with the patients GP as to ocular 
events that yield positive aPL testing should be made for documenting with the 
patients whole medical history for analysis of future medical events or repeat testing. 
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If patients yield two positive results referral to a local haematology department can 
be made for further investigations and management of APS, ie should be a 
multidisciplinary approach.  
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3.5 SUMMARY OF RESULTS  
 
APS is a rare diagnosis in the ophthalmology setting. The incidence of APS was 1% 
in our population of patients over one year. The majority of tests were performed on 
patients presenting with retinal artery or vein occlusions.  
 
This study highlights changes to testing practices that should be employed when 
investigating for aPL, including the exclusion of common risk factors associated 
with thrombosis in the first instance including measuring blood pressure, cholesterol 
and glucose levels to diagnose diabetes. 51.9% of 17 patients with characteristics or 
risk factors for APS yielded positive aPL results. 72.5% of tests in our population 
could potentially have been avoided including one patient already known to have 
APS. False positive results may mean unnecessary long-term anticoagulation for 
some patients. Moreover, indiscriminate and inappropriate testing may lead to 
misdiagnosis and add to increasing health care costs where unnecessary in the 
majority of cases. 
 
Repeat testing in such patients should be requested within the hospital scenario or in 
community within 12 weeks to confirm APS diagnosis to allow for early initiation of 
suitable management to prevent future events. 
 
It is difficult to discriminate between whether retinal vascular occlusions in APS 
patients are caused by or are associated with an increased risk due to the aPL 
antibodies, if known systemic risk factors are also present. 
 
Long term follow up of these patients would be interesting to find out results of 
repeat aPL testing and observe potential systemic and ocular effects in the future. 
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4. Ozurdex - an intravitreal 
Dexamethasone implant for uveitis 
4.1 INTRODUCTION  
 
Uveitis is a cause of 10-15% of irreversible blindness and visual impairment in the 
developed world which is frequently due to oedema accumulating at the macular. 
(119)(4)(120) The prevalence of macular oedema varies between 20 to 30% of 
uveitis cases.(6) Fluid accumulates through the complex actions of inflammatory 
cells involved in inflammation causing an increased production of inflammatory 
mediators such as cytokines, growth factors, free radicals, prostaglandins, 
leukotrienes, interleukins (10 and 6) and vascular endothelial growth factor. Intra-
retinal fluid accumulates expanding extracellular compartments pooling in cystoid 
spaces due to the disruption these inflammatory cells cause, see photograph 4-1. 
Loss of integrity of the healthy inner retinal barrier (retinal capillary endothelial tight 
junctions), outer retinal barrier (tight junctions between retinal pigment epithelium 
cells) and dysfunction of the retinal pigment epithelium pump are seen. (6) Control 
over the actions of these inflammatory cells allows for the successful treatment of 
macular oedema in uveitis. (121) 
 
Corticosteroids have long been used as one such treatment of macular oedema and 
inflammation associated with uveitis.(120) The long-term management of patients 
with uveitis is frequently a difficult balance of efficacy and safety. Currently the 
choice of which agent to use depends on the beneficial action and duration 
outweighing their negative side effect and cost profiles. (3)(6)(119) Systemic (oral 
and intravenous) and local methods (topical, peri-ocular and intravitreal) of steroid 
delivery are available with differing drug potency, biologic activity, duration of 
action, solubility and side effect profiles.  
 
The introduction of sustained release intravitreal implant preparations have provided 
a new treatment alternative to deliver steroids to the posterior segment of the eye. 
Page 112 of 162 
 
This introduction will highlight the current methods available for corticosteroid 
delivery to the eye with particular emphasis on the dexamethasone intravitreal 
implant and the evidence available for its use in non-infectious uveitis. 
4.1.1 Modes of action of steroids 
Corticosteroid actions are multifactorial, they have potent effects mediated by 
cytosolic glucocorticoid receptors within target cells (lymphocytes, monocytes; 
nonpigmented ciliary epithelium, trabecular meshwork, lens epithelium, corneal 
endothelium) to increase the expression of anti-inflammatory proteins that suppress 
the production/transcription of pro-inflammatory cytokines: interleukin 1,2,3,5, 
TNF-alpha, interferon gamma. Inhibitory inflammatory mediators include: 
prostaglandins, leukotrienes, phospholipase A2, thromboxane, histamine release and 
VEGF.(6)(121) Corticosteroids also reducing wound scarring/prevent healing by 
inhibiting fibroblasts and fibrin deposition. and stabilise endothelial cell tight 
junctions preventing leakage of fluid at the macula as discussed earlier. Three most 
commonly used steroids used in uveitic eyes include: triamcinolone acetonide, 
fluocinolone acetonide, prednisolone and dexamethasone, see Table 4-1. Routes of 
administration of the steroids are discussed below, except oral preparations discussed 
in the introduction to this thesis. 
 
4.1.2 Topical corticosteroids 
Topical corticosteroids are the primary form of treatment for anterior uveitis first 
described in the 1950s.(122) Topical routes provide direct delivery of a steroid to an 
eye that penetrates through to the anterior chamber. Topical preparations commonly 
used for anterior uveitis include: Maxidex (dexamethasone 0.1%), Pred Forte 
(prednisolone 1%) and Vexol (rimexolone 1%). Topical drops can be administered at 
frequent intervals depending on the degree of active inflammation. One major 
disadvantage of topical steroids are that they are inadequate when used to treat 
posterior segment inflammation, owing to its poor penetration abilities beyond the 
lens to the vitreous cavity. Side effects of topical treatments are related to the 
corticosteroid dose, duration, rate of penetration into the eye and systemic 
absorption. In general topical steroids have minimal systemic absorption rates 
reducing the risk of systemic side effects.(123) Local side effects associated with 
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topical steroids include cataract formation and increased intraocular pressure. 
Moreover, frequent daily topical treatments may be cumbersome for some patients 
when required long term. In such cases local effective steroid doses for posterior 
segment inflammation can be targeted via periocular or intravitreal routes.(121)  
 
4.1.3 Peri-ocular and intravitreal corticosteroid injections  
Corticosteroids can also be administered locally via trans-scleral absorption with 
orbital floor injections (OFI)/sub-Tenon’s injection or directly as an intraocular 
injection into the vitreous. The latter provides a quicker response but is associated 
with an increased risk of ocular side effects. This route offers the advantage of 
delivering high therapeutic concentrations of a steroid to an inflamed eye within 
close proximity to the retina, macula and optic nerve. Higher local steroid 
concentrations are achieved compared to topical and systemic routes by bypassing 
the blood–retinal barrier, minimising systemic absorption rates and therefore 
reducing the risk of systemic steroid side effects.(2) 
 
Triamcinolone is one such corticosteroid used via this route. (124) IVTA represents 
an important and recent adjunct in the management of macular oedema and vitritis in 
eyes with non-infectious uveitis(125) (120) (9) (126) Uses of IVTA have also been 
investigated in eyes with macular oedema due to diabetic 
retinopathy(127)(128)(129)(130) and retinal vein occlusion. The most commonly 
used Kenalog formulation of IVTA is delivered in a relatively insoluble crystallised 
form prevents its rapid clearance from the eye but clumps of which are occasionally 
visible to the patient. Moreover, the benzyl alcohol addition within the commercially 
available Kenalog formulation of triamcinolone has been linked to retinal toxicity. 
(131) As a suspension it is technically difficult to deliver a consistent dose of IVTA. 
Ober et al(132) found that 0.1 mL of well mixed IVTA (40 mg/mL) can contain 
anywhere from 1.4 mg to 12.9 mg of triamcinolone acetate. The steroid persists in 
the vitreous for approximately 90 days (mean half life of 18.6 days) in non-
vitrectomised eyes and shorter in vitrectomised eyes (half life of 3.2 days).(133) 
Triamcinolone is cleared from the vitreous after approximately 3 months and 
patients often require re-treatment to sustain any further beneficial effects of the 
treatment. 
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Fluocinolone 
 
Dexamethasone 
 
Triamcinolone 
 
Table 4-1: Molecular structure of Fluocinolone, dexamethasone and triamcinolone 
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Local ocular side effects occur including a fivefold increased risk of developing 
cataract than in the general population(121), raised IOP, endophthalmitis, vitreous 
haemorrhage, retinal detachment and central retinal vein occlusion.(134) Peri-ocular 
orbital floor injections have the added risk of inadvertent globe penetration, extra-
ocular muscle injury, ptosis, orbital fat protrusion and local skin depigmentation. 
(121)(124)(135)  
4.1.4 Intravitreal implants  
The evolution of the intravitreal implant has brought about interest to supersede 
current short acting local drug delivery methods to overcome the difficulty of 
delivering effective doses of a steroid into the vitreous cavity with the ability to 
maintain a sustained control of intraocular inflammation. Ocular implants were 
developed based on the Ganciclovir intravitreal implant, Vitrasert, used to treat 
cytomegalovirus retinitis.(136) Steroid based implants used for uveitis are discussed 
below. 
4.1.4.1 Retisert – Fluocinolone acetonide 
Retisert (Envision TD) is a sustained release intraocular implant containing the 
steroid fluocinolone acetonide 0.59mg which is released over a 36-month period 
produced in the US by Bausch & Lomb and Control Delivery Systems for the 
treatment of severe, non-infectious posterior uveitis.(6)  
 
In April 2005 Retisert 0.59mg was approved by the FDA for the treatment of 
chronic, non-infectious, posterior uveitis. The implant is surgically placed into the 
vitreous cavity at the pars plana. It slowly releases the corticosteroid at a nominal 
initial rate of 0.6 µg/day, decreasing over the first month to a steady state between 
0.3-0.4 µg/day over approximately 30 months. The implant is not biodegradable and 
surgical removal of the original implant is associated with an increased risk of 
vitreous or retinal haemorrhage, retinal traction, and possible retinal 
detachment.(137) 
 
Published data from a 3 year, multicenter, randomised trial (138) showed Retisert 
reduced uveitis recurrence and improved or stabilised visual acuity in subjects with 
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non-infectious posterior uveitis where previous treatments have failed. The 
prospective trial included 278 patients treated with either 0.59mg or 2.1mg strength 
agents. In summary uveitis recurrence was reduced from 62% to 4%, 10%, and 20% 
after 1, 2, and 3 years after implants were inserted, for the 0.59mg dose group and 
from 58% to 7%, 17%, and 41%, respectively, for the 2.1-mg dose group. Vision 
was improved by 0.81 logMAR units by 30 months, which was sustained for 
approximately 3 years. Complications including rises in intraocular pressure (≥ 10 
mm Hg) occurred more frequent in treated eyes. Glaucoma surgery was required in 
40% of implanted eyes vs 2% of non-implanted eyes, cataracts were extracted in 
93% of phakic implanted eyes vs 20% of phakic non treated eyes. The implant 
decreased the need for adjunctive systemic and other local steroid treatments.(138)  
 
4.1.4.2 Dexamethasone implants 
Dexamethasone is a synthetic glucocorticoid used to treat systemic and ocular 
inflammatory disorders. It is a relatively small molecule, with an estimated half life 
of 5.5 hours in humans when injected into the vitreous, it has a significantly shorter 
action compared to Triamcinolone and Fluocinolone but is five times more potent 
and hydrophilic than Triamcinolone, which allows for a higher concentration within 
the vitreous. The placement of the implant in the vitreous maximises drug exposure 
to the macula while minimising unnecessary anterior chamber exposure with the aim 
of reducing the incidence of IOP rises.(3)  
 
Preclinical studies using animal models of a non-biodegradable dexamethasone 
implant was first developed by Cheng et al for the treatment of experimental uveitis.  
A sustained release implant of dexamethasone 5 mg in the vitreous of rabbit eyes 
induced to have two episodes of severe panuveitis. Inflammation was reduced in 
treated eyes and the implant appeared to prevent ocular complications from recurrent 
inflammatory episodes.(139) 
Surodex - dexamethasone implant 
Surodex was a biodegradable dexamethasone 60 μg implant developed by Oculex 
Pharmaceuticals in the US (now taken over by Allergan). When inserted intra-
cameraly into the anterior chamber in vivo, it was shown to significantly reduced 
inflammation, protein, cell infiltrates, interferon-gamma and IL-4 in rat eyes.(121)  It 
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was tested for use to reduce post-cataract surgery inflammation in a randomised, 
masked, controlled trial of 104 Asian eyes post extra-capsular cataract extraction 
with intraocular lens implantation. Patients had two Surodex implants inserted into 
their anterior chamber or ciliary sulcus, which reduced flare independent of the 
insertion site. The implant was successful in suppressing postoperative 
inflammation, pain, photophobia and lacrimation after uncomplicated cataract 
surgery whilst also reducing the need for topical anti-inflammatory drops.(121) 
Moreover, when combined with phaco-trabeculectomy surgery the Surodex implant 
provided good control of inflammation.(140)(141)(142)  
The Ozurdex dexamethasone intravitreal implant  
The Ozurdex (Allergan Inc, Irvine, California, USA) biodegradable ‘Novadur’ 
polymer implant is a prolonged method of administering 0.7 mg of Dexamethasone 
via the pars plana to the posterior segment structures of an eye. (121)(143) This new 
drug delivery system contains a poly(lactic acid-co-glycolic acid) (PLGA) matrix 
material, which completely dissolves, omitting the need for surgical removal after 
the drug depletes. The implant is administered using a single use, suture less 
posterior segment drug delivery system applicator see photograph 4-2, which allows 
for the injection of the implant as an outpatient day case basis without the patient 
requiring admission into hospital. This novel drug delivery system is administered 
from the lateral aspect of the globe out of view from the patient and has been shown 
to be generally well tolerated. The steroid is released by diffusion in a controlled, 
biphasic fashion where the highest doses are provided for up to six weeks, peaking at 
2 months and followed by subsequent lower doses for up to six months. Animal 
studies have shown that an intravitreal implant allows for a higher concentration of 
dexamethasone to be administered to the retina compared to oral and peribulbar 
routes. (144)(145) 
 
4.1.4.3 Contraindications for Ozurdex use 
Use of the implant is contraindicated in cases of advanced glaucoma and 
corticosteroid hypersensitivity in addition to eyes with active or suspected ocular or 
peri-ocular infections. Moreover, the immunosuppressive actions of the steroid 
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implant may enhance the establishment of secondary ocular infections caused by 
bacteria, fungi, or viruses. 
 
4.1.4.4 Phase II clinical trials of the Dexamethasone implant 
A randomised controlled trial of a intravitreal dexamethasone drug delivery system 
(DDS) was tested by Kuppermann et al in patients with persistent macular oedema. 
(146)(147) 315 patients with a BCVA of 6/12 or worse with persistent macular 
oedema for over 90 days secondary to CRVO, BRVO, diabetic retinopathy, uveitis 
or Irvine-Gass syndrome that had not responded to laser or medical therapy. Patients 
were randomised into three groups: observation or 0.35 mg/0.7 mg dexamethasone 
implant treatment groups. The primary outcome measure was the percentage 
achieving a 10 letter improvement in BCVA at day 90.  
 
In summary the primary objective was achieved more frequently in the 0.7 mg 
implant group for over 180 days compared to observation, regardless of the cause of 
macular oedema. Both treatment groups saw a significant reduction in central retinal 
thickness and leakage (seen on FA) after 90 days compared to the observation group. 
No statistically significant differences in BCVA were seen between the 0.35 mg 
treatment and observation groups. The implant was surgically implanted and was 
generally well tolerated. Cataract prevalence was not found to be statistically 
different between treatment and observation groups at 90 days and raised IOP (≥10 
mmHg from baseline) was found in 3%, 12% and 17% in the observation, 0.35 mg 
and 0.7 mg treatment groups, respectively. (146)(147) 
 
4.1.4.5 Phase III safety and efficacy studies of the Ozurdex implant  
In June 2009 the implant was approved by the United States FDA to treat macular 
oedema due to BRVO, CRVO and in September 2010 for non infectious posterior 
segment uveitis. The Ozurdex implant was approved by used in CRVO eyes by 
NICE in the UK and more recently in BRVO if and when laser photocoagulation did 
not prove to be beneficial or unsuitable due to excessive haemorrhage. (148) 
Guidelines were published in May 2011 for the treatment of macular oedema 
secondary to RVO in adults. For eyes with CRVO, an Ozurdex implant is required 3-
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4 monthly and approximately lasts 5 months in eyes with BRVO. At the time of 
publication, the 700 microgram implant and applicator was £870.00. The actual 
number of treatments required is not known.  
 
4.1.4.6 RCTs supporting Ozurdex for macular oedema secondary to retinal 
vein occlusion 
Two multicentre randomised clinical trials studied the efficacy and safety of the 
Ozurdex implant in 1267 adult patients with macular oedema secondary to CRVO or 
BRVO.(63) Eyes with macular oedema persisting for between 6 weeks to 12 months 
were randomised into either sham or 0.35 mg or 0.7 mg dexamethasone implant 
treatment groups. One eye was selected for treatment according to the inclusion and 
exclusion criteria shown in Table 4-2. Patients were treated with an initial 6 month 
regime. Patients were re-treated if BCVA was measured less than 84 letters or OCT 
showed continual increases in central macular thickness over 250. The primary 
efficacy outcome was the time to reach a 15 letter improvement for both phase III 
studies pooled together from baseline BCVA.  
 
In summary the results from the pooled analysis showed that the eyes receiving the 
Ozurdex implant achieved a 15 letter improvement in BCVA significantly greater in 
both implant groups and significantly faster than controls from day 30 through day 
90, with the greatest response (29%) at day 60 (P < 0.001). The mean increase from 
baseline VA was also significantly greater in both implant groups than controls from 
day 30 through day 180 (P≤0.006), with the greatest between group difference 
(approximately 10 letters) at day 60. The mean decrease in CRT was significantly 
greater in both implant groups compared with the sham group at day 90 (P < 0.001) 
but not by day 180. The response to the implant was greater among eyes with a 
shorter duration of macular oedema at baseline (≤90 days) and worse if prolonged 
(>90 days). Eyes with CRVO did not respond as well to therapy as eyes with BRVO 
but did not improve with no treatment.  
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Inclusion criteria 
BCVA of
 
10 to 75 letters  
(0.2 LogMAR or worse) 
Past ocular history of non-
infectious intermediate or 
posterior
 
uveitis 
Vitreous haze score of +1.5  
(on
 
a scale of 0-4) on examination 
Exclusion criteria 
BCVA <34 letters in the
 
non study eye 
History of glaucoma, ocular 
hypertension, Steroid related 
ocular hypertension, IOP >21 
mm Hg at baseline, use of IOP 
lowering medications within 
the last month  
 
OFI in the study eye
 
8 weeks prior to 
the trial 
IVTA of 4mg <26 weeks prior to the 
trial  
Previous Retisert or Ozurdex implant 
in the study
 
eye 
Changes to steroid medication within 
the first 8 weeks of the original trial 
Active infectious uveitis 
Uveitis unresponsive to 
prior steroid treatment 
Uncontrolled systemic 
diseases 
Table 4-2: Inclusion and exclusion criteria for the Phase III Ozurdex for retinal vein occlusion 
trial (63) 
 
Open label extension of the trial observed the 12 month safety and efficacy 
evaluations of single and repeated treatments with the Ozurdex 0.7mg implant.  
 
Conjunctival haemorrhage is a common adverse drug reaction due to the insertion 
procedure of the implant itself and not due to the effects of the steroid. With the 
exception of cataract, there were no statistically significant differences in the 
incidence of ocular adverse events between patients who received 2 implants and 
patients who had been treated initially with sham and received one implant at day 
180 only. No surgical procedures were required in eyes treated with one 0.7mg 
implant or those treated later. The 12 month incidence of cataract in the single 0.7 
mg and 0.35 mg implant groups were 7.6%  and 7.7%  respectively and 5.7% in 
untreated groups (P=0.849).  
 
Overall, 32.8% of study eyes in the retreated implant group had at least a 10 mmHg 
increase in IOP at some point in the 12 month study resolving by 180 days managed 
with observation or medication. 25.5% of patients began treatment with IOP 
lowering medication during the masked phase of the study, and in the subgroup that 
qualified for retreatment and received a second implant day 180, an additional 10.3% 
of patients began treatment with IOP lowering medication. 14 study eyes required 
laser or surgery to reduce IOP compared to no patients in the observation groups. 
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4.1.4.7 Ozurdex for inflammation associated with non-infectious posterior 
uveitis  
Lowder et al (119) investigated the 6 month outcomes of using the Ozurdex implant 
in patients with non-infectious intermediate or posterior uveitis. The main outcome 
measure was the proportion of eyes with a vitreous haze score of 0 at week 8. 
Patients were recruited from different  centres according to the inclusion and 
exclusion criteria shown in Table 4-3. 
 
Inclusion    
Non-infectious 
intermediate or 
posterior uveitis 
Vitreous haze score 
of at least +1.5 
Visual acuity of 
10 to 75 letters  
 
Stable doses of 
topical steroids 
and NSAIDs for 
at least 2 weeks 
prior to the trial 
20 mg/day or less of 
oral prednisone stable 
for at least 1 month 
prior to the trial 
systemic 
immunosuppressants  
with stable doses  for 3 
months prior to the trial 
  
Exclusion    
Visual acuity of  
less than 
34 letters in the 
non-study eye  
 
uveitis unresponsive 
to prior steroid 
treatment 
active ocular disease or 
infection 
uncontrolled systemic 
disease 
previous steroid 
intravitreal 
implant in the 
study eye 
periocular 
corticosteroid 
injections in the study 
eye 8 weeks or less 
prior to the treatment 
visit on day 0 
any intravitreal drug 
injected into the study eye 
<26 weeks pre-trial  
excluding IVTA <4mg 
injected 26 weeks or more 
the use of IOP-lowering 
medications within the 
last month 
history of glaucoma, 
ocular hypertension, or 
clinically significant IOP 
elevation in response to 
corticosteroid treatment; 
IOP > 21 mm Hg at 
baseline 
NSAID = nonsteroidal antiinflammatory agents 
Table 4-3: Inclusion and exclusion criteria for Ozurdex in non-infectious uveitis trial(1) 
 
Patients were randomised into either sham or treatment groups. Patients in the 
treatment group were then randomised into receiving either the 0.7mg or 0.35mg 
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steroids implant using a
 
1:1:1 allocation ratio. Randomization was performed 
centrally
 
and was stratified by baseline vitreous haze score
 
of +1.5, +2 ,+3 or +4), see 
Table 4-4.
 
The treatment investigator performed the implant placement and
 
other 
treatment procedures and was responsible for the overall
 
safety of study participants. 
All study medication information was kept
 
confidential and the treatment 
investigator was not involved in the follow up visits. Patients
 
were masked with 
regard to study treatment, and the key efficacy
 
variables were collected and 
evaluated by follow-up investigators
 
who were also masked with regard to study 
treatment.
 
During the study the use of systemic immunosuppressive
 
therapy or 
steroids (systemic, periocular, intravitreal,
 
or topical) or surgery was prohibited 
unless vitally necessary and recorded. Anti-inflammatory medications could be used 
if haze increased.  
 
0   no inflammation 
+0.5   trace
 
inflammation (slight blurring of the optic disc margins and/or
 
loss of the nerve fibre 
layer reflex) 
+1 mild blurring
 
of the retinal vessels and optic nerve 
+1.5 optic
 
nerve head and posterior retina view obscuration greater than
 
+1 but < +2 
+2 moderate blurring of the
 
optic nerve head 
+3 marked blurring of the optic
 
nerve head 
+4 optic nerve head not visible. 
Table 4-4: The standardised photographic scale for measuring vitreous haze ranging from 0 to 
4(1) 
 
Prior to each treatment, standard clinical practices for eyes undergoing intravitreal 
injection were adhered to and
 
topical anaesthetics were used to prepare the eye. The 
implant was inserted into the vitreous cavity
 
through the pars plana using a 
specialised, single use, 22 gauge
 
applicator. The sham procedure followed the same 
protocol but
 
used a needleless applicator. Patients were prescribed a post-procedural 
topical antibiotic prior to and 3 days after the implant/sham.
 
Patients were followed 
up from baseline (date of implant/sham) and at days 1 and 7 and weeks
 
3, 6, 8, 12, 
16, 20, and 26.
 
Visual acuity was measured using a standardised Early Treatment
 
Diabetic Retinopathy Study protocol and central macular thickness
 
from OCT 
measurements. Adverse events were monitored which included IOP
 
 
Page 123 of 162 
 
The primary outcome measures of the original study was based on the amount of 
vitreous
 
haze that reduced visualisation of the fundi at week 8.  
 
In summary their results showed that the primary outcome was successfully 
maintained for 26 weeks by 47% of patients in the 0.7mg treatment group, 36% with 
the 0.35mg implant and 12% of controls (p< 0.001). Visual outcome was 
significantly better in the treatment groups where patients experienced a gain of >15 
letters from baseline throughout the trial.  
 
Complications from the implant were not found to be statistically significant. 
Common adverse events occurred in approximately 2% of eyes within the first 6 
months of administration of the steroid implant, which included eye pain (P = 0.023) 
and anterior chamber cells (P ≤ 0.031). IOP rises were seen in 7.1%, 8.7 % and 4.2% 
in the 0.7mg, 0.35mg and control groups respectively (p>0.05). The percentage of 
eyes receiving IOP lowering medication increased in the dexamethasone implant 
groups from 6% at baseline to 24% at day 180, while there was no change in the 
sham group. Cataract developed in 15%, 12% and 7% of 0.7mg, 0.35mg and control 
groups respectively (p>0.05). Rare complications included endophthalmitis and 
retinal detachment and there were no statistically significant differences between the 
treatment groups and the incidence of cataract.(119)  
 
It is in this uveitis population we went on to further study the long term evaluation of 
patients treated with the Ozurdex implant for macular oedema and inflammation in a 
subset enrolled in MEH.  
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4.2 METHODS 
4.2.1  The aims and purpose of this study 
Current local steroid treatments for uveitis are short lived and are associated with 
significant complications that impact on patient’s quality of life. The purpose of this 
chapter is to evaluate the long term outcome of the Ozurdex implant and the 
strategies employed as and when patients relapsed, comparing these outcomes with 
those of the Ozurdex implant.      
 
This study aims to:  
1. outline when and what additional therapies are needed after a single Ozurdex 
implant due to disease recurrence 
2. document any differences in outcomes with alternative therapies used 
compared to after a single dexamethasone implant 
3. outline complications associated with a single Ozurdex implant including 
ocular hypertension, cataract progression and surgery and compare to the 
additional therapies needed. 
 
4.2.2 Patients 
The patients used for this study were identified from our cohort enrolled in the 
HURON Ozurdex for uveitis trial (Lowder et al).(119) The original trial was a 26 
week, prospective, multicenter, masked, randomised,
 
parallel group, sham controlled 
clinical trial. 28 patients were identified from the Moorfield’s eye hospital 
population that were randomised into either treatment or control arms. Notes were 
obtained for the patients from Moorfields hospital.  
 
Patients were included if they were followed up for greater than 6 months after the 
trial period at Moorfields eye hospital. Data was collected for both treatment and 
sham patients. 16 patients were treated with the steroid implant upon the original 
trial. One patient had no follow up past 6 months and another entered another 
clinical trial, so both were excluded from this study.  
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Data about further treatments used to manage disease recurrence (inflammation and 
macular oedema) over 6 months to 1 year, 1 year to 2 years and 2 years to 3 years, 
respectively where available were documented. Specific treatments of interest 
include: oral steroids, OFI and IVTA.  
 
In addition changes to doses of oral steroids and immunosuppressive agents were 
also documented. Details about complications such as high IOP and cataract were 
collected. Changes in IOP from baseline to final follow up, including occasions 
when IOP rose above 21mmHg and the use of medical or surgical interventions were 
also documented. Lens status in the study eye was documented at baseline and 
progression followed until final follow up including any cataract surgery performed. 
Any other complications that would affect the VA of the patient including retinal 
detachment and endophthalmitis were noted.  
4.2.3 Statistics 
Data was input into an Excel spreadsheet and analysed using SPSS. Visual acuity 
was converted from snellen to logMAR using the scale in chapter two. Tests for 
significance of continuous data including LogMAR visual acuity and intraocular 
pressure were measured using unpaired or paired t tests. Mean time for improvement 
in outcomes were measured from treatment date to best visual acuity and highest 
IOP documented. A significance level of p<0.05 was deemed statistically significant. 
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4.3 RESULTS  
 
Demographic details were obtained for 26 patients of the original 28 patients 
involved in Lowder et al's trial, see Table 4-5, 15 patients received the implant.  
 
 
Sham 
(n=11) 
Ozurdex Treatment group 
(n=15)  
Mean age (years) at implant/sham(SD) 
55.91 (12.05)  
range 34 to 77 
49.6 (10.87) 
 range 32 to 70 
% >50 years 7(63.6%) 8(53.3%) 
Gender, %male 36.4% 46.7% 
Eye %Left 54.5% 53.3% 
Uveitis diagnosis 
Birdshot Retinochoroidopathy 1 (0.9%) 0(0%) 
HLA B27+ posterior uveitis 1 (0.9%) 0(0%) 
Sarcoid uveitis 
 (intermediate/posterior uveitis) 
2 (18.2%) 3(20%) 
Idiopathic posterior/panuveitis uveitis 5 (45.5%) 2(13.3%) 
Idiopathic intermediate uveitis and 
vasculitis 
2(18.2%) 10(66.7%) 
Table 4-5: Demographic and baseline details for Ozurdex treated and sham control patients 
4.3.1  Outcome results from the 26 week trial period 
Of the 15 patients treated with the Ozurdex steroid implant, 29% gained ≥15 letters 
and 57% gained >10 letters of improvement in BCVA by the end of the clinical trial. 
Table 4-6 shows the change in visual acuity between baseline and 26 weeks. Vitritis 
was present in 10(66.67%) eyes by 26 weeks and macular oedema was present in 
9(60%) eyes at baseline and completely resolved in 7(77.78%) of these eyes at 26 
weeks. 2(13.33%) eyes however had macular oedema that persisted to 2 years of 
follow up. 
.  
 
 
 BASELINE 6 MONTHS 
Mean LogMAR VA 0.45 0.39 
Standard deviation 0.31 0.47 
Range 0.1 to 1.25 -0.2 to 1.20 
Table 4-6: Change in LogMAR visual acuity from baseline and at 6 months of follow up of 
Ozurdex treated eyes 
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4.3.2 When were additional treatments required? 
Patients with a mean follow up of 25 months after the initial 26 week trial are shown 
in Table 4-7. 
  
 6 months 1 year 2 years 3 years 
Ozurdex treatment group  15 14 10 6 
Sham Group 11 9 4 2 
*until data collection ceased 2011 
Table 4-7: Patients with follow up appointments at Moorfields eye hospital after the initial trial* 
 
The persistence of vitreous cells was seen in 10 treated eyes after the 26 week end 
point of which two eyes had persistent macular oedema. The two eyes with macular 
oedema required additional IVTA injections and two eyes with vitreous cells 
required OFI. More than one treatment was required in one eye to settle the 
inflammation (IVTA then OFI).  
 
Disease recurrence characterised by the development of posterior segment 
inflammation and macular oedema was seen in 3(20%) eyes within one year and one 
eye within two years after the Ozurdex implant. IVTA was used to manage 
inflammation and macular oedema in 3(20%) eyes, where one patient required repeat 
injections within the same year. 
 
In the sham group 5 eyes required rescue treatments during the 26 week trial to 
control inflammation and/or macular oedema where 80% had IVTA injections. 
Disease recurrence was documented in 5(45%) eyes during 1 year. 
4.3.3 Did additional interventions improve visual acuity and 
inflammation 
In this sub-group of 4 patients in the treatment arm that required further steroid 
treatments (OFI or IVTA) Table 4-8 mean improvement in BCVA was matched by 
further interventions but starting BCVA was worse. Macular oedema, where present 
in eyes requiring further interventions improved 2 months after IVTA. Vitreous cells 
persisted in 75% of cases.  
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 Ozurdex 
N=10 
Ozurdex + IVTA/OFI 
N=5 
Mean improvement (LogMAR) 0.26  0.22 
Pre-treatment BCVA (LogMAR) 0.71  0.85  
Post-treatment BCVA (LogMAR) 0.45  0.63  
t test significance in mean change in BCVA p=0.0014 p=0.1477 
Table 4-8: Change in visual acuity in Ozurdex treated eyes compared to eyes that required 
further IVTA/OFI 
4.3.4 Oral steroid and second-line immunosuppressive agents 
13(86.67%) patients started the initial trial without oral Prednisolone or second line 
immunosuppressive agents and they were not required on completion of the trial or 
at subsequent follow up periods over 1,2 or 3 years of follow up (where data 
available) (excluding pre-cataract operation doses). 
 
Details for the medication changes for two patients that did require oral prednisolone 
and a second line immunosuppressants are shown in Table 4-9. These two patients 
experienced disease recurrence after Ozurdex treatment. One patient was managed 
with a maintenance dose throughout 3 years of follow up with the addition of IVTA 
injections. And the second saw a reduction in second agent and prednisolone dose 
over three years with the addition of IVTA for disease recurrence. The Ozurdex 
implant did not removed the need for oral prednisolone or immunosuppressant 
requirements after the trial period in patients that were taking them during the trial.  
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Ozurdex Ozurdex + 
IVTA/OFI 
Sham Sham + 
IVTA/OFI 
Start of study number of patients taking oral 
prednisolone<10mg + immunosuppressant 
therapy*,** 
0 2 1 1 
Start of study number of patients taking oral 
prednisolone<10mg 
0 0 0 1 
Post-26weeks number of patients that 
required increase in oral prednisolone dose 
(excluding pre-cataract extraction) 
0 0 0 3 
Number of patients on oral prednisolone and 
immunosuppressant therapy after the 26 week 
trial *,** 
0 2 0 1 
* MMF - Mycophenolate mofetil, **MXT - Methotrexate 
Table 4-9: Oral steroid and immunosuppressant use in eyes before, during and after the 26 
week trial 
 
In the sham group, two patients required oral prednisolone <10mg a day in addition 
to  immunosuppressants prior to entry in the trial. After additional treatments with 
IVTA or OFI two eyes required increases in oral steroid doses to manage 
inflammation and/or macular oedema but were reduced to ≤10mg within the same 
year. 
4.3.5 Cataract formation/progression 
In the Ozurdex treatment arm, 7(46.7%) had a clear lens, 6(40%) had lens opacities 
and 2(13%) were pseudophakic prior to entering the trial compared to 1(9%), 
6(55%) and 4(36%) in the sham control group. Changes in lens status according to 
treatment and retreatment groups are shown in Table 4-10.  
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 Lens status Ozurdex 
implant 
N=10 
Ozurdex + 
IVTA/OFI 
N=5 
Sham 
 
N=7 
Sham + 
IVTA/OFI 
N=4 
Baseline % clear lens 
% lens opacities 
% pseudophakic 
7(70%) 
2(20%) 
1(10%) 
0(0%) 
4(80%) 
1(20%) 
0(0%) 
3(43%) 
4(57%) 
1(25%) 
3(75%) 
0(0%) 
6 month post-
treatment  
% clear lens 
% Lens opacities 
% pseudophakic 
5(50%) 
4(40%) 
1(10%) 
0(0%) 
4(80%) 
1(20%) 
0(0%) 
3(43%) 
4(57%) 
1(25%) 
3(75%) 
0(0%) 
1 year post-
treatment 
% clear lens 
% lens opacities 
% pseudophakic 
3(33%)* 
3(33%)* 
3(33%)* 
0(0%) 
3(60%) 
2(40%) 
0(0%) 
3(43%) 
4(57%) 
1(25%) 
0(0%) 
3(75%) 
* of 9 patients with follow up for 1 year 
Table 4-10: Change in lens status in treatment and sham groups over 1 year post-trial 
 
During the post-trial period to 12 months of follow up, 22%, 25%, 0% and 75% of 
phakic patients required cataract surgery from the Ozurdex, Ozurdex +IVTA/OFI, 
sham and Sham + IVTA groups respectively. Adjunctive steroids were provided for 
all patients undergoing cataract extraction in the form of pre-op oral steroids or intra-
operative IVTA injections. 2 patients who received peri-operative IVTA treatments 
developed sterile endophthalmitis immediately after. Details of cataract surgery in 
Ozurdex treated eyes are shown in Table 4-11. 
 At 6 months At 1 year At 2 years At 3 years 
Number of eyes 15 14 10 6 
Number of phakic eyes 13(86.67%) 9(64.29%) 3(30.00%) 1(16.67%) 
Eyes requiring cataract 
extraction 
0 6(42.86%)*$ 1(10.00%) 0 
* 1 Patient had Vitrectomy post implant prior to cataract extraction 
$1 patient had Retinal detachment surgery post implant prior to cataract extraction 
Table 4-11: Cataract extraction required in Ozurdex treated eyes 
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Visual acuity declined from baseline to pre-cataract extraction date by a mean 0.65 
LogMAR units (95% CI 1.12-0.18) (p=0.0152)(Paired samples t test). Post-cataract 
extraction, visual acuity improved by a mean 0.84 LogMAR units (95% CI 0.31-
1.37) (p value = 0.0080)(paired samples t test) see Table 4-12.  
 
 
 
Baseline BCVA pre-
treatment 
BCVA prior to cataract 
extraction 
Best BCVA post 
implant 
Number of eyes 7* 7 7 
BCVA mean 0.4 1.05 0.21 
Range 0.1-0.7 0.5-1.78 -0.1-0.3 
Stdev 0.22 0.49 0.15 
* Total excluding 6 Phakic eyes that had not had removal of a lens at final follow up and 2 Pseudophakic prior to the trial 
Table 4-12: LogMAR BCVA improvement in Ozurdex treated eyes after cataract extraction 
4.3.6 Intraocular pressure 
Table 4-13 shows mean highest IOP after steroid implant and IVTA/OFI 
interventions. 8(53.3%) eyes in the treatment arm experienced raised IOP 
(>21mmHg) after an average of 47.25 days (range 7 to 112) during the initial 26 
week trial.  
 
Mean highest IOP was greater in the Ozurdex treatment arm compared to the sham 
control during the 26 week trial t test p=0.0056. 3(37.5%) eyes saw an increase over 
30mmHg. Mean IOP at baseline in eyes treated with the Ozurdex implant was 
13.93mmHg (SD 1.91). A significant rise in IOP of 9.87mmHg (95% CI 7.72-
12.01)(p value 0.0001) (paired t test) was seen from baseline to highest IOP reading. 
60% of eyes commenced on topical IOP lowering treatments in the Ozurdex arm 
continued during the post-trial period. No patients required surgical interventions. 
 
6(40%) eyes in the Ozurdex group that required further interventions experienced 
raised IOP during the post trial period, 4(66.67%) eyes were associated with IVTA 
treatment, 1(16.67%) eye post OFI and 1(16.67%) with uveitis recurrence, see 
Figure 4-1. 2 patients were newly started on IOP lowering medication during this 
period. 2 eyes were already on treatment from the trial period. Mean highest IOP was 
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greater in sham eyes that required further interventions (t test p=0.1283). Topical 
IOP lowering treatment was started in 5 of these eyes.  
 
 Ozurdex treatment 
arm  
Sham control  Ozurdex + 
IVTA/OFI 
Sham + 
IVTA/OFI 
Mean highest IOP (mmHg) 23.80 18.18  20.60 24.00 
Median 23 18 22 20 
Range 18-32 12-30 12-29 18-42 
Standard deviation 4.66 4.62 8.29 10.12 
Table 4-13: Highest intraocular pressure (IOP) in different treatment and sham groups 
 
 
 
Figure 4-1: Box plot showing  mean highest IOP in eyes treated with one Ozurdex implant 
during the 26 week trial, Sham, and eyes that required further IVTA/OFI 
 
On comparison of mean highest IOP in eyes treated with the Ozurdex implant and 
eyes later treated with IVTA/OFI in the Ozurdex and sham groups the difference was 
found not to be statistically significant, (23.80mmHg vs 22.30mmHg t test 
p=0.5862).  
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4.4 DISCUSSION  
This study demonstrates that 13% of eyes with uveitis treated with an Ozurdex 
implant may require additional treatment for macular oedema and 13% for persistent 
vitreous cells within one year. Moreover, disease may recur in 20% of eyes within 
one year. 
 
Intravitreal triamcinolone - IVTA 
Habot-Wilner et al showed IVTA is an effective adjunct to systemic therapy for the 
treatment of uveitic macular oedema. On review of the literature there were 4 studies 
investigating IVTA treatment in eyes with non-infectious uveitis.  (125) (120) (9) 
(126)  
 
In summary from the literature IVTA has been shown to improve visual acuity in 
85%. Mean improvement of 0.26 to 0.33 LogMAR units, by mean 4 to 6.2 weeks 
has been shown. (120)(9) Resolution of macular oedema can be seen in 88% of eyes 
but 26-50% may persist or relapsed (126) after a mean 4.2 months (range 2.5-5.5) 
(120). The effects of an IVTA injection are better if macular oedema is present for 
less than 12 months and in patients less than 60 years old. (9) Dosage of oral 
corticosteroids and/or second-line immunosuppressive medication can be reduced or 
stopped in 54.5%(9) - 82.8%(120) of cases after single or multiple IVTA injections. 
IVTA (2 or 4 mg)  has been shown to improve macular oedema secondary to non-
infectious uveitis in eyes of children in 3 weeks (range, 1-24 weeks) where 31% 
disease relapsed after 7 months (range, 3-13 months).(149) 
 
In our sample population of uveitis patients, visual acuity was improved by a mean 
0.22 LogMAR units with an IVTA injection compared to mean 0.26 LogMAR units 
with a single Ozurdex implant.  33% and 45% of eyes in the Ozurdex and sham 
groups respectively needed further IVTA/OFI treatments within 1 year of starting the 
trial to manage inflammation and/or macular oedema.  
 
Macular oedema persisted in two(22%) eyes at 6 months after Ozurdex insertion 
treated with IVTA with which 50% resolved with one treatment. 4 eyes required 
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IVTA injections to control inflammation and/macular oedema of which 2(50%) 
required repeat treatment.  
 
The study shows that with a single Ozurdex implant systemic corticosteroid use and 
other immunosuppressive agents can be decreased or oral prednisolone doses 
maintained less than 10mg. The implant allows for oral steroid and 
immunosuppressant agents to be kept at a low maintenance dose for up to 3 years 
shown in two cases. Disease recurrence in these patients were managed with IVTA 
injections.  
 
Complications associated with the dexamethasone implant include Vs IVTA 
Corticosteroids increase the IOP by increasing the resistance of the aqueous humor 
outflow facility, which is mediated by alteration of the mechanical structure of the 
trabecular meshwork, extracellular matrix deposition in the trabecular meshwork, 
and reduction of the functional and phagocytic activity of the trabecular cells. (150) 
responding worse in eyes with prior compromised aqueous outflow pathway 
systems. Steroid response in a normal population is shown in Table 4-14. IVTA is 
known to be associated with a higher side effect profile including ocular 
hypertension and cataract progression compared to other ocular treatments such as 
anti-VEGF agents and laser photocoagulation. (127)(128)(129)(130) 
 
Table 4-14: Intraocular pressure response to topical steroids (41) 
 
 
IVTA can cause a mean rise in IOP by 10.3 mmHg where raised IOP over 21mmHg 
can occur in 32-49% of cases. (9)(151) Except for in steroid responders, raised IOP 
with IVTA treatment is transient in most cases and responds well to topical 
Type of responder Distribution in a 
normal population 
IOP increase 
High responders 5% >15 mm Hg and >31 mm Hg after daily corticosteroid 
use for 4 - 6 weeks. (37-38) 
Moderate 
responders 
Approximately 1/3 6 to 15 mm Hg and had IOP between 20 and 31 mm 
Hg. (37-38) 
Non-responders Approximately 2/3 <6 mm Hg and IOP of <20 mm Hg. (37-38) 
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medications. (9)(126)(151) 51% of eyes require topical anti-glaucoma medications 
for raised IOP for a mean 17.4 weeks. (9) Drainage or glaucomatous tube surgery 
may be required. 83% raised IOP at 10 weeks (125) Rises in IOP greater than 15 mm 
Hg were noted in 31% of eyes of children. (149) Over half of patients treated with an 
Ozurdex implant might experience raised IOP greater than 21mmHg within two 
months. IOP rises can be managed with topical lowering medications however, 60% 
of patients may required treatment lasting longer than 6 months. Known steroid 
responders were excluded from this trial. 
 
Steroid induced cataract progression is likely in 17 - 20% of eyes treated with IVTA. 
(126)(120). Cataract was observed in over half (55%) of children in one small study 
of 15 eyes. (149) Patients treated with either Ozurdex, IVTA or OFI in this study 
were more likely to see progression of cataract. This study also showed that cataract 
surgery is likely in 31% of eyes treated with the Ozurdex implant within one year 
and an additional 31% will see progression in lens opacities compared to untreated 
uveitis patients. 
 
The complications associated with the Ozurdex implant such as raised IOP and 
cataract progression is greater when IVTA is used in conjunction. There is also an 
additional risk of post-operative complications such as sterile endophthalmitis when 
IVTA is used as steroid cover during cataract surgery. 
 
Comparison with OFI in uveitis 
A retrospective cohort study by Leder et al(152) studied the effects of OFI when 
used to manage macular oedema due to non-infectious causes of uveitis in 126 
patients with anterior uveitis, intermediate uveitis and panuveitis. Patients were re-
treated if they had evidence of persistent macular oedema for more than 1 month 
after the first OFI. Macular oedema resolved in 53% at 1 month and 57%  at 3 
months but recurred in over half by a median 20.2 weeks. 26% required retreatment, 
81% after subsequent OFI had no macular oedema at 1 month, 48% had no macular 
oedema at 3 months and 15% did not respond. 
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A retrospective comparative study of OFI and IVTA by Roesel et al(153) studied 
their differences in cases of chronic non-infectious uveitis. 97 patients received a 
single injection of either IVTA or OFI. A summary of results are shown in Table 
4-15. Both IVTA and improved BCVA and macular oedema in eyes with chronic 
non-infectious uveitis, where IVTA significantly improved macular oedema 
compared to OFI at3 months. Effects were more effective in eyes treated with IVTA 
but were transient for both treatments as initial improvements in BCVA at 3 months 
were not maintained at 1 year. A retrospective study by Roesel et al(124), followed 
up 94 eyes of 86 patients with acute non-infectious uveitis over 6 months after one 
OFI 40 mg. They found OFI improved AC and vitreous inflammation P<0.01, but 
BCVA did not differ before and after. Macular oedema at 6 months was unchanged 
in 59% and worse in 14%. Ocular hypertension was noted in 8% of eyes and cataract 
progression in 29% at 6 months. 
 
 IVTA  
(n = 48) 
OFI  
(n = 49) 
Significance 
BCVA improvement of ≥2 lines at 3 months 50%  34%  p = 0.23 
BCVA improvement of ≥2 lines after 12 months 18%  20%   
Improvement in macular oedema within the first 
month 
100%  76%  p = 0.36 
Improvement in macular oedema after 3 months 100%  20%  p < 0.01 
Cataract progression at 1 year 68% 27% p < 0.01 
Raised IOP at 4 weeks 21% 0% p <0.01 
Table 4-15: Results from Roesel et al OFI vs IVTA for chronic non-infectious uveitis 
 Use of OFI in eyes of children with uveitis 
A retrospective non-comparative interventional case series 15 consecutive children 
(19 eyes) with various forms of uveitis treated with OFI of 40 mg/ml 
methylprednisolone acetate or a combination of 20 mg/0.5 ml Triamcinolone and 2 
mg/0.5 ml dexamethasone.(154) The mean LogMAR BCVA improvement of 0.18 
was achieved (p<0.001) at mean of 6 weeks (range, 4-20), 4-7 weeks post-OFI 
(median of 4 weeks) 74% had significant improvement in inflammation. Effects 
were transient, half of patients experienced a relapse of uveitis after a median time of 
4 months (range, 2-5 months). 21% of eyes required further injections. Adjunct 
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immunosuppressive systemic therapy was reduced or stopped in half of patients. 
Cataract was present in 21% of eyes approximately 5 months post-injection. 
 
Ozurdex verses Retisert 
There are many advantages of the dexamethasone implant including its 
biodegradable properties. The implant can be inserted in an outpatient setting in 
comparison to the surgically implanted polymer ease of sequential implants 
compared to Retisert and potentially lowers the cost of implantation without the need 
to surgically remove older devices. The actual cost of the dexamethasone implant is 
significantly lower than the cost of Retisert by approximately 65%. This cost 
approximation also does not take into consideration cataract extraction and glaucoma 
filtering procedures that may be necessary as a result of complications from the 
steroids and the disadvantage of chronic ocular inflammation requiring multiple 
implants per year.  
 
It is difficult to compare the efficacy and safety profile of the dexamethasone 
intravitreal implant with other sustained release corticosteroid implants, specifically 
Retisert given the different pharmacokinetic properties and duration of effect half-
lives of the two implants and the current lack of a randomised controlled trial to 
compare them.  
 
Limitations of this study 
The major limitation of this study was that we were not able to differentiate between 
which patients received the 0.7mg and 0.35mg dexamethasone implants to discern 
any differences between the various outcomes measured. Other limitations include 
the retrospective nature of the study. There was no control over examination findings 
and drugs and doses documented at various time points of follow up. Another 
disadvantage of the retrospective nature of this study included the lack of control 
over when and what additional treatments were administered by medical staff at 
follow up after the 26 week clinical trial ended. As no guidelines were stated or 
followed IVTA, OFI, systemic steroid or IS treatments were given based on the 
decision made by the consulting Ophthalmologist. 
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4.5 SUMMARY OF RESULTS  
 
There is significant visual loss associated with uveitis due to macular oedema 
associated with posterior segment inflammation. Macular oedema is thought to 
improve in eyes with a good presenting BCVA when treated within 12 months from 
onset. Corticosteroids administered systemically and locally have been used to 
reduce inflammation, macular oedema and prevent long term visual loss in patients 
with non-infectious uveitis but are associated with significant adverse effects.  
 
The Ozurdex dexamethasone drug delivery system is a novel approach to the 
treatment of uveitis and has been shown to be efficacious in the treatment of non-
infectious uveitis with potentially fewer adverse effects than other steroids with ease 
of use in an outpatient setting. Advantages of the polymer structure design of the 
dexamethasone implant include its slow and consistent effects to last longer at the 
back of the eye than a typical bolus IVTA injection requiring less frequent injections, 
less patient discomfort, hospital visits and reduced risk of endophthalmitis.  
 
Future studies will need to determine the relative long term efficacy and safety 
profiles among the different intravitreal steroid implants and the long term effects of 
repeated use of the dexamethasone implant in the treatment of recurrent uveitis in 
order to be able to effectively compare adverse effects to other longer acting steroid 
implants.  
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5. Conclusions 
The overall purpose of this thesis was to document retinal vascular involvement in 
uveitis and new treatment options, specifically the intraocular Ozurdex steroid 
implant. The aims were to: 1) determine the relationship between exposure to steroid 
treatments and other immunosuppressive agents, cardiovascular disease risk factors 
and retinal vein occlusion events in patients with uveitis. 2) outline anti-phospholipid 
antibody testing in an Ophthalmology scenario and make recommendation for testing 
and 3) provide information about the long term outcome of the Ozurdex implant and 
the strategies employed as and when disease relapsed, comparing these outcomes 
with those of the Ozurdex implant.      
 
This study outlines demographic and clinical findings and presentation and 1 year of 
follow up. Clinical features of retinal vein occlusion in uveitis patients are similar to 
the general population, including examination findings and complications. Uveitis 
patients with a retinal vein occlusion presented with poor visual acuity of mean 0.79 
logMAR units where over half improved over a year. Risk factors such as raised 
intraocular pressure and haematological conditions for vein occlusions were rarely 
associated with this population. Worse presenting visual acuity and visual outcome 
at one year was seen in eyes with a central retinal vein occlusion. Over half of eyes 
with branch retinal vein occlusions seen an improvement in visual acuity over 1 year. 
Macular oedema, vitreous haemorrhage and signs of ischaemia were seen in under 
half of eyes at presentation or during 1 year of follow up. 10% of eyes experience 
disease recurrence in the same or fellow eye.  
 
Steroid and immunosuppressant treatments are used to manage inflammation and 
macular oedema associated with uveitis in the form of different systemic and local 
preparations. Such treatments have extensive ocular and systemic side effect profiles 
including inducing hyperlipidaemia, hypertension and diabetes. Moreover, these 
systemic conditions increase a patient's risk of suffering from a retinal vein occlusion 
associated with sight threatening complications such as macular oedema, vitreous 
haemorrhage and ischaemia. This study shows that uveitis patients are at a higher 
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risk for retinal vein occlusion not as a direct consequence of inflammation but likely 
due to the above systemic cardiovascular disease risk factors induced by previous or 
current steroid and immunosuppressant use. 
 
The characteristics of these high risk group of uveitis patients are in their early 50s 
or younger and who would normally be classed as low risk for cardiovascular 
disease based on their relatively young age are less likely to be commenced on 
prophylactic medication according to current cardiovascular disease risk guidelines. 
Therefore it is postulated from the results of this chapter that uveitis patients that 
require systemic steroid or immunosuppressant treatments, especially those on long 
term regimes, be assessed as high risk for cardiovascular disease and risk factors 
such as hyperlipidaemia, hypertension and diabetes, be diagnosed and managed 
aggressively to prevent cardiovascular disease events. Managing these risk factors 
would therefore aim to reduce visual loss in this population due to retinal vein 
occlusion and its sight threatening complications. 
 
Secondly, the presence of anti-phosphlipid antibodies are a known risk factor for 
sight threatening vascular occlusions thus Ophthalmologists play a role in 
investigation and diagnosis of the disease as ocular presentation may be the initial 
vascular event. Testing for the presence of these autoantibodies is made through 
laboratory testing of serum blood samples taken from the patient and diagnosis is 
based on two positive samples taken 12 weeks apart in association with a 
thromboembolic or pregnancy loss event. The presence of these autoantibodies are 
not specific for antiphospholipid syndrome and can be raised in the presence of 
infection and cancer for example. Currently there are no specific guidelines outlining 
which patients and who should be performing these investigations in an 
ophthalmology setting. This study shows that over a year a very small percentage of 
patients presenting to Moorfield's eye hospital with a retinal vascular event are 
diagnosed with circulating antiphospholipids. Less than 20% of patients who had 
circulating aPL were re-tested as per laboratory request/guidelines. 
Recommendations for testing for aPL have been made based on patient 
characteristics and clinical features on presentation of an ocular event and serum 
blood test result. Due to the small percentage of patients that would be diagnosed 
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with APS in an ophthalmology setting it is recommended that aPL testing be 
performed in young patients under 50 years of age, with unilateral or bilateral retinal 
vascular disease once all other common systemic and ocular risk factors are rules out 
with repeat testing after 12 weeks to confirm the diagnosis either on further follow 
up in the Ophthalmology department or through communication with the patients 
GP. Thereafter prophylactic management of APS upon diagnosis can be initiated by 
a Haematologist and follow up for ocular complications can be managed by the 
ophthalmologist. Patients with concurrent infections, cancer that would yield high 
false positive rates as results cannot be interpreted correctly and haematological 
opinion be sort. Patients on anti-coagulation should be clearly stated on request 
forms.  Guidelines for aPL testing for Ophthalmologists would help reduce the cost 
of unnecessary laboratory tests and clear outlining of patient and clinical details upon 
request for aPL investigations would assist interpretation of results and the need for 
further testing.  
 
Thirdly, the innovation of the Ozurdex intravitreal dexamethasone implant has 
brought about a new drug delivery system to manage inflammation and macular 
oedema associated with visual loss in non-infectious intermediate, posterior and 
panuveitis. The implant also allows for oral steroid and immunosuppressant doses to 
be kept to low maintenance doses or were not required in some patients.  
 
After a single Ozurdex implant, 33% of eyes will require further IVTA or OFI due to 
disease recurrence or persistent macular oedema. Intraocular treatments such as 
IVTA or OFI can match the improvement in visual acuity but repeat treatments 
within a year are required in most eyes to maintain this. 
 
The implant is not without side effects, approximately 22% of phakic patients will 
require cataract extraction within one year after implant insertion, which increases to 
a quarter of patients that have additional IVTA or OFI treatments. Raised intraocular 
pressure is common in half of eyes within the first two months from implant 
insertion, patients are managed with topical IOP lowering medication which 
continue for over 6 months. IVTA or OFI are associated with higher IOP rises in a 
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higher percentage of eyes compared to the Ozurdex implant alone, which again 
require topical IOP lowering medication. 
 
Future considerations based on the results of this study 
Data on more than one Ozurdex implant for the treatment of non-infectious uveitis 
and head to head studies of other steroid treatments will provide long term 
information and efficacy of the implant. Steroid  have uses in managing macular 
oedema due to diabetes as well, and results of the Ozurdex implant alone or in 
combination with current laser and or anti-VEGF treatments are awaited, although 
the Iluven steroid implant has been shown to improve vision in such eyes. The use of 
intraocular implants for long term delivery of drugs to the posterior segment of the 
eye are in progress and will be of use in other ocular conditions such as age related 
macular degeneration and diabetes.  
 
Changes in practice for the diagnosis of APS in the ophthalmology setting should be 
made and investigation into the long term outcomes of these patients should be 
investigated as well as the outcomes for patients as a result of guideline 
implementation.  
 
Moreover the outcome of aggressive management of cardiovascular disease risk 
factors in uveitis patients taking systemic steroid and immunosuppressants on visual 
outcome and frequency of retinal vein occlusion events should be  investigated. 
 
In conclusion this thesis provides results and discussion of methods and a new 
treatment to reduce the risk and manage visual loss in specific sub-groups of 
Ophthalmology patients with uveitis and those at high risk of retinal vascular 
occlusion.  
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Photographs 
 
Photograph 2-1: Colour fundus photo of a branch retinal vein occlusion 
 
 
Photograph 2-2: Colour fundus photo of a central retinal vein occlusion 
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Photograph 4-1: OCT image of macular oedema 
 
 
Photograph 4-2: Ozurdex dexamethasone intravitreal implant drug delivery system 
 
 
 
 
 
 
 
